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CHAPTER I 
 
GENERAL INTRODUCTION 
7
 CHAPTER I: GENERAL INTRODUCTION 
 
A. Embryology 
Normal synovial joint formation consists of two phases. First, the developing mesenchymal 
blastema differentiates into a cartilaginous model of the future long bone. Adjacent skeletal 
elements are separated by thin bands of mesenchymal cells known as interzones. Although the 
biology of the interzone is poorly understood, it is believed that these structures differentiate into 
three layers; two outer chondrogenic layers that will cover the cartilage anlage, and an intermediate 
layer that contributes to the formation of intra-articular structures such as ligaments, menisci, and 
the synovium. Subsequent to the formation of the interzone is joint cavitation, the process by which 
adjacent cartilaginous elements separate to form two distinct articulating joint surfaces (Figure 1).  
 
 
Figure 1.(A) Progress of cavitation in a paraffin section at E17±5 of a rat. Cavitation has advanced at the 
femoromeniscal junction (arrowhead) and has started between the tibia and the posterior horn of the lateral meniscus 
(PM) in this sagittal section. No cavitation is seen between the tibia and the anterior horn of meniscus (AM). Azan 
staining. Bar, 100 m. (B) Initial appearance of cavitation in a coronal epoxy section at E18±5. Cavitation (arrows) has 
begun in the peripheral part of the intermediate zone, both between the femur and the meniscus (M), and between the 
tibia and the meniscus (M). Toluidine blue staining. Bar, 100m. Pictures courtesy of Ito MM and Kida MY. J Anat. 
2000.   
 
Only if both of these developmental processes proceed undisturbed will normal formation and 
maintenance of synovial joints be observed.
1
 Mechanical stimulation during the embryogenesis is 
essential for the maintenance of the meniscus. In the absence of functional muscle contractions, the 
early meniscus condensations initially form but degenerate and disappear quickly thereafter.  
8
 In the developmental progression of matrix gene expression in the mouse meniscus 4 distinct stages 
of meniscal morphogenesis have been identified: stage 1, mesenchymal cell condensation between 
the articular surfaces of the femur and tibia; stage 2, differentiation of meniscal fibrochondroblasts 
within the rudimentary meniscus; stage 3, meniscal ECM synthesis and deposition; and, stage 4, 
meniscal ECM maturation.
3
 The appearance of discrete meniscal condensations during stage 1 
correlates with the expression of BMP-4 and GDF5 by mesenchymal cells that aggregate to form 
the meniscal rudiment.
 3
  Once this condensation is complete, mesenchymal cells differentiate into 
fibrochondroblasts. Acquisition of a chondrocyte-like phenotype by meniscal cells is coincident 
with the loss of expression of BMP-4 and GDF-5 (stage 2).
 3
  Meniscal cells now begin matrix 
synthesis, producing an extracellular matrix of type I and type III collagen and aggrecan (stage 3).
 3
  
Type II collagen expression by meniscal cells occurs late in meniscal morphogenesis (stage 4).
 3
  
These results suggest that the meniscus is a unique connective tissue with a distinct developmental 
profile.  
 
B. Gross anatomy 
The knee joint menisci are a pair of wedge shaped semilunar fibrocartilages which are interposed 
between the femoral condyles and tibial plateaux (Figure 2).   
 
Figure 2. The knee joint menisci are a pair of wedge shaped semilunar fibrocartilages interposed between the femoral 
condyles and the tibial plateaux. 
 
They measure approximately 35 mm in diameter, and are attached to the joint capsule by their thick 
convex-shaped peripheral rim, which has a length of approximately 110 mm including the length of 
9
 the insertional ligaments.
4,5
 The anterior and posterior meniscal horns are firmly attached to bone 
via insertional ligaments. The lateral meniscus covers approximately 80% of the corresponding 
tibial plateau and the medial one approximately 60%, the proportions of which remains constant 
throughout growth. The most common congenital abnormality of the meniscus in man is a discoid 
meniscus with a frequency of 1.5±4.6% for the lateral, and 0.3% for the medial one.
 6,7
   
 
C. Functional anatomy and joint biomechanics 
The incongruency between the round shaped femoral condyles and comparably flat tibial plateau is 
adapted by the concave upper meniscal surface facing the former, and the lower, flat meniscal 
surface facing the latter. The contact area in the femorotibial joint thereby increases significantly, 
and the stresses on tibial cartilage are reduced (Figure 3A).
8,9
   
 
 
Figure 3. (A) By adapting the convex femoral condyl to the flat tibial plateau, the contact area in the femorotibial joint 
is significantly increased. (B) After removal of the meniscus, the peak stresses on the cartilage are considerably 
increased, leading to progressive cartilage degeneration and osteoarthritis. 
 
In a loaded, in vitro situation, 70% and 50% of the loads in the lateral and medial compartments, 
respectively were transmitted though the corresponding menisci, reflecting their proportion of 
coverage of the respective  compartment.
10
  After removal of the menisci, contact areas in the 
femorotibial joint were largely reduced and the peak stresses on tibial cartilage considerably 
increased (Figure 3B).
 8,10
 The load distributing function of the menisci is made possible by their 
strong anterior and posterior entheses to bone which prevent the menisci from extruding from the 
joint during axial loading. Joint loading will tension the insertional ligaments and also the 
circumferential fibres of the meniscus. Thus part of the axial load will be transformed into hoop 
stresses at the meniscal periphery.  
10
 The decrease in contact area and subsequently the increase in peak stresses on the tibial plateau 
after meniscal transection are regarded as the main reason for the frequent bone and cartilage 
changes found after meniscectomy.
 1,10
 The adaptation of the femoral condyles and tibial plateaux 
by interposition of the menisci is provided in all knee flexion and rotation angles, since the menisci 
follow the motion of the opposing joint surfaces.
 11,12
 The lateral meniscus displaced by 
approximately 10 mm on the tibial plateau during knee flexion and extension, which is twice as 
much than that of the medial one.
 11
 Also the shape of the menisci deforms during knee joint motion 
because the anterior horns are displaced more than the posterior ones.
 12
 Menisci also probably play 
significant roles in shock absorption, joint stabilisation and joint lubrication. 
  
D. Chemical composition and organisation of normal meniscal tissue 
Normal human meniscal tissue has been found to be composed of approximately 72% water, 22% 
collagen, 0.8% glycosaminoglycans that are assembled in proteoglycans, and 0.12% DNA (Tabel 
1).
 13-14
  
Table 1. The chemical composition of articular cartilage and meniscus tissue 
These collagen fibres and proteoglycans such as aggrecan are organized in complex supramolecular 
structures that account for the tissue’s resistance against tensile and compressive stress (Figure 4).  
11
  
Figure 4. Combined functions of collagens and proteoglycans in articular cartilage and meniscus tissue. Large 
hydrophilic proteoglycans such as aggrecan are entrapped within this collagen network. The collagen molecules 
withstand tensional strains, while aggrecans give articular cartilage and meniscus the ability to undergo reversible 
deformation. 
 
The meniscal body consists predominantly of a dense framework of coarse type I collagen fibres, 
the main orientation of which is circumferential (Figure 5).  
 
Figure 5. The meniscal body consists predominantly of a dense framework of coarse type I collagen fibres, the main 
orientation of which is circumferential. Radial fibres are found throughout the tissue but are less numerous. These latter 
may act as a ‘tie’ holding the circumferential fibres together, thereby resisting longitudinal splitting of the menisci. 
 
Radial fibres are found throughout but are less numerous. These latter may act as a ‘tie’ holding the 
circumferential fibres together, thereby resisting longitudinal splitting of the menisci.
 15-17
 Type I 
12
 collagen accounts for over 90%, and types II, III,V and VI collagens for the remaining meniscal 
tissue collagens.
 18,19
 The distribution of the different collagens shows significant regional 
variations. Except for trace amounts (1%) of types III,V and VI collagens, the peripheral two-thirds 
of bovine menisci consist solely of collagen type I, whereas type II collagen (60%) predominated 
over type I collagen (40%) in the inner third.
 20
 Recent research has shown that type II collagen is 
organised in a specific network within the canine meniscus.  
 
A specific colocalisation of type I and type II collagen within the canine meniscus was observed 
within bundles of circumferential  fibrils and a thinner fibrillar system perpendicular to the former.
 
21
 Types III and V collagens are predominantly found pericellularly and in meniscal surface layers.
 
18,22
 A matrix containing types I, III and V collagens is found as early as at 25 d in the rabbit fetus. 
Type II collagen is only detected at 3 weeks postnatally, the content of which increases with further 
maturation.
 22
 Apparently, appearance of collagen type II is associated with the increase in joint 
loading during postnatal development. 
23
  
Normal human meniscal proteoglycans contain approx. 40% chondroitin 6 sulphate, 10-20% 
chondroitin 4 sulphate, 20-30% dermatan sulphate, and 15% keratan sulphate, the proportions of 
which are maintained under tissue culture conditions by a corresponding glycosaminoglycan 
production.
 13,24
 In dry weight, the inner third of the meniscal body 8% glycosaminoglycans, and its 
peripheral third only 2% glycosaminoglycans. Aggrecan has been found to be a major proteoglycan 
in adult bovine and canine menisci (Figure 6).  
Its biosynthesis and accumulation begins in meniscal tissue and insertional ligaments during fetal 
development.
 25
 Meniscal tissue explants from inner and middle zones produce predominantly 
aggrecan like proteoglycans under culture condition, but also smaller proteoglycans. Explants from  
peripheral zones produce in general less proteoglycan and, preferentially, smaller ones.
26
 Aggrecan 
is not produced in the outer region of the canine meniscus.
 27
 In general the concentration of 
aggrecan produced in the meniscus averages 1/8
th
 to 1/10
th
 of the concentration in articular 
cartilage.
 27
 Biglycan and fibromodulin were found in higher amounts in the inner and middle than 
the peripheral zones of pig menisci. Decorin, on the other hand, is found more extensively in the 
peripheral zone.
 28
 The apparent regional distribution of proteoglycans certainly reflects the tissue 
adaption to local loads, which is even maintained under tissue culture conditions. Specific 
proteoglycans (aggrecan, biglycan, fibromodulin) seem to accumulate in the inner compressed 
region of the meniscus.  
13
  
Figure 6. (A) The structure of aggrecan aggregate. Aggrecan monomers (square) are attached on a hyaluronan backbone 
(arrow) to form aggregates of different sizes. (B) In the aggrecan monomer, the three globular domains (G1,G2 and G3) 
are separated by two extended segments which carry the glycosaminoglycans chrondroitin sulphate and keratan 
sulphate. The link protein stabilizes the aggregate structure between hyaluronan and the aggrecan monomer. Up to 200 
aggrecan monomer may bind to one hyaluronan. 
 
E. Cellular composition of meniscal tissue 
The meniscus is defined as a fibrocartilage, because of the rounded or oval shape of most of the 
cells and the partly fibrous appearance of the extracellular matrix in the light microscope.
29
  
Ghadially et al. classified cells in the meniscus as chondrocytes, fibroblasts, or cells of intermediate 
morphology, based on their shape and the presence or absence of a territorial matrix.
 29
 The work of 
Eyre and Muir in the 1970’s established that type I collagen is the major fibrillar collagen in the 
meniscus, in contrast to articular cartilage where the major fibrillar collagen is type II.
 30
 This 
difference in expression can be used as a molecular criterion in the distinction of fibrocartilage 
14
 (type I collagen) and hyaline cartilage (type II collagen) and of meniscus cells and chondrocytes. 
There are, however, small amounts of type II collagen in the meniscus. Given that most of the 
collagen is type I collagen in the meniscus and the amounts of type II collagen are reportedly small, 
it is clear that the cell in the meniscus with its round/oval, chondrocyte-like morphology is not a 
true, hyaline cartilage chondrocyte. McDevitt et al. were the first to refer to these oval-shaped cells 
as fibrochondrocytes.
 19
 There appear to be three and possibly four distinct cell populations in the 
meniscus: (a) the fibrochondrocytes, located predominantly in the inner half of the meniscus where 
the forces are predominantly compressive; (b) fibroblast-like cells that occupy the outer, more 
fibrous portion of the meniscus that influences tensile forces; (c) superficial zone cells, located in 
the surface zone of the meniscus that interfaces with the synovial fluid (Figure 7). Cells of 
intermediate morphology between that of a fibrochondrocyte and fibroblast are located in the outer 
portion of the tissue.  
 
Fibrochondrocyte 
A fibrochondrocyte is defined as a round or oval-shaped cell that synthesizes type I collagen as its 
major fibrillar collagen and that has a territorial, pericellular matrix. The pericellular matrix appears 
in the transmission electron microscope as fine filamentous material with a distinct transition to the 
fibrous interterritorial matrix.  
 
Figure 7.Schematic representation of the human meniscus showing the distinct cell type populations and their regional 
distribution. Fibrochondrocytes are round cells with no cellular projections, located in the avascular portion of the 
meniscus, while fibroblast-like cells are located in the vascular portion and reveal thin cytoplasmatic projections. Cells 
from the superficial area are fusiform. 
15
  
The interterritorial matrix synthesized by the fibrochondrocyte contains relatively small amounts of 
type II collagen and type III collagen. Type VI collagen is a distinctive component of the 
pericellular matrix of the fibrochondrocyte, as it is for the articular chondrocyte. 
The fibrochondrocyte is the main cell in the body of the middle and inner meniscus. The location, 
shape, and properties of the fibrochondrocyte are consistent with this cell functioning in that portion 
of the meniscus that predominantly experiences compressive forces.  
 
Fibroblast-like cells 
These cells lack a pericellular matrix and are located in the outer portion of the meniscus. Staining 
with the anti-vimentin antibody revealed the presence of cells with several long, thin cytoplasmic 
projections that extend out from the main body of the cell to make contact with other cells (via gap 
junctions, connexion 43 staining) and different regions of the matrix.
31
 Moreover, these cells 
contained two centrosomes, one associated with a primary celium whose structure suggested a 
sensory rather than motile function. The location of the cells with extended projections in the outer 
portion of the meniscus led the authors to conclude that these cellular structures enable the cells to 
respond to different types of mechanical loading (circumferential or compressive).
 31
  The presence 
of cells with long extensions that make contact with other cells enables these cells to maintain 
homeostasis by sensing both the immediate and more distant environment.  
 
Cells of the superficial zone 
These cells have a characteristic fusiform shape, have no cytoplasmic projections, and reside in the 
superficial zone just below the surface of the tissue.
 29,31
 These cells have long been recognized as 
having a different shape to the main body of cells in the interior of the 
tissue. In an in vivo canine model for wound healing it was noted by Kambic et al. that the 
superficial zone cells expressed alpha SMA and appeared to migrate into the wound. SMA-positive 
cells were also concentrated at the interface of the wound and adjacent meniscus.
 32
 The intriguing 
possibility arises that the superficial zone contains specialized cells, perhaps progenitor cells, which 
initiate the wound-healing process.  
The significance of cells outside a wound site staining positively for alpha SMA is unclear. 
Ahluwalia et al. noted that about 25% of the non-vascular cells in menisci from total knee 
arthroplasties of older humans (average age 66 years) expressed alpha SMA, suggesting it may be 
part of a remodelling response in the tissue.
 33
 Hu et al. concluded from a scanning electron 
microscope study of the rabbit meniscus surface (ie, the superficial zone) that the progressive 
16
 change in shape of the cells of the superficial zone towards a more flattened morphology was 
consistent with the idea that these cells originated in the synovium and moved out into the surface 
zone of the tissue.
 34
  
 
F. Blood supply 
Blood vessels could be identified in the peripheral third of the menisci around the wk 22 of 
gestation in man.
 35
 At birth, almost the entire meniscus was vascularised. In the second year of life 
an avascular area developed along the central margins of the menisci. Vascular supply to the 
menisci is provided by the lateral and medial geniculate arteries which form a perimeniscal 
capillary plexus with radial branches directed towards the centre of the joint (Figure 8).
 36
 In the 
adult, the degree of vascular penetration from the periphery was 10-30% of the width of the medial 
meniscus and 10-25% of that of the lateral meniscus. The anterior and posterior horns of the 
menisci are more vascularised than their bodies.
 36
  
 
 
 
Figure 8. The degree of vascular penetration from the periphery is 10-30% in width. Picture reproduced from Arnoczky 
SP,Warren RF. 1982.
36
 
 
G. Innervation 
Innervation to the menisci arises mainly from the posterior articular nerve, but part of the 
innervation of the medial meniscus is provided by branches of the medial articular nerve.
 37
 There is 
general agreement that the nerve supply to menisci is more extensive in the horns than the body 
similar to vascularisation, but reports vary as to whether any nerves at all are present in the latter.
 38
 
It is evident from the literature that encapsulated end organs with mechanoreceptor function 
predominate at the horns and attachment structures, and that free nerve endings are found 
throughout except for the inner third of the meniscal body. The menisci without doubt have a 
17
 sensory function, and especially their horns and insertional ligaments may provide important 
proprioceptive information related to joint position. 
 
H. Healing response in the injured meniscus 
The capability of a meniscus to heal has been illustrated in 3 models of meniscus injury: (1) 
transection of the anterior cruciate ligament, (2) the devitalized plug model and (3) the meniscus 
tear. 
 
Model I: Transection of the anterior cruciate 
Transection of anterior cruciate ligament is known to induce increased mechanical stresses on the 
menisci, especially the medial meniscus. This injury pattern has been used in multiple animal 
models to evaluate histologically and functionally the response of the meniscus cells in an in vivo 
situation.
 23,39-43
  In general, histological observations showed a progressive destruction of both the 
meniscus and the articular cartilage after ACL transection.
 23,40
 There is also evidence of meniscus 
cell cluster formation following ACL transection. Immunohistochemistry demonstrated increased 
staining for type I and type III, and particularly for type II collagen, in the pathologic specimens 
compared with controls.
 23
 Specific proteoglycans staining indicated an increased expression of 
these molecules in the pathological meniscus.
 23
 Functional analysis reveals that catabolic enzymes 
such as MMP-1, MMP-3 and particularly MMP-13 mRNA levels were higher in the pathologic 
meniscus compared with controls (Tabel II).
 39 
18
 Table 2. Overview of the matrix-metalloproteinases (MMPs) 
In the medial meniscus significant increases in the mRNA levels for type I, II and VI collagen, 
TIMP-1, aggrecan, biglycan, and iNOS were noted in the pathologic specimens compared with 
controls. Type VI collagen is a protein whose expression is increased in wound healing and 
remodelling scenarios in  different connective tissues, so the increased levels of col6a3 mRNA are 
presumably a vigorous attempt at repair.
 39
 In summary, the meniscus responds to injury by 
increased expression of genes for matrix protein and enzymes. 
 
19
 Model II: Plug Model 
In this interesting canine model, a plug was removed from a non-vascularized portion of the 
meniscus, rendered acellular by repeated freeze-thawing cycles and then reimplanted into the 
defect.
 32
 This model was used to observe cellular migration upon injury. One year after the injury, 
the plug was repopulated by cells with a variety of shapes. Cells from the superficial region 
appeared to play a crucial role in the repair response. They expressed SMA and appeared to migrate 
into the wound. 
 
Model III: Tear model 
Tears in the vascularised zone in the peripheral third of the meniscus body heal similarly as for 
other vascular tissues.
 44-46
 The initial formation of a haematoma and fibrin clot in the gap acts as a 
scaffold for ingrowth of vessels from the perimeniscal capillary plexus. The vascular ingrowth is 
accompanied by migration and proliferation of undifferentiated mesenchymal cells, possibly 
originating from the synovium. Eventually, the lesion becomes filled with a highly cellular 
fibrovascular scar tissue. Final remodelling of this scar tissue required several months until it 
acquired a meniscus tissue like shape and biomechanical properties. 
47,48
 The clinical experience 
with this type of tear is usually good. Repair of peripheral, longitudinal tears show a high frequency 
of healing and good functional results.
 49-51
 It also seems that a once healed meniscal tear remains as 
stable as an initially intact meniscus.
 51,52
  
In contrast to tears located in the vascularised zone, the more frequently encountered ruptures in the 
avascular zone heal poorly.
 44,53
 Because of the obvious advantages of meniscal repair many efforts 
have been made to improve the healing of tears in these regions. Longitudinal incisions in the 
nonvascularised portion of the meniscus were successfully induced to heal by connecting the lesion 
to peripheral vasculature by ’vascular access channels’, which resulted in a similar healing process 
as described for tears in the vascular region.
 46,54
 For this procedure, a major radial split through the 
peripheral third of the meniscus to create the channel should be avoided to minimise damage of the 
circumferential collagen framework, which is a prerequisite for normal meniscal function. Another 
possibility for improving healing in avascular tears is the use of free synovium, or a synovial 
pedicle flap which is sutured directly or through a tunnel into the lesion.
 55-59
 Use of fibrin clot alone 
or together with endothelial cell growth factor or autogenous precultivated stem cells and even 
implantation of porous polymers did improve the healing response of experimentally created lesions 
in the avascular region of the meniscus.
 60-64
 However, the strength of the scar tissue which was 
measured after use of fibrin clot and stem cells only achieved 40% of normal within 4 months after 
implantation.
 62
 Thus there is no doubt that tears in the avascular lesion can be made to heal with 
20
 various methods, although the healing frequency for this type of lesion is clinically lower than after 
repair of more peripherally located tears.
 53
 However, it is also doubtful whether repair of these tears 
reestablishes normal meniscal function. Thus there is no evidence for now that repair of a tear in the 
avascular region is better than partial meniscectomy.  
  
I. Rationale for meniscal replacement 
Substantial research has already been performed to substitute the resected meniscus in case of a 
total or partial meniscectomy, in order to prevent or delay cartilage degeneration, improve 
biomechanics and relieve pain. Possible surgical approaches include the use of autologous or 
allogenic tissues: e.g. tendon, pediculated Hoffa fat pad, periosteal tissue, perichondral tissue, small  
intestine submucosa, meniscal allografts, meniscus scaffolds based on native polymers (collagen  
and hyaluronic acid) or purely synthetic scaffolds such as poly-lactic acid, poly-glucuronic acid and 
poly-urethane.
 65-74
 Other than meniscal allografts and a collagen type I based meniscus scaffold 
(CMI®, Regen Biologics, Franklin Lakes, NJ, USA), none of these materials have advanced to 
human clinical use. These surgical approaches are based on the concept of a timely colonization of  
the acellular scaffold or allograft tissue by host cells which are probably derived from the synovium 
and joint capsule (Figure 9).
 75,76
  
 
Figure 9.Acellular meniscus grafts or scaffolds (*) are colonized by host cells (arrow) which are probably derived from 
the synovium and the joint capsule (**). 
 
The phenotype of these host-derived scaffold-colonizing cells ultimately determines the 
biochemical composition and biomechanical behaviour of these repopulated scaffolds or tissues.  
Another critical variable in this approach is the time needed for colonization of the scaffold or 
tissue: since these scaffolds or tissues are biodegradable, the colonization and healing by host cells 
21
 should be faster than the degradation process, for the regeneration or healing of the meniscus 
substitute to be successful (Figure 10).  
 
 
Figure 10. (A) Idealistic degradation kinetic of a resorbable scaffolds (grey line) related to tissue healing (dashed grey 
line). The sum of these processes (black line) guarantees the stiffness of the construct. (B) In the human model, tissue 
healing is considered much slower than the resorption of many grafts and scaffolds, resulting in reduced stiffness 
(arrow) and early failure of the construct. 
 
Previous animal studies have provided evidence that fresh meniscus allografts are quickly invaded 
by host cells within one month after transplantation.
75,77
 In the human model, however, only limited 
data is available. A previous study performed at our institution, has provided evidence that this 
process of colonization is considerably slower in the human model: DNA fingerprint analysis, 
performed on human viable meniscal allograft biopsies taken up to 36 months after transplantation, 
showed that these allografts contained only donor-derived cells in a number of cases.
78
 These data 
substantiate observations published elsewhere on transplanted human deep-frozen meniscal 
allografts and collagen scaffolds. Histological sections on these specimens showed a decreased 
cellularity after transplantation, indicating insufficient repopulation of the graft or scaffold (Figure 
11).
76,79
   
22
  
Figure 11. Histological section of a deep-frozen meniscal allograft 6 months post-transplantation in a human 
demonstrating only superficial cell repopulation. The central core of the grafts remains acellular. Picture reproduced 
from Rodeo SA et al., 2000 
76
 
 
Hence, an increase of the initial cell number at the defect site and thereby a decrease of the time 
needed for colonization can be accomplished by (1) transplantation of a in vitro cultured ‘viable’ 
meniscal allograft or (2) seeding autologous cells with a proven meniscus repair potential on or in a 
biodegradable scaffold prior to implantation.    
 
J. Meniscus allograft: Immunological considerations 
The avascular meniscus tissue is considered to be immunoprivileged because the meniscus cells are 
embedded in a dense proteoglycan rich extracellular matrix inaccessible to immunoreactive cells.  
Histological data showed the presence of HLA class I and II epitopes around synovial and 
endothelial cells within the in meniscus tissue. The meniscus cell itself expressed class I HLA 
episodes.
80
 The different preservation methods did not significantly affect the presence of HLA 
class I and II epitopes in deep frozen and fresh human allografts. Allograft bone has shown to 
induce a more important immune reaction therefore the transplantation of a meniscal allograft with 
bone blocks might elicit a more important immune response.
81,82
 
Human clinical data suggest that a humoral and cellular immunological reaction is present.
76
 
Synovial biopsies taken after transplantation of deep frozen human meniscal allograft showed the 
presence of immunological active cells in small quantities. Another study documented a 
sensitization in 11 of 18 recipients of a cryopreserved meniscus allograft against Human Leucocyte 
Antigens.
83
 
These data support the existence of a subtle immune response. Its clinical relevance remains to be 
determined, since this phenomenon may modulate graft healing, incorporation, revascularisation 
and most importantly repopulation. In general there is no evidence for graft failure or rejection. 
23
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 CHAPTER II: AIM OF THIS THESIS 
The surgical treatment of meniscus lesions is the most common procedure in the orthopaedic field 
today. Over 400.000 surgical cases involving the meniscus are being performed annually in Europe 
and over 1 million in the United States. The majority of these lesions results in a meniscectomy 
while only a small percentage can be successfully repaired. The discovery 50 years ago that 
complete removal of a meniscus in the knee joint led to development of cartilage degeneration in 
the long term, changed substantially the therapeutic approach to this common work or sports injury. 
Total meniscectomy is now almost completely abandoned in favour of partial meniscectomy and 
meniscus-repairing procedures. Both procedures have the theoretical advantage of being less 
damaging to the articular cartilage. Long term data are, however, still missing to substantiate this 
hypothesis. Nevertheless, total or subtotal meniscectomy remains necessary for large irreparable 
tears. 
-1- In order to restore normal knee biomechanics and anatomy and thus prevent further cartilage 
degeneration after total or subtotal meniscectomy, the transplantation of viable meniscus allografts 
has been introduced into clinical practice in the late eighties. Encouraged by the satisfactory early 
clinical results, over 150 viable meniscal allografts transplantations have now been performed at the 
Ghent University Hospital. To determine the long term success of this procedure, we have looked at 
the clinical outcome of this procedure in our patient population. Using validated clinical scoring 
tools, the 100 first transplanted patients were evaluated. Additionally, based on clinical endpoints a 
survivorship analysis was performed. 
-2- To determine the anatomical outcome of the transplanted tissue and to asses the progression of 
secondary osteoarthritis in the affected knee joints, different imaging techniques, e.g. radiology, 
magnetic resonance imaging have been adapted for the use in this patient population. The data 
obtained in 41 patients with 42 allografts with a minimal follow-up of 10 years were taken into 
consideration. Magnetic resonance imaging and ultrasound were shown to be a clinically useful and 
reproducible method for evaluating lateral meniscal extrusion in normal and transplanted knees.  
-3- The availability of meniscal allografts has dramatically decreased over the years due to a 
shortage in organs donors. To overcome this shortage and to introduce a reparative treatment for 
partial meniscectomized patients, we started a meniscus tissue engineering program at our hospital 
in 2001. The aim of this program is to gather insights into the basic biology of the human meniscus 
in order to develop possible repair and regeneration strategies. The human meniscus cell was 
isolated, cultured in vitro and characterized by its production of extracellular matrix proteins and 
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 the expression of specific cell membrane markers. This approach would enable us to set the gold 
standard of the cellular phenotype that should eventually be obtained in the in vivo setting.  
-4- A different approach to the meniscus tissue engineering consisted of the use of in vitro expanded 
human bone marrow derived mesenchymal stem cells in combination with a collagen matrix. 
Preliminary data was available that this cell type could be differentiated towards cartilage, bone and 
muscle lineages. We hypothesized that this cell type could also have a fibrochondrogenic or 
meniscus-like differentiation potential. Since mesenchymal stem cells can be easily harvested from 
the iliac crest and expanded in vitro, this approach would enable us to avoid the need for an intra-
articular biopsy to obtain cells. In combination with a scaffold these cells could be implanted into 
the meniscus defect thus increasing the repair/regeneration potential. 
-5- The ultimate goal to meniscus tissue engineers is to prevent the degeneration of the underlying 
articular cartilage and to restore the knee biomechanics. Therefore, the study of the articular 
chondrocytes and the biological processes responsible for the cartilage degeneration remain 
important as such. The knowledge on this cell type is much more extended compared to the 
meniscus cell type. Obviously, certain biological pathways present in the articular chondrocyte will 
also be implicated in meniscus degenerative as well as reparative processes. Specific differences in 
the expression of anabolic and catabolic factors were analyzed in normal and degenerated articular 
cartilage. Furthermore, the effect of anabolic pharmaceuticals was studied, in order to reduce 
cartilage degeneration in general and more specifically cartilage degeneration secondary to 
meniscectomy. 
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 CHAPTER III: RESULTS     
 
III.A Viable meniscal allograft transplantation - surgical technique 
and long-term clinical results 
In this study, we present the results of a survival analysis of the clinical outcomes of our first 100 
procedures involving transplantation of viable medial and lateral meniscal allografts performed in 
ninety-six patients. The surgical procedure was described in detail. Thirty-nine medial and sixty-one 
lateral meniscal allografts were evaluated after a mean of 7.2 years. Survival analysis was based on 
specific clinical end points, with failure of the allograft defined as moderate occasional or persistent 
pain or as poor function. An additional survival analysis was performed to assess the results of the 
sixty-nine procedures that involved isolated use of a viable allograft (twenty of the thirty-nine 
medial allograft procedures and forty-nine of the sixty-one lateral allograft procedures) and of the 
thirteen viable medial meniscal allografts that were implanted in combination with a high tibial 
osteotomy in patients with initial varus malalignment of the lower limb. 
Overall, eleven (28%) of the thirty-nine medial allografts and ten (16%) of the sixty-one lateral 
allografts had failed. The mean cumulative survival time (11.6 years) was identical for the medial 
and lateral allografts. The cumulative survival rates for the medial and lateral allografts at ten years 
were 74.2% and 69.8%, respectively. The mean cumulative survival time and the cumulative 
survival rate for the medial allografts used in combination with a high tibial osteotomy were 13.0 
years and 83.3% at ten years, respectively. 
It was concluded that transplantation of a viable meniscal allograft can significantly relieve pain and 
improve function of the knee joint. Survival analysis showed that this beneficial effect remained in 
approximately 70% of the patients at ten years. This study identified the need for a prospective 
study comparing patients with similar symptoms and clinical findings treated with and without a 
meniscal allograft and followed for a longer period with use of clinical evaluation as well as more 
objective documentation tools regarding the actual fate of the allograft itself and the articular 
cartilage. 
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 Introduction 
In the well selected patient, viable meniscal allograft transplantation produces good clinical results 
with a satisfactory survival rate at ten years following transplantation
1
. The purpose of this technical 
paper is to present, in detail, a viable medial and lateral meniscal allograft transplantation procedure 
through a parapatellar arthrotomy. The chronological sequence of an associated high tibial 
osteotomy (HTO) or anterior cruciate ligament (ACL) reconstruction is also discussed.     
 
Preoperative considerations 
The transplantation of viable meniscal allografts implies the availability of viable donor tissues, 
cultured in vitro immediately following harvest. Once a patient is deemed to be a candidate for this 
type of procedure, 30 to 50 ml of autologous serum is prepared and frozen at -21°C. The patient’s 
height and weight are documented for subsequent allograft size matching. The waiting time for a 
viable meniscal allograft averages 2 months, ranging from 14 days to 6 months at our institution. 
Once an appropriately sized meniscus allograft is harvested,  the patient is notified and an operation 
is planned within the next 14 days.  In contrast with the use of fresh-frozen or cryopreserved grafts, 
a strict time schedule from harvest to transplantation is mandatory.  
 
Allograft harvest and culture 
The allograft is harvested within 24 hours postmortem in strictly aseptic conditions in the operating 
theatre from donors who have died from a disease of short duration, such as a stroke, or a car 
accident. Sizing of the allograft is based on sex, height and weight of the donor. Donor tissues are 
obtained from the Ghent University Hospital Tissue Bank, which has a strong collaboration with the 
Ghent University Hospital and other hospitals in the region, and has experience in tissue culture. 
This ensures adequate background information on the donor’s medical history and allows quick 
transfer of the harvested allograft material from and to the operation room preserving tissue 
viability. A maximum of 45 years of age is set for the donors. Antemortem administration of 
cytostatic drugs or corticosteroids is an exclusion criterion for allograft harvesting since these 
medications could negatively influence cell viability and metabolism. The allograft is maintained in 
culture for 2 weeks in Dulbecco’s Modified Eagle Medium (DMEM, Gibco Invitrogen Co, 
Merelbeke, Belgium) supplemented with 20% autologous serum prior to transplantation. The 
culture medium is changed every three days and sterility is checked at these intervals. Previous 
studies have demonstrated that meniscus cells remain viable and continue to synthesize their 
extracellular matrix molecules in this culture system
2
.  The purpose of the meniscal tissue culture 
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Figure 1. The lateral viable meniscal allograft is fixed by three  25 gauge needles on a specially designed cork board. 
The synovial tissue is dissected from the allograft meniscus at the menisco-synovial junction level and is discarded. 
 
 
 
 
 
 
 
 
Figure 2. Horizontal sutures are placed every 3 mm through the meniscus allograft starting in the posterior horn. These 
sutures are then fixed in a suture holder in sequence from posteriorly to anteriorly. 
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 period is to allow time for screening of the donor for transmissible diseases according to the 
International Tissue Bank Standards, and to comfortably plan the surgical procedure. 
 
Surgical Technique 
 
ANAESTHESIA AND SURGICAL PREPARATION 
The choice of anaesthesia is made in consultation with the surgeon, the anaesthesiologist and the 
patient and depends on the age, the comorbidity and the history of the patient with regard to 
previous anaesthesia. Most commonly general anaesthesia is preferred at our institution.   
The patient is then positioned supine on the operating table. Prior to surgical preparation, the 
surgeon examines the index knee to assess the following parameters: range of motion, Lachman 
test, antero-posterior laxity in 90 degrees of flexion, pivot-shift test, reversed pivot-shift test and 
stability in varus and valgus at 0 and 30 degrees of flexion. Previous skin incisions are marked. The 
limb is exsanguinated and the tourniquet is inflated. The limb is then prepared with chlorhexidine 
gluconate-alcohol solution (Hibitane, Regent Medical Overseas Limited, Manchester, UK) and 
draped at the mid-thigh level. 
 
ALLOGRAFT PREPARATION  
Just prior to the operation, the allograft is brought to the operating room in the culture container 
filled with culture medium. The labels on the container (donor code, side, sex, height and weight; 
acceptor name, code) are cross referenced with the labels of the patient by both an assistant surgeon 
and the surgeon. The container is carefully opened by the assistant surgeon and the allograft is taken 
out by the surgeon with forceps. Cultures are obtained from the culture medium and the allograft 
itself for sterility control. The allograft is positioned and fixed on a specially designed cork board 
with three 25 gauge needles (Figure 1). With a scalpel, the residual synovial tissue is dissected from 
the allograft meniscus at the meniscosynovial junction level and discarded.  
The upper side of the allograft is marked with a methylene blue skin marker.  
Horizontal 2/0 polydioxanone surgical sutures (PDS II mounted on a double small needle, Ethicon, 
Somerville, NJ, USA) or 2/0 non-absorbable polypropylene sutures (Prolene mounted on a double 
small needle, Ethicon, Somerville, NJ, USA) are placed every 3 mm through the posterior horn, the 
body and the anterior horn of the allograft and fixed onto a specially designed suture holder (holder 
A) (Figure 2). The senior surgeon (RV) prefers the use of 2/0 Prolene sutures for the posterior horn 
since this suture material comes with slightly smaller needles and therefore has easier surgical 
handling in the more narrow posterior joint space. The sutures are fixed onto the suture holder in 
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 sequence from posteriorly to anteriorly. Generally 6 to 8 sutures are needed to cover the complete 
allograft.  
 
LATERAL MENISCAL ALLOGRAFT TRANSPLANTATION 
A curvilinear lateral parapatellar incision of approximately 8 cm is made with the knee in 90 
degrees of flexion to gain acccess to the lateral compartment of the knee joint (Figure 3). 
Anatomical landmarks for this incision are the tibial tuberosity, Gerdy’s tubercle and the 
superolateral corner of the patella. The incision is made 1 cm laterally to the patella, starting 2 cm 
proximal to its superolateral corner and ending in between the tibial tuberosity and Gerdy’s 
tubercle. The joint capsule is then opened and the anterior horn of the lateral meniscus remnant is 
transected. The iliotibial band is released subperiostally from its distal attachment. To further open 
up the lateral compartment, the insertion the lateral collateral ligament (LCL) and popliteus tendon 
(PT) are detached with a curved osteotomy on the femoral side (Figure 4). The center of the 
osteotomy bone block is first predrilled with a 2.7 mm drill. This facilitates subsequent refixation 
with a screw and washer. The osteotomy is done in a clockwise direction from the 8 o’clock 
position to the 4 o’clock position and is approximately 1.5 cm deep and conically shaped. The bone 
block is gently folded out using a bone clamp and then the osteotomy is completed inferiorly from 
the 4 o’clock to the 8 o’clock position using the osteotome. The lateral joint space can now be 
opened up easily 1 to 2 cm by placing the knee in the figure of 4 position in 70 to 90 degrees of 
flexion with the index foot positioned across the contralateral limb (Figure 5). The lateral meniscus 
remnant is trimmed preferably to a stable meniscal rim with a scalpel anteriorly and with 
arthroscopic instruments posteriorly. Most often, the insertion of the posterior horn is still intact and 
in continuity with the tibial plateau. The insertion of the posterior horn is also trimmed to fit the 
allograft. The meniscal rim deserves surgical attention, as it serves as a strong envelope 
encapsulating the medial or lateral compartment of the knee. 
The meniscus remnant level is then marked with a small mosquito clamp anteriorly as landmark for 
the correct level of subsequent fixation of the allograft. Next, the previously prepared viable lateral 
meniscal allograft is introduced into the lateral compartment (Figure 5C). The sutures are taken 
from the holder in the correct sequence from posteriorly to anteriorly and  driven through the 
meniscal rim one by one in an all-inside fashion from inferiorly to superiorly and transferred to a 
second suture holder (holder B), again in a sequence from posteriorly to anteriorly (Figure 6).  The 
allograft is also sutured to the popliteus tendon. We have found on folluw-up arthroscopies that the 
popliteal hiatus will recreate itself naturally. The insertion of the anterior horn of the meniscus is 
not yet sutured at this stage of the operation. Once the sequence of suture transfer from holder A 
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Figure 3. A curvilinear lateral parapatellar incision, approximately 8 cm in length, is made with the knee positioned in 
90 degrees of flexion. Anatomical landmarks are the tibial tuberosity (TT), Gerdy’s tubercle (GT) and the superolateral 
corner of the patella. 
 
 
 
Figure 4. (A) To allow the lateral compartment of the knee joint to be opened, the lateral collateral ligament (LCL) and 
politeus tendon (PT) are released on the femoral side through an osteotomy with use of  a curved osteotome. The 
osteotomy bone block is conically shaped and approximately 1.5 cm deep. It is performed in a clock wise direction from 
the 8 o’clock position to the 4 o’clock position. The bone block is gently folded out using a bone clamp and then 
completed inferiorly from the 4 o’clock to the 8 o’clock position. (B) Line drawing depicting the osteotomy.   
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Figure 5. (A) The lateral joint space width PRIOR to the osteotomy at the femoral insertion of the lateral collateral 
ligament. (B) Widening of the lateral compartment joint space can be clearly observed after the osteotomy. The lateral 
compartment can be opened up easily 1 to 2 cm by placing the knee in the figure of 4 position in 80 degrees of flexion 
with the index foot across the contralateral limb. (C) This facilitates suture placement especially in the posterior part of 
the joint space as well making introduction of the lateral allograft into the joint compartment easier.  
 
A 
C 
B 
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 If an associated high tibial osteotomy
4
 or anterior cruciate ligament
5
 reconstruction is planned, these 
procedures can easily be performed after the posterior horn and body of the meniscus allograft are 
sutured but prior the refixation of the osteotomy, fixation of the anterior meniscal allograft horn and 
closure of the capsule.  
Finally, the osteotomized medial collateral ligament bone block is repositioned and fixed using a 
bone staple. 
The anterior horn of the medial allograft is sutured to the original meniscus remnant similarly as for 
the lateral meniscus transplant and the capsule is further closed using Vicryl 1/0. 
 
Critical concepts 
 
INDICATIONS: 
A viable meniscal allograft transplantation is indicated in the young or middle-aged (<50 years) 
patient, who has undergone a previous total meniscectomy. The patient should complain of 
moderate to severe pain due to excessive joint loading secondary to meniscal deficiency. 
Professional incapacity is commonly present. Joint space narrowing should be limited to grade 0 
(no narrowing) or 1 (<50% narrowing) as measured on plain postero-anterior weight bearing 
radiographs according to the International Knee Documentation Committee system. At this point, 
we do not recommend prophylactic viable meniscus allograft transplantation in the 
meniscectomized but asymptomatic patient. Ideally, degenerative cartilage changes should be 
limited (grade III is considered borderline) and/or focal. If necessary, focal cartilage defects can be 
treated concomitantly by microfracture, mosaicplasty or chondrocyte transplantation. Because of 
the usually mild degenerative cartilage disease, the relative young age of the patients and their 
desire to lead an active lifestyle, these patients are not candidates for a unicompartimental or total 
knee arthroplasty. The lower limb axial alignment should be normal and the knee joint should be 
stable. Otherwise, an associated corrective osteotomy or stabilization procedure is indicated. 
 
CONTRAINDICATIONS: 
Generalized/Grade IV degenerative compartmental cartilage changes
6,7
 
Marked radiographic changes such as femoral condyle flattening and osteophyte formation
8
 
Axial malalignment
6,9,10
 
Ligamentous instability
11
 
Inflammatory joint disease 
A history of infection in the knee 
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Figure 6. (A) The meniscal allograft is tightly sutured to the meniscal rim . (B) Horizontal sutures are driven through 
the meniscal rim one by one in an all-inside fashion from inferiorly to superiorly in a sequence from posterior to 
anterior. 
 
 
 
Figure 7. The bone block of the lateral collateral ligament and popliteus tendon osteotomy is repositioned and fixed 
with a 35 or 40 mm 2.9 AO cancellous screw with spiked washer. 
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 through the meniscal rim (and popliteal tendon) to holder B is completed, the allograft is introduced 
into the lateral compartment by gently pulling on each suture in a sequence from posteriorly to 
anteriorly. Generally, this procedure has to be performed progressively to establish a secure fit of 
the allograft to the meniscal rim. The suture knots are then securely tied and cut. A fine-tipped 
suture driver and knot pusher are frequently required to securely tighten the posterior sutures. The 
knee is now positioned again in a normal 90 degrees flexed position. The bone block of  the lateral 
collateral ligament and popliteus tendon is repositioned and fixed using a 35 or 40 mm 2.9 AO 
cancellous screw with a spiked washer (Figure 7).  
The anterior horn of the allograft is then sutured to the original insertion of the meniscus remnant 
using polypropylene or polydiaxone suture material. The Hoffa fat pad and knee capsule are closed 
using interrupted Vicryl 1/0 (Ethicon, Somerville, NJ, USA) cross stitches after hemostasis.  
 
MEDIAL  MENISCAL ALLOGRAFT TRANSPLANTATION 
A medial parapatellar incision of approximately 8 cm is made with the knee in 90 degrees of flexion 
to gain access to the medial compartment of the knee joint (Figure 8). Anatomical landmarks for 
this incision are the tibial tuberosity and the superomedial corner of the patella. The curvilinear 
incision in made 1 cm medial to these landmarks, starting 2 cm proximal to the superomedial corner 
of the patella and ending at the level of the tibial tubercle. When an associated tibial osteotomy or 
cruciate ligament reconstruction is planned, the incision can be extended distally on the  medial side 
of the tibia. This allows a high opening wedge osteotomy or the harvest of the hamstrings and tibial 
drilling/tunneling for the cruciate ligament reconstruction.  
The knee capsule is subsequently opened and the anterior horn of the medial meniscus remnant is 
transsected. To further open up the medial compartment, the medial collateral ligament is detached 
on the femoral side with an osteotomy 
3
. A flake osteotomy (0.5 to 1 cm in thickness) is done with a 
straight osteotome at the level of the medial femoral epicondyle. The soft tissues posterior to the 
medial collateral ligament are left in continuity. By gently placing the knee in a valgus position, the 
medial compartment can now be opened up in a controlled fashion.  
The remnant of the medial meniscus is trimmed preferably to a stable meniscal rim by scalpel 
anteriorly and by arthroscopic instruments posteriorly. The same degree of attention should be paid 
to this meniscal rim, as in the lateral meniscal transplantation.  
The prepared meniscus allograft can be introduced into the medial joint compartment and fixed in a 
way similar to the previously described lateral meniscus allograft transplantation.  
The knee is then repositioned in a 90 degrees flexed position.  
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Figure 8. A curvilinear medial parapatellar incision, approximately 8 cm in length, is made with the knee positioned in 
90 degrees of flexion. Anatomical landmarks for this incision are the superomedial corner of the patella and the tibial 
tuberosity (TT). The incision can easily be extended distally in case of an associated opening wedge tibial osteotomy or 
an anterior cruciate ligament reconstruction procedure. 
 
 
 
Figure 9. Anteroposterior and lateral standing radiograph, made 1 year after a lateral viable meniscal allograft 
transplantation, showing the additional anterior horn meniscus allograft horn fixation with an anchor and the fixation of 
the lateral collateral ligament/popliteus tendon osteotomy with a screw and washer. 
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 PITFALLS: 
The primary pitfall of long-term succesful meniscus allograft transplantation is good fixation in 
order to obtain stable healing and ingrowth of the allograft. Two requirements have to be fullfilled 
to achieve this. First, the posterior meniscus remnant rim should not be transsected or resected 
during debridement. It is our conviction that this rim not only serves as an important envelope 
encapsulating the knee joint compartment and thus preventing excessive extrusion of the graft but 
secondly, also provides as site for anatomical and stable fixation of the allograft. Several in vitro 
studies have shown that graft fixation using bone plugs is superior to techniques without bone plug 
fixation
12-15
. These in vitro studies, however, do not take into account the biological healing process 
of the allograft to the meniscal rim. The bone plug fixation procedure itself induces damage to the 
tibial articular cartilage surface, as well as potentially damaging the femoral side due to incongruity 
if the original anatomy is not duplicated
16
. Moreover, bone-plugs fixation necessitates the need for 
near-perfect allograft sizing. Not using bone plug fixation eliminates additional cartilage damage to 
the tibial plateau and simplifies custom tailoring of the allograft to the joint compartment. 
Therefore, we still prefer the use of all inside-sutures over the bone-plug fixation techniques or 
arthroscopic suture techniques with arrows or darts. This open technique also facilitates addressing 
small osteophytes on the femoral condyle or tibial plateau which could cause mechanical 
impingement and subsequently early failure of the allograft.     
Axial malalignment has been shown to result in a higher failure rate and shorter survival time
6,9,10
. 
Therefore, a corrective osteotomy is indicated in these cases. However, caution is needed because 
architectural changes such as flattening of the condyle are frequently already established in varus 
malaligned meniscectomized knees. As these changes are believed to be contraindications to 
meniscus transplantation, an additional corrective osteotomy will not make these knees suitable for 
a meniscus allograft transplantation
7
.  
 
AUTHOR UPDATE: 
To further improve the results of viable meniscal allograft transplantation, we have modified some 
aspects of the procedure since the start of this study.  
Initially, focal articular cartilage defects observed during the preoperative arthroscopic or magnetic 
resonance imaging evaluation would have been left untreated since no surgical treatment was 
considered successful at that time. Extended defects or generalized compartmental degeneration 
were considered, and still are, contraindications
6,7
. More recently, numerous surgical procedures 
have been described for the treatment of focal symptomatic articular cartilage lesions with 
encouraging results. These treatments are based on the transplantation of autologous osteochondral 
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 plugs (mosaicplasty), bone marrow stimulation (microfracture) or the transplantation of isolated 
chondrocytes
17-20
. The current tendency at our department is to fully treat the associated articular 
cartilage defects, the correct timing of the which (either prior to, in association with or after the 
meniscus allograft transplantation) is still controversial and very much dependent on the intended 
treatment. We prefer a microfracture technique for smaller surface articular cartilage defects and 
chondrocyte implantation for larger defects. Ultimately, further controlled studies will be needed to 
analyze any additional beneficial effect of such associated cartilage treatment. For now however, 
the articular surface restoration techniques do not allow extension of the indications for a meniscal 
allograft transplantation in patients with extended cartilage defects or generalized compartmental 
degeneration.  
Another recent modification to the allograft transplantation procedure itself, is the additional 
fixation of the anterior horn of the medial or lateral allograft using an anchor (GII anchor, Depuy 
Mitek Inc, Norwood (MA), USA) to the original anatomical position of the native meniscus (Figure 
9). A previous study performed at our institution demonstrated extrusion of the anterior horn of the 
lateral allograft compared to the position of the anterior horn of a normal meniscus
21
. Although the 
anterior horn is biomechanically of less importance compared to the posterior horn, we hope to 
reduce this extrusion and thus improve the overall biomechanics of the affected compartment by 
this additional fixation device. Future analysis will allow us to come to a conclusion regarding its 
value.   
In the presence of associated mild varus malalignment of the lower limb, we now prefer an opening 
wedge osteotomy to a closing wedge tibial osteotomy
22
. Recent advances in surgical techniques and 
instrumentation, enable us to simply extend the medial incision distally and perform this associated 
procedure. This obviates the need for another, laterally based incision and its potential wound 
problems. Furthermorer, the postoperative rehabilitation protocol of viable meniscus allograft 
transplantation is not influenced or delayed by this associated opening wedge osteotomy. 
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 Introduction 
The meniscus plays an important role in the complex biomechanics of the knee joint. It has 
functions in loadbearing, load transmission, shock absorption, joint stability, joint lubrication and 
joint congruity. Removal of this important anatomical structure eventually leads to degenerative 
changes of the articular cartilage 
1-3
. Therefore, meniscal tissue should be preserved whenever 
possible. In the case of complete loss of the meniscus, transplantation of a meniscus allograft has 
been shown to be a therapeutic option with favourable results in the medium and long term 
 
reducing pain and improving function 
4-7
. These improvements are presumably due to an increase in 
contact area and thus a decrease in contact peak stress when compared to the meniscectomized knee 
8-11
. While decreases in contact stresses can result in pain relief and improved function, there is 
however no reasonable proof that delayed meniscal transplantation prevents or slows down cartilage 
degeneration in either compartment 
6,12
. 
One way to determine the clinical effectiveness of this investigational procedure, is to analyse the 
survival time, especially when patients with different lengths of follow-up are involved. In this 
study, we present a survival analysis of our first 100 viable meniscal allograft transplantations with 
a minimum follow-up of 2 years.  
 
Patients and Methods 
 
PATIENTS 
The indication for a viable meniscal allograft transplantation was the younger patient, who had 
undergone a previous total meniscectomy and who presented with associated moderate to severe 
pain. The patient was not yet old enough to be considered for a knee joint replacement, and had 
good alignment of the lower limb and a stable joint. In case of axial malalignment of the lower limb 
or instability of the knee joint, a corrective osteotomy or stabilisation procedure was performed at 
the time of transplantation. 
One hundred and five (105) meniscal allografts were transplanted in 101 patients between 1989 and 
2001. Two patients received bilateral lateral meniscal allografts and two patients received medial 
and lateral meniscal allografts in the same knee. All operations were performed at different points 
of time. 
The age at transplantation was 35.0 years (SD: 6.7 yrs, range 18-47 yrs). Four meniscal allografts 
were transplanted in 4 patients from abroad, who could not be contacted after the operation for 
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 scoring. One patient was lost to follow up immediately after the transplantation procedure. This 
resulted in 100 meniscal allografts being available for the survival analysis with a mean follow-up 
of 7.2 years (S.D.3.6 yrs, range: 2-14.5 yrs) and a minimum follow-up of 2 years. The follow-up 
rate was 95.2%. 
Thirty-nine (39) medial allografts and 61 lateral allografts were implanted into 70 men and 26 
women. 
For all patients the postoperative lower limb alignment was assessed on weightbearing 
roentgenograms by measuring the anatomical femorotibial axis. These measurements were 
performed in duplicate by a single observer with a one-month interval between observations 
(Intraclass Correlation Coefficient=0.851, p<0.001, Spearman’s Rho test). The roentgenograms 
were taken at the time of osteotomy healing or within a 6-month period postsurgery (Table 1 and 
appendix). 
The articular cartilage status was evaluated at the time of transplantation and at the time of failure 
using a modification of the Outerbridge grading system. For example, a lesions that was graded 
between grade III and IV, was recorded in our file as 3/4  and was given a value of 3.5 (Table 1 and 
appendix). Also, a grade V was also added to the Outerbridge system; it indicated bone on bone 
contact.      
 
SURGICAL TECHNIQUE 
All patients underwent viable meniscal allograft transplantations. The allograft was harvested 
within 24 hours postmortem in strictly aseptic conditions in the operating theater. Donors tissues 
were obtained from the Ghent University Hospital Tissue Bank. The donors died from a short 
disease; in the majority of cases the cause of death was a cerebrovascular incident or a car accident. 
A maximum of 45 years of age was set for the donors. None had received corticosteroids or 
cytostatic drugs. The allograft was maintained in culture for 2 weeks in Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco Invitrogen Co, Merelbeke, Belgium) supplemented with 20% autologous 
serum prior to transplantation. Previous studies have demonstrated that meniscus cells remain 
viable and continue to synthesize their extracellular matrix molecules in this culture system 
13
. 
During the meniscal tissue culture period, there was ample time to screen the donors for 
transmissible diseases.  
All patients were operated on by the senior surgeon (RV). Access to the knee joint was achieved by 
a lateral or medial parapatellar arthrotomy. The insertion of the lateral collateral ligament and 
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 Table 1. Overview of anatomical femorotibial alignment (degrees (DEG)± standard deviation (S.D.)) and cartilage 
status according to the Outerbridge classification per subgroup of allografts (grade ± standard deviation (S.D.)).  
 
 ALIGNMENT CART PRE 
 DEG. S.D. GRADE S.D. 
MMT 5.3 ±2.7 2.6 ±0.8 
MMT+HTO 7.1* ±2.8 2.9** ±0.8 
isol.MMT 4.3* ±2.3 2.4** ±0.7 
LMT 6.1 ±2.5 2.5 ±1 
isol.LMT 6.0 ±2.2 2.4 ±1 
 
* Femorotibial axial aligment of MMT+HTO vs. Isol.MMT, p=0.006 (MWU-test) 
** Cartilage degeneration according to Outerbridge of MMT+HTO vs. Isol.MMT, p=0.062 (MWU-test) 
 
 
 
 
 
 
 
 
 
Table 2. Overview of types of concomitant surgery: combined medial and lateral meniscal allograft in the same knee 
joint (MMT+LMT), high tibial osteotomy for varus malalignment of the lower limb (HTO), femoral varus osteotomy 
for valgus malalignment (FVOS), anterior cruciate ligament reconstruction (ACL RECON), osteochondral plug transfer 
(OPT), microfracture (M#) and isolated allograft procedures (isol.PROC). 
MMT= viable medial meniscal allograft 
LMT= viable lateral meniscal allograft 
* 2 patients received a medial and lateral meniscal allograft in the same knee joint, this results in a total of 4 allografts. 
 
 MMT+LMT HTO FVOS ACL RECON OPT M# Isol. PROC TOTAL 
 N % N % N % N % N % N % N % N % 
MMT 2* 5.2 13 33.0 0 0.0 3 8.0 0 0.0 1 2.5 20 51.3 39 100 
LMT 2* 3.3 2 3.3 2 3.3 0 0.0 4 6.5 2 3.3 49 80.3 61 100 
TOTAL 4*  15  2  3  4  3  69  100  
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 popliteus tendon or the medial collateral ligament was detached through an osteotomy on the 
femoral side 
14
. The osteotomy fragment was later restored by screw fixation or stapling. The 
meniscal remnant was excised leaving only a bleeding meniscal rim. The meniscal rim deserves 
surgical attention, as it serves as a strong envelope encapsulating the medial or lateral compartment 
of the knee. The rim should not be resected nor transsected during the operation. Doing so would 
lead to a breach in the envelope. The viable meniscal allograft was then securely sutured to this rim 
using horizontal polydioxanone surgical sutures (PDS II, Ethicon, Somerville, NJ, USA) every 3 
mm in an all-inside fashion. Bone block fixation to the tibial plateau was not used to augment 
meniscal fixation. Instead the anterior and posterior horns of the transplanted meniscus were sutured 
to the remnant native horns on the tibia. This procedure has been published in detail elsewhere
14
. 
Postoperative rehabilitation comprised 3 weeks of non-weightbearing with mobilization of the knee 
within pain limits with limitation of flexion to 60 degrees. After 3 weeks, the patients were allowed 
to flex the knee to 90 degrees and to start partial weightbearing. At 6 weeks, all patients were 
allowed to walk with one crutch. 
 
CONCOMITANT PROCEDURES 
Concomitant surgical procedures were judged to be essential in a few selected cases and included: a 
high tibial osteotomy (HTO), femoral varus osteotomy (FVOS), anterior cruciate ligament repair, 
osteochondral plugs or microfracturation (Table 2). At the time of meniscal allografting a high tibial 
osteotomy was performed in 13/39 patients with medial allografts and in 2/61 with lateral allografts 
(Table 2). All were valgus osteotomies. The indication for a concomitant HTO in the case of a 
medial transplant was varus malalignment of the lower limb. HTO was also performed in 2 of  61 
patients with lateral allografts to ensure decompression of the medial compartment because of 
articular cartilage degeneration in both the medial and lateral compartment. It was thought that by 
shifting the mechanical axis towards the lateral compartment, the degenerated medial compartment 
could be decompressed while the lateral compartment was protected by the lateral allograft. This 
procedure was only performed twice, in the early nineties. Two lateral meniscal allograft 
transplantations were associated with a femoral varus osteotomy to correct valgus malalignment.  
Reconstruction of an anterior cruciate ligament (ACL) at the time of transplantation was performed 
in 3 of the medial allograft cases and with none of the lateral allografts (Table 2). The 
reconstruction was performed using an intra-articular double-loop tibialis posterior tendon allograft 
following a technique described previously 
15
.
 
The population analyzed thus consisted of patients 
with stable knees or with knees stabilized prior to meniscal allografting. 
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 In most cases, cartilage degeneration at the time of transplantation was limited to Outerbridge grade 
II or beginning grade III changes (Table 1 & E-1) 
16
. Borderline indications for meniscal allograft 
transplantation, i.e. focal grade 4 degenerative cartilage changes, were treated by concomitant 
cartilage surgery such as the autologous osteochondral plug transfer (OATS
®
, Arthrex, Naples, FL, 
USA) (4/63 lateral grafts, no medial grafts) and the microfracture technique (Osteoprep
®
, Linvatec, 
Largo, FL, USA) (1/40 medial allografts and 2/63 lateral allografts) (table 2). All these cases were 
operated on after 1998. Prior to this date, no specific treatment for this type of cartilage lesions was 
performed. 
Two patients underwent transplantation of both a medial and a lateral meniscal allograft in the same 
knee joint as stated earlier. 
Overall, 19 of the 39 (48.7%) medial allografts were associated with another procedure in the index 
knee joint, while only 12 of the 61 (19.7%) lateral allografts underwent concomitant surgery.  
 
CLINICAL EVALUATION OF THE KNEE JOINT 
Since at present, no specific scoring system exists for meniscus surgery, the modified Hospital for 
Special Surgery (HSS) scoring system was used to prospectively evaluate the function of the 
involved knee joint and the meniscal allograft 
17
.
 
This system evaluates pain, function, range of 
motion, flexion deformity and instability of the involved knee (Appendix). Therefore it is an 
indicator of overall knee function 
17
.
 
This knee rating system has been used to determine knee 
function in previous reviews of meniscal allografting procedures and of fresh osteochondral 
allografting procedures in combination with meniscal allografting 
14,18,19
. 
Since meniscal allografting specifically relieves pain and improves function, the pain score and 
functional score of the modified HSS system were used for the evaluation of the clinical outcome 
and for the survival analysis 
4-7
. The involved knee joint was evaluated by experienced examinators 
preoperatively and postoperatively on a yearly basis.  
Statistical comparison between the preoperative pain and function score and the postoperative 
scores at latest follow-up or at the time of failure was performed with the use of the non-parametric 
Wilcoxon signed ranks test, since the postoperative score distribution was determined to be non-
normal according to the Kolmogorov-Smirnov and Shapiro-Wilk tests (P<0.05). Accordingly, 
median score values with the 25
th
  and 75
th
 percentile are presented for all subgroups, as well as 
mean scores ± standard deviation. The level of significance was set at P<0.05. 
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 CLINICAL KAPLAN-MEIER SURVIVAL ANALYSIS 
Survival analysis was based on specific clinical end-points. A failure of the allograft was defined as 
(1) moderate or severe occasional or persistent pain or (2) poor knee function. A modified HSS 
subscore for pain lower than 30 indicates moderate occasional or persistent pain. A modified HSS 
function score lower than 80 was arbitrarily chosen to define poor function.  
Second-look arthroscopies were performed in case of failure or for investigational purposes. 
A number of patients agreed to undergo an investigational follow-up arthroscopy of the knee joint 
at the time of operative removal of a fixation screw or staple, or another procedure not related to the 
knee joint. The indication for removal of the device was frequent irritation of the soft tissues around 
it. Data from these investigational follow-up arthroscopies were used for a separate analysis 
20
. At 
the time of second-look arthroscopy the integrity of the meniscal allograft and its capsular 
attachment, as well as the appearance of the articular cartilage surface were evaluated. A graft that 
had failed mechanically causing a pain score and/or function score below 30 or 80, respectively, 
was characterized by either severe degeneration of the allograft or allograft-capsular detachment 
noted at the time of the second-look arthroscopy. Prominent degenerative articular cartilage changes 
were considered to be the consequence of a malfunctioning meniscal allograft, even if the allograft 
itself showed limited or no signs of degeneration. 
In the case of mechanical failure due to major degeneration and/or tearing, partial resection of the 
meniscal allograft was performed using standard procedures. In the case of mechanical failure due 
to allograft-capsular detachment, sutures were placed according to a standard protocol 
21
.  
Some knees were converted to a total or a unicompartmental knee arthroplasty. All of these knees 
were included in the survival study as failures. The date of failure was set to be the date of at which 
the modified HSS pain or function score fell the threshold.   
Postoperative magnetic resonance imaging (MRI) was performed in a subset of patients for separate 
analysis 
22
. Although MRI has an established role in the diagnosis of meniscal pathology, its value 
in the postoperative assessment of meniscal allografts is less clear. The correlation between MRI 
findings and the clinical outcome has been reported to be poor 
22-23
. Hence, MRI was not used to 
define a clinical failure situation.  
Survivorship analysis was performed for medial (MMT) and lateral (LMT) meniscal allografts 
separately. Since a large number of these allograft procedures were associated with a concomitant 
procedure, an additional survival analysis was performed of isolated allograft procedures 
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 (Isol.MMT and Isol.LMT). A number of medial allografts were combined with an HTO. Therefore, 
this group (MMT+HTO) was also analysed.  
Two patients died during follow up. The causes of death were not related to the allograft 
transplantation procedure. For these two patients, the most recent HSS scores were used. Since 
these modified HSS system scores were higher than the threshold, these data were included in the 
survival analysis, and the allografts were considered not to be failures. 
Kaplan-Meier survivorship analysis was performed using SPSS 11.0 software for Windows XP, 
based on the endpoint criteria as stated earlier. The analysis examined the distribution of times 
between time of meniscal allograft transplantation and failure. However, this data included some 
censored cases. Censored cases were cases for which the second event, i.e. failure, was not recorded 
(in this case, allografts that had not failed at the end of this study). The Kaplan-Meier procedure 
was a method of estimating time-to-event models in the presence of censored cases.  
The study protocol was approved by the Ethics Committee of the Ghent University Hospital and 
informed consent was obtained from each patient enrolled in this study. 
 
FAILURE ANALYSIS 
To test possible predictors of clinical failure, a comparison of the mean values of (1) the initial 
cartilage status, (2) femorotibial alignment, (3) preoperative pain score and (4) preoperative 
function score between failures vs. non-failure in each subgroup was performed using the Mann-
Whitney test. The level of significance was set at P<0.05. 
Observed progression of articular cartilage or meniscal allograft degeneration at the time of failure, 
was measured by subtracting the initial articular cartilage (Outerbridge) grade from the grade at 
time of failure. Meniscal allograft status was considered normal (0 points) at the time of 
transplantation it was scored as normal (0 points), minor degeneration (1 point) or severe 
degeneration (2 points). Possible correlations between these two parameters were investigated using 
the non-parametric two-tailed Spearman’s Rho correlation test.  
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Table 3. Comparative study of overall preoperative and postoperative pain scores (at time of latest follow-up or at time 
of failure) as well as for each subgroup. Median (25
th
 percentile-75
th
 percentile) and mean values (± Standard 
Deviation) are presented with their respective P-values. A significant improvement for all subgroups was observed. 
 
 PAIN SCORE (MAX. 50) 
 PREOPERATIVE  POSTOPERATIVE  
 median  P25-P75 mean S.D. median  (P25-P75) mean S.D. 
P-
value 
FOLLOW-
UP(y) 
MMT 10 10-20 11.9 3.9 40 30-45 34.2 17.2 0.000 8.5 
MMT+HTO 10 10-20 14.2 10.0 45 30-50 37.7 16.2 0.008 10.1 
Isol.MMT 10 10-20 11.6 7.7 40 15-50 33.5 18.6 0.001 8.2 
LMT 10 10-20 14.8 9.3 45 40-50 42.7 10.3 0.000 6.2 
Isol. LMT 10 10-20 15.3 9.4 45 40-50 42.7 10.1 0.000 6.3 
OVERALL 10 10-20 13.7 9.0 45 40-50 39.4 13.9 0.000 7.2 
 
 
 
Table 4. Comparative study of overall preoperative and postoperative function score (at time of latest follow-up or at 
time of failure) as well as for each subgroup. Median (25
th
 percentile-75
th
 percentile) and mean values (± Standard 
Deviation) are presented with their respective P-values. A significant improvement for all subgroups was observed. 
 
 FUNCTION SCORE (MAX.100) 
 PREOPERATIVE  POSTOPERATIVE  
 median  P25-P75 mean S.D. median  (P25-P75) mean S.D. 
P-
value 
FOLLOW-
UP(y) 
MMT 60 50-75 58.6 23.6 100 80-100 83.7 25.14 0.000 8.5 
MMT+HTO 60 50-80 62.5 12.1 100 80-100 86.2 22.3 0.032 10.1 
Isol.MMT 65 40-75 58.7 27.0 100 80-100 83.7 26.3 0.014 8.2 
LMT 60 50-70 61.1 18.4 100 90-100 91.64 17.4 0.000 6.2 
Isol. LMT 60 50-75 61.5 19.5 100 90-100 92.6 15.9 0.000 6.3 
OVERALL 60 50-70 60.1 20.5 100 90-100 88.6 21.0 0.000 7.2 
 
 
Table 5. Overview of number of cases, number of failures, mean survival time and mean cumulative survival rate at 5 
years, 10 years and 14 years for the total group of medial allografts (MMT), isolated medial allograft procedures 
(isol.MMT) and medial allograft procedures combined with a high tibial osteotomy to correct initial varus malalignment 
of the lower limb (MMT + HTO), the total group of  lateral allografts (LMT) and isolated lateral allograft procedures 
(isol.LMT). 
 
 CUMULATIVE SURVIVAL RATE 
 
CASES FAILURES SURVIVAL 
TIME 5 years 10 years 14 years 
 N % N % mean S.E. % S.E. % S.E. % S.E. 
MMT 39 100 11/39 28.2 11.6 ±0.8 86.2 ±5.7 74.2 ±7.4 52.8 ±14.4 
MMT+HTO 13/39 33 2/13 15.4 13.0 ±1.0 100.0 ±0.0 83.3 ±10.7 83.3 ±10.7 
Isol.MMT 20/39 51.3 7/20 35.0 10.7 ±1.0 84.1 ±8.4 72.4 ±10.6 27.2 ±21.1 
LMT 61 100 10/61 16.4 11.6 ±0.7 90.2 ±4.2 69.8 ±9.7 69.8 ±9.7 
Isol.LMT 49/61 80.3 9/49 18.4 11.4 ±0.8 90.9 ±4.4 66.8 ±11.3 66.8 ±11.3 
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 Results 
 
CLINICAL OUTCOME  
Overall as well as in all investigated subgroups, the modified HSS pain and function scores 
improved significantly from preoperatively to the latest follow-up. The overall median (mean) pain 
score (maximum of 50) improved from 10 (13.7) preoperatively to 45 (39.4) at final follow-up. The 
overall median (mean) function score (maximum of 100) improved from 60 (60.1) preoperatively to 
100 (88.59) at final follow-up out. The pain and function score for the specific subgroups are 
presented in table 3 and 4, respectively. 
 
KAPLAN-MEIER SURVIVAL ANALYSIS  
Using the clinical endpoint criteria for failure, a total of 21 allografts (11 medial allografts and 10 
lateral allografts) failed in 18 patients, including two patients with bilateral lateral transplants and 
one patient with unilateral medial and lateral transplant.   
Two patients with the medial failures had undergone a high tibial osteotomy and one an ACL 
repair. None of the viable lateral meniscal allograft failures had undergone an osteotomy, ACL 
repair, osteochondral plug transfer or microfracture at the time of transplantation, or later.    
Overall, 11 out of 39 (28.2%) medial allografts (mean follow up at failure: 6.0 years, S.D. 3.8 years, 
range: 1.2-13.4 years) and 10 out of 61 (16.4%) lateral allografts (mean follow up at failure: 4.8 
years, S.D. 2.8 years, range: 0.5-9.7 years) failed. 
Based on these results, a Kaplan-Meier survivorship plot was drawn for the lateral and the medial 
allografts (fig 1A). The mean cumulative survival time for the medial meniscal allograft was 11.6 
years (S.E. 0.8 y, 95% C.I. 10.1-13.1) (table 6). The mean survival time for the lateral meniscal 
allograft was 11.6 years (S.E. 0.7 y, 95% C.I. 10.3-12.9) (Table 5). 
The cumulative survival rate for the medial allograft at 5 years was 86.2% (S.D. 5.7%), at 10 years 
74.2% (S.D. 7.4%) and at 14.5 years 52.8% (S.D. 14.4%). Cumulative survival rates for the lateral 
transplant at 5, 10 and 14 years were 90.3% (S.D. 4.2%), 69.8% (S.D. 9.7%) and 69.8% (S.D. 
9.7%), respectively. The survival plots for the medial and lateral allograft do not differ significantly 
( p=0.733, log rank test).  
An additional survival analysis was performed on 69 of  100 isolated allograft procedures (20 of  39 
medial allografts and 49 of 61 lateral allografts). The Kaplan-Meier plot is drawn in figure 1B. 
Overall, 7 out of 20 (35.0%) isolated medial allografts and 9/49 (18.4%) isolated lateral allografts 
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Figure 1. Kaplan-Meier cumulative survival plots. Abscissa: years of follow-up. Ordinate  : percentage of cumulative 
survival. MMT: total group of medial meniscal allograft transplantation cases. MMT+HTO: medial meniscal allografts 
transplantation combined with a high tibial osteotomy to correct varus malalignment of the lower limb. Isol.MMT: 
isolated medial meniscal allograft transplantation. LMT: total group of lateral allograft transplantation cases. Isol.LMT: 
isolated lateral meniscal transplantation  (A) Kaplan-Meier survival plot of total group of medial meniscal allografts vs. 
total group of lateral meniscal allografts, (B) Kaplan-Meier survival plot of isolated medial meniscal allografts vs. 
isolated lateral meniscal allografts, (C) Kaplan-Meier survival plot of medial meniscal allograft transplantation 
combined with a high tibial osteotomy vs. isolated medial meniscal allografts. Cumulative survival rates (%±S.E.) at the 
5 years, 10 years and 14 years time point for the investigated patient groups are given in table 5.  
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 failed after a mean period of 6.8 years (S.D. 4.6 years, range 1.2-12.2 years) and 4.8 years (S.D. 2.9 
years, range 0.5-9.7 years), respectively. The mean cumulative survival time for isolated medial 
meniscal allografts was 10.7 years (S.E. 1.0 y, 95% C.I. 8.8-12.6) (Table 4). The mean survival time 
for isolated lateral meniscal allografts was 11.4 years (S.E. 0.7 y, 95% C.I. 9.9-12.85). The 
cumulative survival rate for isolated medial allografts at 5 years was 80.3% (S.D. 8.9%), at 10 years 
72.4% (S.D. 10.6%) and at 13.4 years 27.2% (S.D. 21.1%). The cumulative survival rates for 
isolated lateral transplants at 5, 10 and 14 years were 90.9% (S.D. 4.4%), 66.8% (S.D. 11.3%) and 
66.8 % (S.D. 11.3%), respectively. The survival plots for the isolated medial and lateral allograft 
procedures do not differ significantly (p=0.680, log rank test).  
Since a large number of medial transplants were specifically combined with an HTO (n=13), a 
comparison was made between those with and without an associated HTO. Only 2 out of 13 
(15.4%) with an HTO failed versus 7 out of 20 (35%) with an isolated transplant. The survival plot 
is shown in fig 1C. The mean cumulative survival time and survival rate for the medial allografts 
with associated HTO is 13.0 years (S.E. 0.9 years, 95% C.I. 11.1 – 15.0) and 83.3% (S.D. 10.7%) at 
10 years (table 4). The difference was not statistically significant (p=0.156, log rank test) due to the 
low number of these cases.  
 
FAILURE ANALYSIS 
Between failure cases and non-failure cases in each subgroup, no significant difference was 
observed concerning the initial cartilage status, femorotibial alignment, or the preoperative function 
score. The preoperative pain score, however, differed significantly between failure cases and non-
failure cases for both the medial allograft transplantation subgroup (MMT) as well as for the 
isolated medial allograft transplantation group (Isol.MMT) (P=0.008 and 0.013 respectively). This 
difference was not observed in the remaining subgroups (Table 6) . 
Seventeen out of a total of 21 (81%) failure cases (9 MMT/8 LMT) were characterized by a 
progression of articular cartilage degeneration and 20 of 21 (95%)(11 MMT/9 LMT) failure cases 
showed progression of meniscus allograft degeneration at the time of failure. In this group of 
failures, at arthroscopy a total of 8 allografts showed severe degeneration whereas 12 allografts 
showed only minor degenerative changes. One of the failures, a case of capsular detachment, 
showed a normal meniscal allograft. Degenerative cartilage changes were classified as Outerbridge 
grade V in 9 cases, grade IV in 2, grade III in 6, grade II/III in 2 and grade II in 2 cases (Appendix). 
Out of these 21 knees, 9 were converted to a total or unicompartmental knee prosthesis (6 medial 
allografts, 2 lateral allografts, 1 unilateral medial and lateral allograft) after a mean period of 6.3 
65
 years (S.D. 3.6 years, range: 1-12 years), due to progression of cartilaginous (9 cases grade V, 1 
case grade III) and/or meniscal (5 cases severe degeneration, 5 cases minor degeneration) 
degenerative changes. Two allografts underwent reattachment because of meniscocapsular 
detachment (1 medial allograft, 1 lateral allograft). Both these healed uneventfully. 
Higher grades of articular cartilage degeneration at the time of failure were associated significantly 
with more severe degeneration of the meniscus allograft (Spearman Rho correlation coefficient: 
0.509, P=0.018, indicating a moderate correlation) 
Detailed scatterplots of these articular cartilage and meniscus allograft degenerative changes is 
depicted in the appendix.     
 
Discussion 
The comparison of already published results to our results is difficult due to the large differences in 
meniscal preservation techniques, types of surgical fixation, the concomitant procedures used, the 
clinical scoring systems and, very importantly, the follow-up time 
24,25
.  
This study has shown that medial and lateral meniscal allograft transplantation significantly reduces 
pain and improves function of the involved knee joint as measured by the modified HSS score. Our 
findings substantiate the previously published results on the clinical success of this procedure 
4,7,24-
26
.  
Since clinical outcome and success rates of any surgical procedure are strongly dependent on the 
length of follow-up, we performed a Kaplan-Meier survival analysis. In this survival analysis it is 
assumed that all patients had their operation simultaneously. We thus compared survival time and 
rate for different groups of patients after viable meniscal allograft transplantation  In our series, 
mean survival times and cumulative survival rates are comparable between lateral and medial 
allografts. In contrast, in the van Arkel and de Boer series a considerable difference was noted in; a 
mean survival time of 9.25 years and 5.75 years and a survival rate of 76.54 % at 10 years and 
50.6% at 9 years were reported in their study for lateral and medial allografts, respectively 
27
. In 
their study, the Lysholm score and arthroscopic findings were used to define clinical failures of 
cryopreserved allografts fixed with a comparable soft-tissue fixation technique 
27
. The higher 
survival time and rate for the medial allografts in our series, when compared with data published 
elsewhere, can be attributed to the lower number of ACL-deficient knees in our series
27
. Increased 
anterior tibial translation due to ACL deficiency is known to induce higher stress on the medial 
meniscus and therefore can induce secondary graft detachment and graft failure 
27
.
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 We were able to perform a survival analysis on 20 cases of isolated medial allografts and 49 cases 
of isolated lateral allografts. Again, comparable survival times and rates were observed.  
Different failure rates and survival times were noted when isolated medial meniscus allografts with 
a well-aligned lower limb were compared to medial meniscal allografts combined with an HTO to 
correct varus malalignment. The medial allograft combined with an HTO appears to survive longer 
and to result in less failures. We hypothesize that the shift of the mechanical axis towards the lateral 
compartment unloads the medial meniscal allograft and thus makes it less prone to failure, even 
though the initial cartilage degeneration at the time of transplantation was more severe in the 
osteotomized group. From this, however, it cannot be concluded that an HTO should be performed 
in association with a medial meniscal transplantation in the case of normal axial alignment. Rather, 
it can be concluded that a medial meniscal allograft transplantation in a varus aligned knee should 
be combined with an HTO since varus malalignment is an absolute contraindication to medial 
meniscal allograft transplantation 
5,18,25-28
. 
Overall, we report a failure rate of 21 out of 100 at a mean follow-up of 7.1±3.6 years for both 
lateral and medial viable allografts. A failure rate of 28.2% at a mean follow-up of 8.3±4.0 years for 
the medial allograft group vs. 16.4% at a mean follow-up of 6.2±3.2 years for the lateral allograft 
group, was observed. The overall higher failure rate for the medial allografts when compared to the 
lateral allografts can be explained by the longer mean follow-up of the former. This is due to the 
fact that the number of indications for medial allograft transplantation at our institution was higher 
in the early years of this study. The number of patients with a total meniscectomy in the medial 
compartment and associated pain has dropped since then. However, because the lateral meniscus 
plays a greater role in stress protection, a lateral meniscectomy can result in a painful knee more 
rapidly leading to the higher number of cases requiring lateral meniscal allograft transplantation 
with a lower mean follow-up time 
2
.  
The overall failure rate of viable meniscal allografts is consistent with already published medium-
term and long-term data on deep-frozen and cryopreserved allografts using a bone plug or soft-
tissue fixation technique 
4,5,7
. The observed overall failure rate of 21% is, however, clearly lower 
than the failure rates of deep-frozen, irradiated (44%) or lyophilized allografts 
4,28
.
 
Both 
preservation techniques are known to render the graft acellular and may adversely affect graft 
material properties 
29-32
. In vitro cultured menisci have been shown to remain viable and continue to 
produce extracellular matrix compounds, hence the term ‘viable meniscal allograft’ 
13
. After a two-
week culture period the meniscus is transplanted into the recipient knee. The proportions of cells 
that survive and how long they survive in vivo are unknown. Jackson et al. used DNA probe 
67
 analysis in a goat model and found that all donor cells were rapidly replaced by host cells over a 
period of 4 weeks 
33
. However, a previous study in this department demonstrated the presence of 
donor DNA in the viable human meniscal allograft for as long as 64 months after transplantation, 
indicating that donor cells remain viable for a longer period and that this replacement process by 
host cells is probably slower in the human model 
20
. The biomechanical function of the meniscal 
allograft not only depends on the quality of the surgical fixation technique, but also on the 
phenotype of the cell population of the allograft. It is not known if recipient meniscus-invading 
cells, probably derived from the synovial lining, have the same capacity to produce extracellular 
matrix as have native meniscus cells 
8,34
. It was hypothesized at the start of this study that the use of 
viable meniscal allografts would be more beneficial than using acellular grafts (deep-frozen, 
lyophilized or cryopreserved grafts). In this study, the failure rates and survival times were shown 
to be comparable to already published data but a clear benefit could not be demonstrated. 
Previous studies have shown that meniscal allografts are more prone to failure when implanted into 
severely degenerated or malaligned knee joints 
28,35,36
. Nonetheless, with the numbers available, our 
results did not indicate any significant difference between failure and non-failure cases concerning 
these parameters at the time of transplantation. The preoperative pain score, however, was found to 
be a negative predictor of clinical failure for the overall medial allografts group (MMT) as well as 
for the isolated medial allografts subgroup (Isol.MMT).   
A majority of the failures was characterised by a progressive articular cartilage degeneration in 
combination with meniscal allograft degeneration, or vice-versa. As we did not evaluate the 
articular cartilage and meniscus allograft status in the successful cases at the latest follow-up, we 
can only conclude that articular cartilage degeneration correlates moderately with meniscus 
allograft degeneration at the time of failure. This does indicates an intricate relationship between 
these two articular components.        
Uncertainty still exists about the best surgical fixation technique to use 
37
. Several in vitro 
biomechanical studies on human cadaveric knees have shown superior strength of bone plug 
fixation for both the medial and lateral meniscus over soft tissue fixation 
8-11
. These studies, 
however, have not taken into account the biomechanical behaviour after the allograft has healed to 
the meniscal rim. Until now it has not been documented that bone plug fixation or soft tissue 
fixation leads to a longer survival or better clinical results 
24,25
. 
Finally, this study also has limitations. Firstly, the criteria for failure were based on clinical and 
arthroscopic findings. There may have been meniscal implants that were significantly degenerated, 
torn or unstable but were clinically silent and thus would not be considered a failure. These cases 
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 could have been identified by MRI. MRI has an established role in the diagnosis of meniscal 
pathology, but the correlation between MRI findings and the clinical outcome is still a point at issue 
22,23,38
.  
Secondly, the involved knee joints were evaluated clinically using the modified HSS scoring system 
17
. This scoring system was originally designed for the evaluation of  patients undergoing knee joint 
arthroplasty. When we started our series in 1989 no other clinical scoring system was available to 
evaluate the clinical outcome of meniscal allograft transplantations. Even today, meniscal allograft 
procedures are being evaluated with a variety of scoring systems, indicating the lack of a ‘gold 
standard’ evaluation system. This hampers comparison of results published elsewhere.  
Thirdly, due to the wide variability in surgical techniques, concomitant procedures and clinical 
scoring systems described in the literature, it is impossible to ascertain whether viable meniscal 
allografts has more clinical benefit than cryopreserved or deep-frozen allografts. A controlled study 
should be able to shed some more light on this interesting topic.   
In conclusion, this study has shown that viable meniscal allograft transplantation significantly 
reduces pain and improves function of the knee joint after meniscectomy. This beneficial effect 
remains present in up to approximately 70% of the cases at 10 years post-surgery. Ultimately, this 
study identifies the need for a prospective study comparing patients with  similar symptoms and 
clinical findings treated with and without meniscal allografts, and followed over a longer period 
using clinical as well as more objective documentation tools to measure the actual fate of the 
allograft itself and the articular cartilage. 
 
Appendix: Tables presenting individual patient data, modified HSS scoring system and scatter plots 
of the failure cases can be found on our website at www.jbjs.org .  
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Figure E-1. Scatterplot of failure cases. Abscissa: subgroups. (A) Ordinate: Change is articular cartilage degeneration 
grade according to Outerbridge scale (Cartilage degenerative changes (failure-preop). This was calculated by 
substracting the Outerbridge grade of the articular cartilage at time of transplantation from the grade at time of failure. 
(B) Ordinate: Change is meniscus allograft  degeneration grade (Meniscus degenerative changes (failure-preop). This 
was calculated by substracting the grade of the meniscus allograft at time of transplantation (normal or 0 points) from 
the grade at time of failure. Normal appearance= 0, minor degenerative changes=1, severe degeneration=2. Dots 
represent cases. Bar represents the mean value of change. 
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Legend to Table E-1. Overview of each patient with pertinent data: sex (M/F); age in years; medial or lateral allograft 
(MMT/LMT); concomitant procedure (COM PROC): high tibial osteotomy (HTO); femoral varus osteotomy (FVOS); 
anterior cruciate repair (ACL); osteochondral plug transfer (OPT), microfracture (M#); cartilage status according to 
Outerbridge pre-transplant (CART PRE); femorotibial mechanical axis (AXIS expressed in degrees); follow–up time 
(FU expressed in years); failure (F); comment: total knee prosthesis (TKP), unicompartimental knee prosthesis (UKP), 
suture for allograft-capsular detachment (SUTURE), unrelated death (†); meniscus status at time of failure (MEN 
POST; severe,minor,normal); cartilage status according to Outerbridge at time of failure (CART POST). 
 
CASE SEX AGE MMT/LMT CON PROC CART PRE AXIS FU FAILURE COMMENT MEN POST CART POST 
1 M 34 MMT HTO 3/4 14 14,54     
2 M 48 MMT HTO 2 3 14     
3 M 37 MMT HTO 2/3 5 13,95     
4 M 35 LMT  - 3/4 7 13,95     
5 M 34 MMT  - 2 0 13,63     
6 M 28 MMT  - 3/4 3 13,39 F TKP SEVERE 5 
7 M 32 LMT  - 1 8 12,88     
8 M 30 LMT  - 1/2 5 12,58     
9 M 32 MMT HTO 4 6 11,79     
10 F 40 MMT HTO 2 6 11,78     
11 F 27 LMT  - 2/3 7 11,72     
12 F 26 MMT  - 3/4 4 11,66     
13 M 31 MMT  - 3 4 11,3 F UKP SEVERE 5 
14 M 39 MMT  - 2/3 4 11,26     
15 M 29 MMT  - 1/2 8 11,25     
16 M 31 MMT HTO 2/3 8 11,02     
17 M 32 MMT HTO 4 8 10,88     
18 M 36 MMT  - 2/3 0 10,72  †   
19 M 36 MMT  - 2/3 4 10,42     
20 M 42 MMT HTO 3/4 5 10,35     
21 M 31 LMT   4 5 10,35     
22 M 38 MMT HTO 1/2 8 10,33     
23 F 40 LMT FVOS 4 0 10,23     
24 M 43 MMT ACL 4 3 10,06     
25 F 29 MMT  - 1/2 2 10,05     
26 M 31 MMT  - 3/4 2 9,87     
27 M 22 MMT ACL 1/2 4 9,87     
28 M 39 LMT  - 1 6 9,73     
29 M 50 LMT  - 4 8 9,72     
30 M 36 LMT  - 3/4 10 9,67 F  SEVERE 4 
31 M 45 LMT  - 3 8 9,67     
32 M 45 LMT  - 4 7 9,42     
33 M 50 LMT  - 4 8 9,36     
34 M 31 MMT  - 1/2 4 9,09     
35 M 37 LMT  - 3/4 9 8,99     
36 M 41 LMT  - 1/2 4 8,98     
37 M 33 MMT HTO 2/3 5 8,95     
38 M 29 LMT  - 4 9 8,78     
39 M 32 MMT  - 2/3 6 8,32     
40 M 40 MMT  - 1/2 8 8,32     
41 M 32 LMT  - 3/4 8 8,24     
42 F 33 LMT  - 3 10 7,93     
43 M 33 LMT  - 3 6 7,85 F TKP SEVERE 5 
44 M 37 MMT  - 3 2 7,77 F  SEVERE 3 
45 F 31 LMT HTO 2/3 10 7,77     
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46 F 38 MMT  - 1/2 7 7,75     
47 F 39 MMT  - 2/3 2 7,62 F  MINOR 3 
48 M 43 LMT  - 4 7 7,5     
49 F 30 LMT  - 2/3 7 7,42     
50 F 34 LMT  - 2/3 3 7,3     
51 F 45 LMT  - 1/2 7 6,65     
52 M 33 LMT  - 2/3 8 6,65     
53 F 30 LMT  - 1/2 7 6,45     
54 M 40 LMT HTO 2/3 8 6,29     
55 M 29 LMT  - 1/2 4 6,06     
56 M 50 LMT  - 1/2 7 5,99 F TKP MINOR 5 
57 M 28 LMT  - 2 6 5,87     
58 F 29 LMT  - 2/3 5 5,85     
59 F 33 LMT  - 1/2 3 5,71     
60 F 16 LMT  - 0 6 5,71     
61 M 38 LMT OPT 3/4 8 5,71     
62 F 44 MMT HTO 3/4 8 5,7 F TKP SEVERE 5 
63 M 23 LMT  - 2/3 4 5,46 F  MINOR 3 
64 M 36 MMT HTO 3 10 5,37 F TKP SEVERE 5 
65 M 38 LMT  - 2/3 5 5,37     
66 M 30 LMT  - 1/2 6 5,28     
67 F 27 LMT  - 2 9 5,15 F  MINOR 3 
68 M 25 LMT OPT 1/2 10 5     
69 M 46 LMT  - 2/3 8 4,8 F TKP MINOR 5 
70 M 37 LMT  - 2 7 4,75     
71 M 27 LMT  - 1/2 2 4,55 F  MINOR 3 
72 M 35 LMT  - 2/3 5 4,42     
73 M 46 MMT  - 2/3 8 4,25 F TKP MINOR 3 
74 M 24 LMT OPT 3/4 7 4,2     
75 M 35 LMT  - 1/2 8 4,17     
76 F 40 LMT  - 3 4 4,08     
77 F 33 LMT FVOS 3/4 2 4,02     
78 F 35 MMT  - 2/3 7 4,02     
79 M 38 LMT  - 2/3 6 3,85     
80 M 42 LMT  - 1/2 5 3,79     
81 M 40 MMT  - 1/2 5 3,78 F TKP MINOR 5 
82 F 39 LMT  - 2 3 3,6     
83 M 35 LMT  - 3 4 3,47     
84 F 36 LMT  - 1 7 3,3     
85 F 17 LMT OPT 4 8 3,25     
86 M 38 MMT  - 1/2 6 3,25     
87 M 32 MMT M# 2/3 3 2,93     
88 M 39 LMT M# 3/4 2 2,93     
89 M 35 MMT ACL 2/3 4 2,76 F  MINOR 2/3 
90 M 35 LMT M# 2/3 9 2,73     
91 M 36 MMT HTO 3/4 6 2,5     
92 M 21 LMT  - 2/3 3 2,5     
93 M 42 LMT  - 1/2 5 2,48 F  MINOR 2 
94 M 33 MMT  - 3/4 4 2,4  †   
95 M 29 LMT  - 1/2 6 2,3 F SUTURE MINOR 2 
96 F 32 LMT  - 2/3 2 2,18     
97 F 40 LMT  - 2/3 10 2,18     
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98 M 36 LMT  - 2/3 3 1,48 F SUTURE NORMAL 2/3 
99 M 40 MMT  - 2 6 1,18 F TKP MINOR 5 
100 M 44 LMT  - 4 4 0,47 F  SEVERE 4 
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III.B Viable meniscal allograft transplantation - long-term 
anatomical preservation 
In the first study we present the clinical, radiological and MRI outcome of the meniscus graft and 
the articular cartilage after forty-two meniscus allograft transplantations in 41 patients with a 
minimum follow-up of 10 years. 
A total of 27 medial and 15 lateral meniscal allografts were transplanted. Eleven of the medial 
allograft procedures were associated with a high tibial osteotomy. The patients were evaluated 
clinically at the time of transplantation and at the final follow-up using the modified HSS scoring 
system. The KOOS score was used as an evaluation tool for patientrelated outcome at the final 
follow-up. Joint space width narrowing and Fairbank changes were radiological outcome 
parameters, which were available for 32 patients. Femoral and tibial cartilage degeneration, graft 
extrusion and signal intensity were scored on MRI scans obtained in 17 patients approximately one 
year after transplantation and at the final follow-up (>10 years). For statistical analysis the patients 
were divided into 3 groups: lateral meniscal allograft (LMT), medial meniscal allograft 
transplantation with a high tibial osteotomy (MMT+HTO) and without (MMT). 
The modified HSS score revealed a significant improvement in pain and function at the final 
follow-up for all groups. Further analysis also revealed that an MMT+HTO procedure resulted in a 
greater improvement at the final follow-up when compared to MMT. 
Nonetheless, the KOOS scores obtained at the final follow-up revealed the presence of 
substantial disability and symptoms, in addition to a reduced quality of life. Radiographical 
analysis revealed no further joint space narrowing in 13/32 knees (41%). Fairbank changes 
remained stable in 9/32 knees (28%). MRI analysis showed no progression of cartilage 
degeneration in 6/17 knees (35%). An increased signal intensity of the allograft was present, 
as was partial graft extrusion in the majority of patients at the final follow-up. Seven cases 
had to be converted to a total knee arthroplasty during the follow-up; the overall failure rate 
was 18%. 
Long-term results after viable meniscus allograft transplantation are encouraging in terms of pain 
relief and improvement of function. Despite this significant improvement, substantial disability and 
symptoms were present in all investigated subgroups. Progression of further cartilage degeneration 
or joint space narrowing was absent in a considerable number of cases, indicating a potential 
chondroprotective effect. 
The aim of the second study was to develop a clinically useful and reproducible method to evaluate 
lateral meniscal extrusion in normal and transplanted knees under different axial loading conditions.  
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Magnetic resonance imaging (MRI) and ultrasound (US) were used to assess meniscal extrusion. 
Both types of imaging were performed at least six months postoperatively (mean 23.5 months). 
Coronal MR images (DESS-3D sequence) of the lateral compartments of 10 normal knees and 17 
transplanted lateral knees were analyzed. Extrusion was defined as the distance measured from the 
femoral condyle or tibial plateau to the outer edge of the meniscus. Subjects were examined in the 
supine position.  
Ultrasound print-outs of the lateral compartment of both knees of  10 patients (transplanted side and 
contralateral normal side) were analyzed. Extrusion cross-sectional area and distance were 
measured just anterior to the lateral collateral ligament: the former was defined as the cross-
sectional area of the meniscus outside the knee, the latter as the greatest distance from a line 
connecting the femur and tibia to the outer edge of the lateral meniscus. Patients were examined in 
the supine position, bipodal stance and unipodal stance. 
The viable meniscal allograft was securely sutured to a bleeding functional meniscal rim. No bone 
blocks were used to fix the allograft, instead the anterior and posterior horn were firmly sutured to 
their enthesis.  
A. MRI Results (tibial): The transplanted lateral meniscus is significantly (p<0.005) more extruded 
in comparison to the normal lateral meniscus. The anterior horn (mean 5.8 mm, SD=2.8) of the 
transplanted lateral meniscus tends to be more extruded than the posterior horn (mean 2.7 mm, 
SD=1.48). The posterior horn of the normal lateral meniscus does not (mean 0 mm) extrude, while 
the mean extrusion of the anterior horn is 0.8 mm (SD= 0.92).  
B. US Results:  The transplanted lateral meniscus is significantly (p<0.005) more extruded than the 
normal lateral meniscus in all patient positions. Both cross-sectional surface and distance are 
equally good parameters to determine meniscal extrusion. There is no statistical difference between 
patient positions. The transplanted lateral meniscus extrudes in the supine position, bipodal and 
unipodal stance 6.43mm (SD=1.84), 6.01mm (SD=1.93) and 6.99mm (SD=2.7), respectively. The 
extrusion surface of the lateral transplanted meniscus is 50.50mm
2
 (SD=15.32), 47.24 mm
2
 
(SD=14.35) and 58.61 mm
2
 (SD=29.65) in the supine position and in bipodal and unipodal stance, 
respectively. The normal lateral meniscus extrudes in the supine position, bipodal and unipodal 
stance respectively 3.77 mm (SD=1.76), 3.94 mm (SD=1.66) and 3.79 mm (SD=1.79). The 
extrusion surface of the normal lateral meniscus is 22.42 mm
2
 (SD=12.54), 23.24 mm
2
 (SD=12.74) 
and  24.79 mm
2
 (SD=10.18) in supine position and in bipodal and unipodal stance, respectively. 
The presented data shows that the transplanted lateral meniscus, without bone block fixation but 
with firm fixation of the horns to the original entheses, extrudes in the lateral direction significantly 
more than the normal meniscus. The transplanted lateral meniscus, however, does not extrude more 
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in the lateral direction under axial load. The anterior horn of both normal and transplanted menisci 
is extruded more laterally than the posterior horn.  
Both methods are adequate to measure laterally directed extrusion of the normal and transplanted 
lateral meniscus, but have distinctive advantages and disadvantages: MRI in this series visualizes 
the complete - from posterior to anterior - meniscal body, but only in the supine, non weight bearing 
position. Using ultrasound one can evaluate the meniscal extrusion in different conditions of axial 
loading, but only from a single examination point. 
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Introduction 
The fibrocartilaginous menisci play an important role in the complex biomechanics of the knee 
joint. They improve joint stability, load distribution, shock absorption and articular cartilage 
lubrication. Surgical removal of this tissue can result in dysfunction and pain in the involved 
compartment and ultimately osteoarthritis
1-6
. These degenerative changes are the result of increased 
peak stresses on the articular cartilage due to a decreased contact area in the meniscectomized 
compartment of the knee. Therefore, meniscal tissue should be preserved whenever possible. 
Hence, in case of complete loss of the meniscus, substitution of the meniscus by an allograft will 
result in a decreased contact pressure on the cartilage surface compared to the meniscectomized 
knee
7-10
. Full restoration of the normal contact pressures by an allograft has nonetheless never been 
obtained in the in vitro setting, irrespective of the fixation method used
7-10
. In the late eighties, 
clinical meniscal allograft transplantation appeared a logical approach to improve function, relieve 
pain and prevent further articular cartilage degeneration
11
.  
Since then, numerous medium-term but only few long-term reports on meniscal allograft 
transplantation have been published, showing a significant improvement in function and relief of 
pain
12-18
. However, it has not been substantiated in the literature that this procedure prevents or 
slows down cartilage degeneration
19
.   
The purpose of this prospective study was to report on the long-term clinical results of viable 
medial or lateral meniscal allograft transplantation in 38 patients out of a total of the 41 (follow-up 
rate 93%) who had undergone this procedure more than 10 years ago We also report on a specific 
subgroup of patients who had a medial allograft transplantation in combination with a high tibial 
osteotomy to correct an initial varus malignement of the lower limb. We hypothesized that viable 
meniscal allografting would significantly reduce pain and increase function of the involved joint in 
the long term. 
To determine the clinical effectiveness, the preoperative modified Hospital for Special Surgery 
(HSS) score was compared with the score at final follow-up (>10 years)
 20
. To ensure that this 
treatment also satisfied the need of the patient, the recently developed patient-related Knee injury 
and Osteoarthritis Outcome Score (KOOS) was included as a primary clinical outcome 
measurement tool at final follow-up
21
.  
 A secondary goal of this study was to document possible graft failure or progressive degenerative 
changes in the articular cartilage using conventional radiology and magnetic resonance imaging as 
objective outcome measuring tools.  When available, standing X-rays and MR images taken shortly 
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after the meniscal allograft transplantation procedure were compared with images acquired at final 
follow-up. Changes is femorotibial joint space width as measured on standing X-rays  has been 
recommended as the primary measure of biological effect in osteoarthritis by expert consensus
22
. 
MR imaging was used to visualize possible progression of degenerative changes in the articular 
cartilage and the transplanted meniscal tissue. 
 
Patients and Methods 
Between 1989 and 1993, 42 meniscal allografts were transplanted in 41 patients (table 1). The 
indication for meniscal allograft transplantation was the young or middle-aged patient who 
presented with moderate to severe pain due to a previous total meniscectomy. These patients were 
not considered for a knee arthroplasty because of the relatively limited and/or focal articular 
cartilage degenerative changes and their relatively young age. In case of axial malalignment of the 
lower limb or instability of the knee joint, a corrective osteotomy or stabilisation procedure was 
performed at the time of transplantation.  
The study group consisted of 35 men and 6 women, with an average age of 35.2 years (range: 22 to 
50 years) at the time of transplantation (table 1). Three patients were lost to follow-up: one patient 
(lateral meniscus allograft) was lost immediately after the operation, 2 patients (medial meniscal 
allograft) died of unrelated causes during follow-up. This resulted in 38 patients (follow-up rate 
93%) with 39 grafts who were available for follow-up in 2004 (mean follow-up time 12.1 years, 
range 10.0-14.8 years) (table 1). Of these, 7 patients (7 grafts) were converted to a total knee 
prosthesis after a mean follow-up of 6.5 years (S.D. 4.3 years) due to a progressive increase of pain 
and decrease of function.These patients were considered failures and were evaluated at the time of 
failure. 
 
Table 1. Overview of the different patient groups. Age: age at the time of transplantation (years). Follow-up: follow-up 
duration (years), excluding patients which were converted to a total knee arthroplasty, lost to follow-up or had died. 
Axial alignment: femorotibial axis measured on standing X-rays after surgery. Outerbridge: Outerbridge grading of 
cartilage degeneration at the time of transplantation. Mean values are given with standard deviation (S.D.). 
 
 MMT (N=16) MMT+HTO (N=11) LMT (N=15) Overall (N=42) 
 mean ±1 S.D. mean ±1 S.D. mean ±1 S.D. mean ±1 S.D. 
Age 33.1 ±6.0 37.2 ±5.2 35.7 ±8.2 35.4 ±6.7 
Follow-up 11.9 ±1.4 12.7 ±1.8 11.8 ±1.5 12.1 ±1.6 
Axial alignment 4.4 ±2.7 6.3 ±3.5 4.7 ±3.6 5.1 ±3.3 
Outerbridge 2.5 ±0.9 3.0 ±1.1 2.7 ±1.1 2.7 ±1.0 
 
At the time of transplantation all articular cartilage degenerative changes were focal: 2 knee joints 
(5%) had Outerbridge grade I degenerative changes of the articular cartilage, 8 (19%) grade I to II, 
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4 (9.5%) grade II, 9 (21.5%) grade II to III, 3 (7%) grade III, 9 (21.5%) grade III to IV, and 7 
(16.5%) grade IV, as documented visually during the arthrotomy
23
.  
The study protocol was approved by the Ethics Committee of the Ghent University Hospital and 
informed consent was obtained from each patient enrolled in this study. 
 
SURGICAL TECHNIQUE 
All patients underwent viable meniscal allograft transplantation. Donor allograft menisci were 
obtained from the Ghent University Hospital Tissue Bank. The donors had died from a short 
disease; in the majority of cases the cause of death was a cerebrovascular incident or a car accident. 
A maximum age of 45 years was set for the donors. None had received corticosteroids or cytostatic 
drugs. The allograft was harvested within 24 hours postmortem in aseptic conditions in the 
operating theatre and maintained in culture for 2 weeks in Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco Invitrogen Co, Merelbeke, Belgium) supplemented with 20% autologous serum 
prior to transplantation. Previous studies have demonstrated that meniscus cells remain viable and 
continue to synthesize their extracellular matrix molecules in this culture system
24
. During the 
meniscal tissue culture period, ample time was available to screen the donors for transmissible 
diseases.  
All patients were operated on by the senior surgeon (RV). Access to the knee joint was achieved by 
a lateral or medial parapatellar arthrotomy. The insertion of the lateral collateral ligament and 
popliteus tendon or of the medial collateral ligament was detached through an osteotomy at the 
femoral side
25
. The osteotomy was later repositioned by screw fixation or stapling. The meniscal 
remnant was excised leaving only a bleeding, functional meniscal rim. The meniscal rim deserves 
surgical attention, as it serves as a strong envelope encapsulating the medial or lateral compartment 
of the knee. The rim should not be resected or transected during the operation. Doing so would lead 
to a breach in the envelope. The viable meniscal allograft was then securely sutured to this rim 
using horizontal polydioxanone surgical sutures (PDS II, Ethicon, Somerville, NJ, USA) every 5 
mm in an all-inside fashion. Bone block fixation to the tibial plateau was not used to augment 
meniscal fixation. Instead the anterior and posterior horn of the transplanted meniscus were sutured 
to their remnant native horns on the tibia. The technical procedure has been published in detail
17
. 
Postoperative rehabilitation comprised 3 weeks of non-weightbearing with mobilization of the knee 
within pain limits and limited to 60 degrees of flexion. After 3 weeks, the patients were allowed to 
flex the knee to 90 degrees and to start partial weightbearing. At 6 weeks, all patients were allowed 
to walk with one crutch. 
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Concomitant surgical procedures were judged essential in a few selected cases and included  a high 
tibial osteotomy (HTO), femoral varus osteotomy (FVOS) or anterior cruciate ligament (ACL) 
reconstruction. Twenty-seven patients underwent a medial meniscal allograft transplantation 
(MMT). In eleven of these patients (41%) an HTO was associated to correct varus malalignment of 
the lower limb. ACL reconstruction at the time of transplantation had to be performed in 3 of the 
medial allograft cases and in none of the lateral allografts. ACL reconstruction was performed using 
an intra-articular double-loop tibialis posterior tendon allograft following a technique described 
previously
26
. The population analyzed thus consisted of patients with stable knees or with knees 
stabilized prior to meniscal allografting. Fourteen patients underwent a lateral meniscal allograft 
transplantation (LMT). In one of them an FVOS was associated to correct an obvious valgus 
malalignment. Another patient had a transplantation of the lateral meniscus in both knees. 
  
CLINICAL EVALUATION 
All patients were evaluated clinically preoperatively and at the final follow-up by an independent 
orthopaedic surgeon using the modified Hospital for Special Surgery (HSS) score
20
. This scoring 
system evaluates pain, function, range of motion, flexion deformity and instability of the involved 
knee (table 2). Therefore, it is an indicator of the overall knee function
20
.
 
This knee rating system 
has been used to determine knee function in previous reviews of meniscal allografting procedures 
and of fresh osteochondral allografting procedures in combination with meniscal allograft 
transplantation
17,25,27
. 
At the final follow-up (>10 years), the modified HSS score was available for all patients (N=31). 
Twenty-five patients (81%) also performed KOOS self-assessment tests. The Knee injury and 
Osteoarthritis Outcome Score (KOOS, Dutch version LK 1.0) is a 42-item self-administered knee-
specific questionnaire based on the WOMAC Osteoarthritis Index
21
. KOOS was developed to be 
used for short- and long-term follow-up studies of knee injuries, and it comprises 5 subscales: Pain, 
Symptoms, Activities of Daily Living (ADL), Sports and Recreation Function (S&R) and knee-
related Quality of Life (QOL). A score ranging from 0 to 100, where 100 represents the best result, 
is calculated for each subscale. The questionnaire and scoring manual can be downloaded from 
http://www.koos.nu. KOOS is valid, reliable and responsive in follow-up of meniscectomy, ACL 
reconstruction and total knee replacement for osteoarthritis
3,28,29
. The participants completed the 
KOOS questionnaire answering questions on their operated knee. 
In order to ascertain patient satisfaction, patients were also asked at the final follow-up if they 
would undergo the procedure again. 
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Those patients that were converted to a total knee arthroplasty and were considered a failure (N=7), 
were evaluated separately using the modified HSS score at the time of failure. KOOS score was not 
available for these patients.  
 
RADIOLOGY 
For all patients, standing postero-anterior plain radiographs with 15 degrees of flexion of the 
involved knee joint were taken within 6 months of the operation. Radiographic femoro-tibial 
alignment was thus recorded shortly after transplantation. Joint space narrowing of the medial and 
lateral compartment was graded using the International Knee Documentation Committee system 
(0=no narrowing, 1= <50% narrowing, 2= > 50% narrowing, 3= obliteration of the joint space)
 30
. 
Fairbank changes (narrowing of the joint space, flattening of the femoral condyle, bone spur 
formation) were also recorded
4
. 
At the final follow-up (>10 years), 25 patients (81%) were available for standing radiographic 
examination of the index knee (9 MMT,6 MMT+HTO,10 LMT). 
Standing radiographs of the index knees were also available for all failures just prior to the 
conversion to a TKA (N=7). 
All plain radiographs were analyzed and compared retrospectively by an experienced radiologist 
(KV) in a blinded fashion.   
 
MRI EVALUATION 
Twenty five patients underwent an MRI examination on a 1.0 tesla magnet (Magnetom Expert, 
Siemens, Erlangen, Germany) of the operated knee joint within one year of the operation. Three 
mm sagittal proton-density and T2-weighted images, 2 mm coronal mixed T1-T2-weighted DESS-
3D gradient-echo images and 1mm sagittal fat suppressed T1-weighted 3-d spoiled gradient-echo 
images were obtained for optimal visualisation of all portions of the menisci and to assess the 
articular cartilage
31,32
. Seventeen of them (6 MMT, 5 MMT+HTO, 6 LMT) were available for 
objective MRI analysis of the involved knee at the final follow-up (>10 years). Cartilage 
degeneration of the femoral condyle and tibial plateau of the involved compartment was graded 
separately as described by Yulish with slight modifications (table 3)
 33
. For example, a lesion that 
was graded between grade III and IV, was recorded as 3/4  and was given a nominative value of 3.5.  
Signal intensity, extrusion and tears of the meniscus allograft were recorded. Three grades of signal 
intensity were identified according to Thornton
34
. Grade I signal intensity is globular and not 
adjacent to either articular surface. A grade II signal is a linear signal within the meniscus. A grade 
III signal is a linear signal that extends to either the superior or inferior articular surface. Extrusion 
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of the meniscus body was evaluated on the coronal sections as none (0), partial (1) or complete (2)
 
35
. If a tear of the graft was identified, the location (red, red on white, white zone) and the 
configuration of the tear were described (horizontal, vertical or complex).  
MRI data was unavailable for all failure cases. 
Cartilage and allograft status of the involved compartment were compared to the initial MR scan. 
All MR images were analyzed retrospectively by an experienced radiologist (KV) in a blinded 
fashion. 
   
Table 3. Arthroscopic (modified Outerbridge) and MR (Yulish) classification system to grade cartilage lesions. 
 
Arthroscopic and MR Classification of Cartilage Lesions 
Arthroscopic Classification MR Classification 
Grade 0 Normal Grade 0 Normal 
Grade 1 Softening, without morphologic 
defect 
Grade 1 Normal contour +/- abnormal 
signal 
Grade 2 Superficial blistering or fraying; 
erosion or ulceration of less than 
50 % 
Grade 2 Superficial fraying; erosion or 
ulceration of less than 50 % 
Grade 3 Partial-thickness defect of more 
than 50% but less than 100% 
Grade 3 Partial-thickness defect of more 
than 50% but less than 100% 
Grade 4 Ulceration and bone exposure Grade 4 Full-thickness cartilage loss 
 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed on subgroups of patients who had undergone (1) an MMT 
without a HTO (N=16), (2) an MMT+HTO (N=11), or (3) an LMT (N=15 allografts in 14 patients) 
(table 1). 
SPSS version 11.0 for Windows XP was used as software for statistical analysis. Normality of 
distribution for the investigated clinical, radiological and MRI parameters was tested within each 
subgroup using the Kolmogorov-Smirnov and Shapiro-Wilk test and was not achieved but in KOOS 
subscales. Therefore statistical analysis was performed using non-parametric tests. Comparison of 
the postoperative to the preoperative clinical and radiological/MRI parameters was performed using 
the Wilcoxon signed rank test. Comparison among different patient groups was done using the 
Mann-Whitney test. Correlation studies between modified HSS and KOOS subscales and between 
specific radiological/MRI parameters and clinical outcome were performed using the Spearman’s 
Rho 2-sided test. These tests were performed on the overall data, as well as on the different 
subgroups. Statistical significance was set at p-value < 0.05.   
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Results 
 
CLINICAL OUTCOME  
The preoperative mean modified HSS pain score was 14±8.4, 13.3±10 and 15.8±7.9 for the MMT 
group, the MMT+HTO group and the LMT group, respectively (table 4 and fig 1). These pain 
scores did not differ significantly at baseline. At the final follow-up, these values improved 
significantly when compared to the preoperative values: 35±10.5 (p=0.01), 45.5±6.3 (p=0.011) and 
38.7±14 (p=0.004), respectively. The pain score of the MMT+HTO group was significantly higher 
than of the MMT group (p=0.017) at the final follow-up.  
Range of motion increased slightly in all groups, as did anteroposterior and mediolateral stability. 
Changes were, however, not significant. 
The mean modified HSS walking score significantly improved at the final follow-up when 
compared to the preoperative score for all groups: 19.5±16.1 to 44.0±8.4 (p=0.007), 24.4±10.1 to 
46.2±5.2 (p=0.007), 27.5±10.6 to 49.1±2.9 (p=0.002) for the MMT, MMT+HTO and LMT group, 
respectively. This was also true for the stair climbing ability score: 25.5±15.4 to 44.0±5.2 
(p=0.011), 35.6±7.3 to 47.8±4.4 (p=0.018), 37.5±8.7 to 46.7±6.5 (p=0.009), respectively. Details of 
the modified HSS score are presented in table 4 and fig 1. 
The KOOS scores at the final follow-up for the different groups are given in table 4 and fig 2. The 
MMT+HTO group scored substantially higher on all subscales compared to the MMT and LMT 
group. These differences did not reach statistical significance (p-values between 0.065 and 0.130, 
data not shown).  
Further KOOS data analysis (see appendix A) revealed that, compared to the MMT group, the 
MMT+HTO group complained significantly less of swelling (question S1) and stiffness (question 
S7) of the knee. These patients also had significantly less frequent pain (question P1), had less 
difficulties with going up or downstairs (question P6), rising from bed (question A10), and getting 
in and out of bath (question A13). Additionally, these patients had more confidence in their knee 
(question Q3). 
At the final follow-up, over 90% of all patients were satisfied with the outcome of the operation and 
would consider this procedure again if necessary.   
Four MMTs (25%), 2 MMT+HTOs (18%) and 1 LMT (7%) were converted to total knee 
arthroplasty (TKA) during follow-up (mean FU 6.5 years, S.D. 4.3 years) due to intolerable pain 
and loss of function. Thus, with conversion to TKA as an end point, the overall failure rate was 
18% (7/39 grafts) in this series. At the time of conversion the mean pain, walking and stair climbing 
87
  
 
Figure 1. Preoperative and postoperative subscales according to the modified HSS system. Y-axis: mean ± standard 
deviation (S.D.). X-axis: pain (max. 50), range of motion (ROM, max. 25), anteroposterior stability (AP stab, max. 10), 
mediolateral stability (ML stab, max. 15), walking (max. 50), stairs (max. 50). MMT: medial meniscus transplantation; 
MMT+HTO: medial meniscus transplantation combined with a high tibial osteotomy; LMT: lateral meniscus 
transplantation. All subgroups improved significantly postoperatively when compared to the preoperative score. The 
MMT+HTO subgroup improved significantly more than the MMT subgroup. 
 
 
 
 
 
 
Figure 2. Postoperative KOOS subscales. Y-axis: mean ± standard deviation (S.D.). X-axis: pain (max. 100); symptoms 
(max. 100); activities of daily life (ADL, max. 100), Sports and Recreation (S&R, max. 100); quality of life (QoL, max. 
100). The MMT+HTO subgroup scored substantially better postoperatively than the MMT and LMT subgroup.  
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Figure 3. Details of the joint space on standing postero-anterior plain radiographs at baseline (radiographs taken within 
6 months of the transplantation) and at the final follow-up (> 10 years). Variable progression of joint space narrowing 
(graded according to IKDC) is seen during the follow-up.  Patient A (LMT): no progression; Patient B (MMT): minimal 
progression by 1 grade; Patient C (MMT+HTO): progression by 1 grade; Patient D (MT+HTO, previous ACL): 
progression by 2 grades; Patient E (LMT): progression by 3 grades. 
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Figure 4. Sagittal MR images of the 
involved compartment at baseline (within 
one year of the operation) and at the final 
follow-up (>10 years) of 5 patients. 
Femoral and tibial cartilage degeneration 
was graded according to Yulish, meniscal 
allograft signal intensity was graded 
according to Thornton and tears of the 
allograft were documented. Images were 
selected to illustrate specific changes in 
MRI variables. Patient 1 (MMT) showed 
no progression in cartilage degeneration. 
Grade 3 signal intensity of the allograft was 
observed at baseline and at the final follow-
up. Patient 2 (MMT+HTO) showed 
progession by 1 grade of both femoral and 
tibial cartilage degeneration during follow-
up. Signal intensity of the allograft was 
normal. Patient 3 (LMT) showed 
progression by 1 grade of femoral cartilage 
and by 1.5 grades of tibial cartilage 
degeneration. Signal intensity of the 
allograft changed from normal to grade 3 
during follow-up. An artefact signal is 
observed in the femoral condyle due to a 
fixation screw (arrow). Patient 4 
(MMT+HTO) showed no progression of 
cartilage degeneration and allograft signal 
intensity. Patient 5 (LMT) showed focal 
grade 4 cartilage lesions and a normal 
signal intensity of the graft at baseline. 
Focal grade 4 cartilage lesions were still 
observed at the final follow-up. Signal 
intensity of the graft was graded as 3 at the 
final follow-up.  
Complete capsular ingrowth was 
documented in each patient. 
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scores according to the modified HSS scale were 10±14.1, 24.3±12.7 and 15±18.3, respectively, 
indicating a poor results. These scores were not included into the final follow-up (>10 years) data.   
 
RADIOLOGY  
Plain radiographs of thirteen knees out of 25 (52%) that were available at the final follow up 
(12.0±1.5 years) did not show any change in joint space width (table 5). Progression of joint space 
narrowing was observed in 12/25 cases (48%): 8 knees were narrowed by 1 grade (32%), 3 by 2 
grades (12%) and 1 by 3 grades (4%). Fairbank changes remained stable in 9 knees (36%). 
Progression was seen by 1 grade in 8 knees (32%) and by 2 grades in 8 knees (32%). Details are 
presented in table 5.  
All failure cases (N=7, conversion to TKA) were characterized by progression in joint space width 
narrowing (2 by 1 grade and 5 by 2 grades) and Fairbank changes (6 by 1 grade and 1 by 2 grades). 
Overall, considering both success and failure cases, joint space width remained stable in 13/32 cases 
(41%) in the course of the study. JSWN progressed by 1 grade in 11 cases (34%) , by 2 grades in 7 
cases (22%) and by 3 grades in 1 case (3%). Fairbank changes did not progress in 9 cases (28%). 
Fourteen cases showed progression by 1 grade (44%), and 9 cases by 2 grades (29%). 
 
 
MRI EVALUATION  
Absence of further degeneration of the femoral cartilage was noted in 8 knees (47%) out of a total 
of 17 that were available for evaluation at the final follow-up (11.9±1.4 years) (table 6). One knee 
(6%) showed further degeneration by half a grade, 5 knees by 1 grade (29%), 2 knees by 1 and a 
half grades (12%), and 1 knee by 2 grades (6%).  
No progression of tibial cartilage degeneration was observed in 7 knees (41%). Three knees (18%) 
showed progression by half a grade, 4 (23%) by 1 grade, 2 (12%) by 1 and a half grades and 1 by 2 
grades (6%). Six out of 17 (35%) knees did not show any progression of both femoral and tibial 
cartilage degeneration. 
At the final follow-up, the signal intensity of the allograft was graded as grade III in 10 allografts 
(59%) (5 MMT,1 MMT+HTO,4 LMT) and as normal or grade 0 in the remaining allografts. 
However, grade III signal intensity had already been observed in 5 MMTs, 1 MMT+HTO and 1 
LMT on the initial MRI scans, taken within one year of the procedure. Hence, no change in signal 
intensity was observed in 14/17 (82%) allografts. Grade I or II signal intensity of the allograft was 
never observed on the initial scans or at final follow-up. Normal signal intensity at baseline and at 
the final follow-up was most frequently observed in the MMT+HTO group. The MMT group 
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Table 5. Overview of radiological parameters for the different patient groups at final follow-up ( N=25, >10 years). 
Preoperative (pre) and postoperative (post) values are presented as well as the number of patients presenting 0-3 grade 
changes in the different parameters considered during follow-up ( grade). Joint space narrowing (JSN) and changes 
according to Fairbank as measured on standing X-rays obtained in 25 patients. Radiological parameters for the failure 
cases, i.e. conversion to TKA, are not included in the table. 
  MMT MMT+HTO LMT TOTAL 
 GRADE pre post   grade Pre post   grade pre post   grade  grade 
0 7 2 3 4 1 3 10 5 7 13 
1 3 3 4 3 3 2 1 1 2 8 
2 0 4 2 2 1 1 1 3 0 3 
JSN 
3 0 0 0 0 1 0 0 1 1 1 
0 3 1 1 2 1 4 3 1 4 9 
1 6 2 5 2 1 2 7 3 1 8 
2 1 2 3 2 2 0 1 1 5 8 
Fairbank 
changes 
3 0 4 -  3 2 0 1 5 0 0 
 
Table 6. 
Overview of some magnetic resonance imaging parameters for the different patient groups (N=17, >10  years). 
Preoperative (pre) and postoperative (post) values are presented as well as the number of patients presenting x grade(s) 
changes in the different variables considered during follow-up (grade). 
Femoral and tibial cartilage degeneration (according to Yulish), meniscus signal intensity (according to Thornton) and 
meniscus position (coronal sections), as measured on MRI scans obtained in 17 patients.  
  MMT MMT+HTO LMT TOTAL 
 GRADE pre post   grade pre post   grade pre post   grade  grade 
0 2 1 2 0 0 2 1 1 4 8 
0 to 1 0 0 1 0 0 0 0 0 0 1 
1 0 0 1 0 0 2 0 0 2 5 
1 to 2 1 0 1 1 1 1 0 0 -  2 
2 1 1 1 1 0 -  1 1 -  1 
2 to 3 0 1 -  1 0 -  2 0 -  -  
3 2 0 -  1 1 -  0 0 -  -  
3 to 4 0 2 -  1 1 -  0 2 -  -  
Femoral 
cartilage 
degeneration  
4 0 1 -  0 2 -  2 2 -  -  
0 1 1 3 0 0 2 1 0 2 7 
0 to 1 0 0 -  0 0 1 0 0 1 3 
1 0 0 -  0 0 1 0 0 1 4 
1 to 2 1 0 1 0 0 1 0 0 1 2 
2 1 2 2 1 0 -  1 0 1 1 
2 to 3 1 1 -  2 1 -  2 1 -  -  
3 0 1 -  0 1 -  0 0 -  -  
3 to 4 1 0 -  2 1 -  0 3 -  -  
Tibial 
cartilage 
degeneration 
4 1 2 -  0 2 -  2 2 -  -  
0  1 1 6 4 4 5 5 2 3 14 Meniscus 
signal 
intensity 3 5 5 -  1 1 -  1 4 3 3 
normal 6 1 1 4 2 3 5 1 2 6 Meniscus 
position 
part. extr. 0 5 5 1 2 2 1 5 4 11 
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without HTO showed grade III signal intensity on the initial MRI scans. These allografts, however, 
showed no increased signal intensity during follow-up. In contrast, the LMT group showed 
progressive grade III signal intensity in 3 grafts. Only 2 out the 6 grafts were graded as normal at 
the final follow-up.  
At the final follow-up, the position of the allograft was evaluated as normal in 4 knees (24%) (1 
MMT,2 MMT+HTO,1 LMT), and as partially extruded in 12 knees (70%) (5 MMT,2 
MMT+HTO,5 LMT). Partial extrusion of the midbody and anterior horn of the allograft was most 
frequently observed. On the initial scans, the position of the graft was graded as normal in 15 knees 
(6 MMT,4 MMT+HTO,5 LMT) and as partially extruded in 2 knees (1 MMT+HTO,1 LMT). 
Overall, the position of the graft did not change over 10 years in 6/17 knees (35%). The extrusion 
was progressive in 10/17 knees (59%). In one MMT+HTO knee, only a small remnant of the graft 
was present. Details are presented in table 6.    
In two knees, the allograft showed a tear of the posterior horn at the final follow-up. One MMT was 
diagnosed with a vertical tear in the red zone, while one LMT had a minor, horizontal tear in the 
white zone. Except for the graft with the vertical tear in the red zone, all grafts showed capsular 
ingrowth. 
 
 
 
CORRELATION STUDIES 
The modified HSS pain, walking and stair-climbing subscales correlated significantly with each 
other (Spearman Rho test, range 0.465-0.675, P<0.007).  
Significant correlations were also found between the different KOOS subscales (Spearman Rho test, 
range 0.611-0.938, P<0.001).  
The modified HSS pain, walking and stair-climbing subscales also correlated with the different 
KOOS subscales (Spearman Rho test, range 0.475-0.813, p<0.014).  
No significant correlations were found between any of the measured radiological or MRI 
parameters and the clinical subscales, nor did the status of cartilage degeneration correlate with any 
of the clinical subscales at the time of transplantation or at the final follow-up.  
Axial alignment did not correlate with progression of femoral/tibial cartilage degeneration and 
signal intensity of the graft.   
 
Discussion 
Meniscal transplantation is still considered an investigational procedure. Long-term follow-up data 
are scarce in the literature
18
. The comparison with published results remains troublesome due to the 
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variety of associated procedures, preservation technique, graft fixation technique, clinical scoring 
systems and duration of follow-up
15,36
. Nonetheless, based on the available short and medium-term 
data, it is generally accepted that meniscal allograft transplantation relieves pain and improves 
function in the symptomatic meniscectomized knee
12-18,36,37
. 
The modified HSS scoring system, which was initially designed to evaluate the outcome of a total 
knee arthroplasty, was used as primary outcome measure in this study, because of the lack of a 
more appropriate measuring tool for the outcome of meniscus allograft transplantation in the late 
eighties and early nineties
20
. Since then, several scoring systems have been proposed and tested. 
However, compared to ACL reconstruction, ‘meniscus reconstruction’ has received little attention 
with respect to the functional outcome, in particular from the patient’s perspective. At the final 
follow-up, the authors, therefore, included the patient-assessed KOOS score which has been shown 
to be sensitive and reliable for meniscus pathology
3,21
. 
We were able to show that, after 10 years,  patients had a significant improvement of function and 
relief of pain compared to the preoperative situation. In this study, the long-term clinical outcome 
after isolated medial or lateral transplantation was comparable. In contrast, others have noted a 
considerable difference between these two grafts. In that series, MMT were more prone to failure 
due to a higher number of patients with associated ACL laxity
38
. Increased anterior tibial translation 
due to a deficiency of the ACL is known to induce higher stress on the medial meniscus and 
therefore can induce secondary failure
38
. In our series all knees were stable at the time of 
transplantation or underwent a concomitant ACL reconstruction. 
Further analysis also revealed that an MMT+HTO resulted in a significantly greater improvement 
of the modified HSS pain score at the final follow-up when compared an MMT alone. We 
hypothesize that shifting the mechanical axis towards the lateral compartment by an osteotomy, 
results in unloading of the graft and the involved compartment. This makes them less prone to 
failure and degeneration, even though the articular cartilage was slightly more degenerated at the 
time of transplantation.  
However, despite the significant improvement in pain and function for all investigated subgroups, 
substantial disability and symptoms in addition to a reduced quality of life and activity levels were 
evident at the final follow-up. This indicates that patients have difficulties with running, jumping 
and squatting. Most knees also have a reduced range of motion compared to the contralateral knee, 
although flexion generally achieves more than 115 degrees. The majority of patients is very well 
aware of their operated knee and adapt their lifestyle considerably. Nonetheless, when asked if they 
would undergo the procedure again, a vast majority answered positively, indicative of a high patient 
satisfaction rate at the final follow-up.  
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Cartilage degenerative changes at the time of transplantation are considered to be an important 
predictor of failure in the case of cryopreserved or irradiated meniscal allografts
14,39
. In the 
presented series of viable meniscal allografts, however, we could not find any correlation between 
initial cartilage damage and clinical or radiological outcome parameters. This is in accordance with 
a previously published survivorship analysis of an identical but extended series of viable meniscal 
allografts where initial cartilage damage was neither able to predict clinical failure
17
. A possible 
explanation for this observation could be, firstly, that viable meniscal allografts are more resistant to 
mechanical failure compared to irradiated or cryopreserved grafts
14,39
. The latter  preservation 
techniques are known to render the graft acellular and may adversely affect the material 
properties
40-43
. In contrast, in vitro cultured menisci have been shown to remain viable and continue 
to produce extracellular matrix compounds, hence the term ‘viable meniscal allograft’
24
. The 
cultured allograft is transplanted into the recipient knee after 14 days. The proportions of cells that 
survive and how long they survive in vivo are unknown. A DNA probe analysis in a goat model 
found that all donor cells were rapidly replaced by host cells over a period of 4 weeks
44
. However, a 
previous study in this department demonstrated the presence of donor DNA in the viable human 
meniscal allograft for as long as 64 months after transplantation, indicating that donor cells remain 
viable for a longer period and that this replacement process by host cells is probably slower in the 
human model
45
. The biomechanical function of the meniscal allograft not only depends on the 
quality of the surgical fixation technique, but also on the phenotype of the cell population of the 
allograft. It is not known if recipient meniscus-invading cells, probably derived from the synovial 
lining, have the same capacity to produce extracellular matrix as have native meniscus cells
46
. 
Secondly, the authors hypothesize that focal cartilage lesions have a less detrimental effect on the 
long-term outcome compared to generalized compartment degeneration. A high number of patients 
were transplanted with focal grade III and even focal grade IV cartilage lesions with exposure of the 
subchondral bone. In contrast, extended grade IV lesions are considered a contraindication for this 
type of surgery, because of the increased mechanical friction and decreased shock adsorption and as 
a consequence were excluded from the study
14,15,36,39
. Nowadays, focal cartilage defects would be 
treated in our institution with a chondrocyte transplantation, microfracture or osteochondral plug 
transfer depending on its size. However, at that time, no such treatment was available in our 
institution and therefore these focal lesions were left untreated. This does not alter the fact that no 
significant correlation could be observed between the cartilage status at the time of transplantation 
and any clinical or radiological outcome parameter. The statiscal analysis could have been 
influenced by the limited numbers. 
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 Axial alignment is also considered an important predictor of failure
12,14,39
. As previously published, 
we were able to show a significantly better clinical outcome at the final follow-up in the 
MMT+HTO group than in the MMT group
17
. This indeed shows that outcome is affected by axial 
alignment. However, the osteotomy was performed in case of varus malalignment and thus one 
might argue that a population consisting of symptomatic meniscectomized knees with varus 
malalignment and treated by an isolated osteotomy, i.e. without the meniscal transplant, would be a 
more appropriate control group. Long term outcome data on HTO specifically for the treatment of 
symptomatic meniscectomized knees, however, are also lacking in the literature, making any 
comparison impossible for now. Nonetheless, in our series axial alignment did not significantly 
correlate with any of the investigated clinical and radiological or MRI parameters. A possible 
explanation for this observation could be that we corrected each varus aligned lower limb by an 
HTO, thereby eliminating this patient group –with a known risk factor for early failure, i.e. varus 
alignment- from the study 
Limited data is available on the progression of degenerative articular changes after this type of 
surgery. No previous medium and long-term reports have indicated that meniscus allografting halts 
or slows down further degeneration. We have provided proof that progression of cartilage 
degeneration according to MRI and radiological criteria was halted in a number of patients, 
indicating a potential chondroprotective effect. Progressive articular cartilage degeneration changes 
is reported in the literature to occur in up to 89 percent of the cases after total meniscectomy, as 
radiographically observed in long-term follow-up studies
5,6
. No such long-term follow-up studies 
exist using MRI criteria. The presented patient population here consisted of persons with total 
meniscectomized knees who eventually became symptomatic enough to warrant a meniscal 
transplantation. It is likely that this fraction of patients with symptoms and signs of excessive joint-
loading secondary to meniscal deficiency develops osteoarthritis faster than the asymptomatic 
subpopulation. The absence of further joint space narrowing in 41% at final follow-up (>10 years) 
in this series thus seems favourable to the previously published data on radiographical changes after 
total meniscectomy
5,6
.       
The lack of a control group consisting of conservatively treated symptomatic post-meniscectomized 
patients in this study is a limitation observed in all studies published on meniscal allografting: 
ethically it is unacceptable to refuse any proven treatment -i.e. in this case a meniscal allograft, 
TKA or osteotomy- to a symptomatic patient.  
Grade III signal intensity of the graft was frequently observed already on the initial scans, and 
showed little tendency to change over time. Although grade III signal intensity of the meniscus is 
generally described as a linear signal extending to the surface of the meniscus, the observed signal 
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changes within the allograft meniscus were described as non-uniform patchy gray appearance and 
not linear
34
. Therefore, the authors hypothesize that these signal changes do not represent tears of 
the allografts, but rather changes in water content and extracellular matrix composition when 
compared to the normal meniscus. This phenomenon takes place quite rapidly after the 
transplantation procedure and could be induced by a repair or remodelling process. The exact 
biological and histological significance of this phenomenon remains unknown. Of note is the small 
number of grafts with grade III signal in the MMT+HTO group. The effect of the osteotomy on this 
phenomenon remains a focus of future research. Progression of graft extrusion was also frequently 
noted. Extrusion is considered a sign of ensuing joint degeneration by some authors
47,48
. However, 
we did not find a statistical difference in progression of cartilage degeneration between those with 
and those without extrusion, possibly due to the small numbers within each group.  
In this study, the MRI outcome did not correlate with the clinical outcome. This observation has 
already been published by several authors
31,49
. The evaluation of the outcome after meniscus 
allograft transplantation should therefore primarily be a clinical one. Nonetheless, MRI is 
considered an objective tool to assess the cartilage and the meniscus, and should hence be included 
when possible
50
. 
The limited number of patients available for MRI analysis however could have influenced the 
statistical analysis. 
In conclusion, long-term results are encouraging in terms of pain relief and improvement of 
function. Despite this significant improvement, substantial disability and symptoms were present in 
all investigated subgroups. Progression of further cartilage degeneration or joint space narrowing 
was absent in a considerable number of cases, indicating a potential chondroprotective effect. 
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Legend to Appendix A 
Test statistics 
Questions 
Mann-
Whitney U 
Wilcoxon 
W 
Z-value 
Asymp. 
Sig. (2-
tailed) 
Exact Sig. 
[2*(1-tailed 
Sig.)] P-
value 
S1 11 47 -2.26977 0.023221 0.028127 
S2 16.5 52.5 -1.67271 0.094385 0.104895 
S3 20.5 56.5 -1.47162 0.141123 0.234499 
S4 20 56 -1.84871 0.0645 0.234499 
S5 19 55 -1.48342 0.137964 0.194872 
S6 13 49 -2.0982 0.035888 0.049883 
S7 12 48 -2.23607 0.025347 0.037918 
P1 8 44 -2.59808 0.009375 0.010412 
P2 16.5 52.5 -1.71169 0.086954 0.104895 
P3 18 54 -1.80739 0.070701 0.160528 
P4 31.5 67.5 -0.05576 0.955531 0.95913 
P5 21.5 57.5 -1.20761 0.227195 0.278632 
P6 12 48 -2.24733 0.024619 0.037918 
P7 18 54 -1.65145 0.098648 0.160528 
P8 11 47 -2.47717 0.013243 0.028127 
P9 13 49 -2.16995 0.03001 0.049883 
A1 19 55 -1.44743 0.147778 0.194872 
A2 22 58 -1.11803 0.263552 0.328205 
A3 22 58 -1.12938 0.258736 0.328205 
A4 16 52 -1.87523 0.060761 0.104895 
A5 28.5 64.5 -0.38651 0.699119 0.720901 
A6 24 60 -0.97301 0.330549 0.441803 
A7 14 50 -2.18282 0.029049 0.064957 
A8 18.5 54.5 -1.49815 0.134094 0.160528 
A9 15 51 -2.07379 0.038099 0.082984 
A10 12 48 -2.56776 0.010236 0.037918 
A11 15 51 -2.07379 0.038099 0.082984 
A12 20 56 -1.5667 0.117185 0.234499 
A13 12 48 -2.58199 0.009823 0.037918 
A14 14 50 -2.19578 0.028108 0.064957 
A15 16 52 -2.2188 0.0265 0.104895 
A16 15.5 51.5 -1.83107 0.067089 0.082984 
A17 15 51 -2.07379 0.038099 0.082984 
SP1 27 63 -0.56662 0.57097 0.645377 
SP2 14 50 -2.03984 0.041366 0.064957 
SP3 18.5 54.5 -1.52597 0.127018 0.160528 
SP4 13 49 -2.06815 0.038626 0.049883 
SP5 25.5 61.5 -0.69983 0.484034 0.505361 
Q1 26 62 -0.6475 0.517309 0.573737 
Q2 27 63 -0.54339 0.586859 0.645377 
Q3 11.5 47.5 -2.20886 0.027184 0.028127 
Q4 17 53 -1.64054 0.100892 0.130381 
 
Specific KOOS data analysis (Mann-Whitney U test) on specific questions rated within the subscales Symptoms (S1-7), 
Pain (P1-9), Activities of Daily Living (A1-17), Sports and Recreation (SP1-5) and Quality of Life (Q1-4) for medial 
allografts with or without a high tibial osteotomy. Significant p-values , i.e. less than 0.05, are in bold.  
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CHAPTER III.B.2 
 
 
 
 
 
Normal and transplanted lateral knee menisci: 
evaluation of extrusion using Magnetic Resonance 
Imaging and Ultrasound 
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Introduction 
Over fifty years ago, Fairbank observed that the removal of the meniscus led to degenerative 
changes in the knee joint in the long term
1
. Nowadays the meniscus is repaired rather than removed, 
provided that the meniscal tissue quality is still good. In the more frequent cases of degeneration of 
the meniscus, partial instead of total meniscectomy is propagated in order to minimize loss of this 
anatomically and functionally important structure.  
Besides lubrication, proprioception and joint stabilization, load transmission is believed to be one of 
the major functions of the knee meniscus. The incongruence between the semicircular femoral side 
and the rather flat tibial side of the knee joint is adapted by the presence of the meniscus. In 
extension almost 70% of load in the lateral compartment is transmitted through the meniscal body, 
reducing stress on the cartilage and subchondral bone
2
. It is believed that this load-distributing 
function is only possible by the strong anterior and posterior enthesis to bone, thus preventing the 
extrusion of this wedge shaped meniscal body from the joint
3
.      
Growing knowledge about the biomechanical and physiological function resulted in the concept of 
meniscal transplantation in the younger patient with incapacitating pain who underwent a previous 
total meniscectomy  and has a correct alignment of the lower limb
4-9
.  The possible goals of the 
transplantation are to decrease pain, slow down cartilage degeneration and improve biomechanics. 
Improvement of biomechanics through transplantation can theoretically only be achieved if the 
meniscal body is fixed in such a way as to prevent extrusion
10-12
. Therefore, we designed a study to 
measure the extrusion of the meniscal body in normal and transplanted lateral menisci.  
 
Material and Methods 
 
SURGICAL TECHNIQUE 
All patients underwent a viable lateral meniscal allograft transplantation
7
. The allograft was 
harvested within 24 hours postmortem. Donors died from a short disease. None had received 
corticosteroids or cytostatic drugs. The allograft was cultured during a 2 week period in vitro in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco Invitrogen Co, Merelbeke, Belgium) 
supplemented with 20% autologous serum prior to transplantation
13
. Donors were screened for 
transmittable diseases.  
All patients were operated on by the senior surgeon (RV). Access to the knee joint was created  
using an lateral parapatellar arthrotomy.The insertion of the lateral collateral ligament and popliteus 
tendon were osteotomized at the femoral side
7
. The osteotomy was later repositioned by screw 
fixation. The meniscal remnant was excised leaving only a bleeding, functional meniscal rim. The 
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viable meniscal allograft was then securely sutured to this rim using horizontal 2/0 PDS sutures 
every 3 mm in an all-inside fashion. No bone block fixation to the tibial plateau was used to 
augment meniscal fixation, instead the anterior and posterior horn of the transplanted meniscus was 
sutured to their original entheses (=remnant horns) on the tibia. 
Postoperative rehabilitation comprised 3 weeks of non weight bearing with mobilization of the knee 
within pain limits and limited to 60 degrees of flexion. After 3 weeks, patients were allowed to flex 
the knee to 90 degrees and to start partial weight bearing. At 6 weeks, all patients were allowed to 
walk with one crutch. 
 
PATIENT GROUP (table 1) 
The investigated patient group consisted of 14 men and 13 women. Seventeen patients underwent 
the magnetic resonance imaging (MRI) study and 10 patients underwent the ultrasound (US) study. 
Patients were allocated to either MRI or US investigation group in chronological order, meaning 
that the first ten patients seen at follow-up were allocated to the US study while the next 17 patients 
were allocated to the MRI study. The combination of both techniques on the same patient was not 
performed. Mean age was 33.9 years (range 18-47 years). Eleven left knees and 16 right knees were 
operated. All patients had undergone the surgical procedure at least 6 months prior to this study and 
were regarded as fully rehabilitated and had resumed professional activities (mean follow-up of 
23.5 months (range 6-111m)). 
 
Table 1. Overview of the number of menisci evaluated per group. 
 
 LATERAL MENISCUS 
 normal transplanted 
MRI 10 17 
US 10 10 
 
 
Controls for the MRI study consisted of a group of 10 people with no history of knee pain or 
meniscal pathology and normal axial alignment (mean age 33.9, range 9-55).  
For the ultrasound study, the non-operated contralateral knee of the transplanted patient served as 
control.     
 
MRI STUDY 
The study was performed on a 1.0T MR Unit (Magneton Expert, Siemens, Erlangen, Germany) 
using DESS-3D (double echo steady state, matrix 192x256, 2 mm slice thickness, TR 26.8, TE 9.0, 
TA 5min30s) sequencing. A positioning device was used for the ankle and knee to ensure 
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Figure 1. Laterally directed extrusion in the MRI study was assessed on coronal sections by drawing a line 
perpendicular to a horizontal line connecting both distal surfaces of the femoral condyles, and touching the outer edge 
of the articular cartilage of the femoral condyle, the tibial plateau and meniscal outer edge. Extrusion was defined as the 
distance from the femoral condyle (i.e.femoral extrusion) or tibial plateau (i.e. tibial extrusion) to the outer edge of the 
meniscus. (A: schematic, B: MRI). ). In the presence of a peripheral osteophyte, this line was drawn parallel to a line 
drawn perpendicular to the outer edge of the osteophyte. 
 
 
 
 
Figure 2. Meniscal extrusion was measured on ultrasound in three patient positions (supine, bipodal and unipodal 
stance). The probe was placed just anterior to the collateral ligament. Visualization of the transition between the red and 
white zone was done using the Doppler function .  Extrusion distance was defined as the greatest distance measured 
between the former line and a line connecting femoral and tibial cortex . Extrusion surface was calculated as the surface 
area of the meniscus situated between these two lines.
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uniformity between subjects. The acquired images were analyzed using standard software to 
measure distances and angles, provided by the manufacturer of the MRI unit.  
Subjects were only examined in a non weight bearing, supine position.  
Extrusion was assessed by drawing a line perpendicular to a horizontal line connecting both distal 
surfaces of the femoral condyles, and touching the outer edge of the articular cartilage of the 
femoral condyle, the tibial plateau and meniscal outer edge (fig 1). In the presence of a peripheral 
osteophyte, this line touched the outer edge of the osteophyte to ensure reproducibility. Extrusion 
was defined as the distance from the femoral condyle or tibial plateau to the outer edge of the 
meniscus and resulted in a femoral and tibial extrusion distance. These measurements were 
performed on 20 coronal sections (2mm thickness), in a posterior to anterior direction, thus 
covering the whole meniscal body
14,15
. The intra-observer intraclass correlation coefficient (ICC) 
for medial meniscus extrusion was 0.981 (p<0.001) for the femoral measurement and 0.954 
(p<0.001) for the tibial measurement. The ICC for the lateral meniscus measurement was 0.907 
(p<0.001) (femoral) and 0.831 (p<0.001) (tibial) in case of a normal lateral meniscus and 0.943 
(p<0.001) (femoral) and 0.962 (p<0.001) (tibial) in case of a transplanted lateral meniscus 
(Spearman’s Rho test). In order to calculate ICC, the measurements were performed in duplicate, 
with a one month interval, by a single observer.    
 
ULTRASOUND STUDY 
All knees were evaluated by an experienced physician (MDM), in 3 patient positions: supine, 
bipodal stance and unipodal stance. These 3 positions enabled us to assess the extrusion in a non 
loading position (i.e. supine position) as well as in 2 weight bearing positions: bipodal stance and 
unipodal stance. We used a high frequency linear probe (8, 10 or 12 MHz, Sonoline Sienna, 
Siemens, Erlangen, Germany). 
The probe was applied in a vertical way, just anterior to the lateral collateral ligament, where 
visualization of the lateral meniscus is optimal. We were able to visualize the transition between the 
red and white zone using the Power Doppler function. This transition was reproducible in every 
knee and was marked on screen by a line (=transition line). Afterwards, the greatest distance from 
this line to the middle of a line connecting the femoral and tibial cortex was measured and 
determined as the extrusion distance (fig 2). The extrusion cross-sectional area (CSA) was defined 
by the transition line and the line connecting femur and tibia (fig 2). Both parameters were digitally 
calculated on a PC using AutoCAD 2000 Software (Autodesk, USA).  
The intra-observer intraclass correlation coefficient (ICC) was 0.933 (p<0.001) and 0.883 (p<0.001) 
for the distance measurement in the transplanted lateral and the contralateral normal lateral 
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meniscus, respectively. The ICC for the surface measurement were 0.950 (p<0.001) 
and 0.883 (p<0.001) for the surface measurement for the transplanted lateral and the 
contralateral normal lateral meniscus. (Spearman’s Rho test). In order to calculate 
ICC, the measurements were performed in duplicate, with a one month interval, by a 
single observer.    
 
 
 
 
 
Figure 3. Histogram of the extrusion of the lateral meniscus measured by MRI in transplanted (fig 
4A,B) and normal knee (fig 4C,D). Extrusion of the meniscus was measured from the femoral condyle 
(fig 4A,C) and from the tibial plateau (fig 4B,D). The Y-axis represents the distance of extrusion (mean 
± 2SE) in millimeters and the X-axis represents the different coronal sections from posterior to anterior 
in the knee. The lateral transplanted meniscus is more extruded than the normal meniscus. The 
maximal extrusion is situated more anterior in the knee.  
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Results 
 
MRI STUDY: THE NORMAL KNEE   
Ten normal knees, i.e. 10 normal lateral compartments, served as controls. Mean age of the control 
population was 33.9 years (range 9-55 years). Sex distribution was 6 males / 4 females.  
The lateral meniscus shows only little tendency to extrude, if measured from the tibial plateau (fig 
3D). Maximal extrusion was observed in the more anterior coronal sections; the anterior horn 
extrudes 0.8 mm (SD=0.92), while the posterior horn does not extrude (mean 0 mm). On the 
femoral side, however, the extrusion distance histogram has a typical parabolic course with a 
maximal extrusion of 3 mm situated in the midportion of the lateral meniscus (fig 3C).  
 
MRI STUDY: THE TRANSPLANTED KNEE  
Seventeen transplanted lateral knees were evaluated. Mean patient age was 34.05 years (range 18-
46y) with a mean follow-up of 23.45 months (range 6-111m). Sex distribution was 9 males / 11 
females.  
The lateral transplanted meniscus is clearly more extruded then the normal meniscus (p<0.005, 
Mann-Whitney test) in every section, and shows the same tendency as the normal meniscus to 
extrude more anteriorly (mean 5.8 mm, SD= 2.8) than posteriorly (mean 2.7 mm, SD=1.48), when 
measured from the tibial plateau (fig 3B). When measured from the femoral condyle, the same 
observation could be made for the transplanted lateral meniscus compared to the normal lateral 
meniscus: femoral extrusion is obvious, with a parabolic course located somewhat more anteriorly 
than in the normal lateral meniscus (fig 3A). 
 
ULTRASONOGRAPHIC STUDY 
Extrusion surface and distance 
Ten normal lateral menisci were evaluated in 3 positions: supine, bipodal stance and unipodal 
stance. Mean patient age was 33.8 years (range 20-47 years). Mean extrusion CSA was 22.42 mm
2
 
(SD=12.5) in the supine position, 23.24mm
2
 (SD= 12.7) in the bipodal stance position, and 24.79 
mm
2
 (SD=10.18) in the unipodal stance position (fig 4). Mean extrusion distance was 3.77mm 
(SD=1.76) in the supine position, 3.94mm (SD=1.66) in the bipodal stance position and 3.79mm 
(SD=1.79) in the unipodal stance position (fig 5).  
Ten transplanted lateral menisci were analyzed in the same 3 positions. Mean extrusion CSA in the 
supine position was 50.05 mm
2
 (SD=15.3), in the bipodal stance position 47.24 mm
2
 (SD=12.34), 
and in the unipodal stance position 58.61 mm
2
 (SD=29.64) (fig 4). Mean extrusion distance in the 
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Figure 4. Boxplot representation of the extrusion surface of the lateral meniscus measured by ultrasound, in three 
positions (supine, bipodal and unipodal) in transplanted and normal knees. A statistically significant difference was 
observed between transplanted and normal knees in the three positions (supine: p<0.005, bipodal : p<0.005, unipodal : 
p<0.007). (TX= transplant, NO= control) 
 
 
 
Figure 5. Boxplot representation of the extrusion distance of the lateral meniscus measured by ultrasound, in three 
positions (supine, bipodal and unipodal) in transplanted and normal knees. A statistically significant difference was 
observed between transplanted and normal knees in the three positions (supine: p<0.005, bipodal : p<0.005, unipodal : 
p<0.005). (TX= transplant, NO= control 
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supine position was 6.43 mm (SD=1.84), in the bipodal stance position 6.14mm (SD=1.93), and in 
the unipodal stance position 6.99mm (SD=2.70) (fig 5).  
Comparing transplanted lateral menisci to the contralateral normal lateral menisci, a statistically 
significant difference was found between the three positions of both groups: supine position 
(p<0.005), bipodal stance (p<0.005) and unipodal stance (p<0.007 for surface and p<0.005 for 
distance) (Mann-Whitney test). This demonstrates that the transplanted lateral meniscus extrudes 
more in every position than the normal lateral meniscus. 
Using the Wilcoxon test, no significant difference could be noted between the three positions of 
both groups, indicating that there is no increase in extrusion of the normal and transplanted 
meniscus during axial loading.  
         
Discussion 
To our knowledge this is the first study to compare meniscal extrusion between normal and 
transplanted lateral menisci using two different techniques: MRI and ultrasound.  
MRI was chosen because of its widely accepted use for visualization of meniscal pathology
16
. 
 
The 
major advantage of the MRI is the high resolution of the images, allowing precise measurement of 
the extrusion (fig 6A,B). A drawback in this study, is the inability to visualize the meniscus under 
axial loading since the patient is scanned in the supine position. Therefore, ultrasound examination 
of the normal and transplanted meniscus was performed in three different positions, including two 
positions with axial load across the knee. This enabled us to evaluate possible meniscal extrusion of 
both normal and transplanted lateral menisci under axial load (fig 7).  
The transplanted lateral meniscus shows a clear tendency to extrude partially from the joint cavity 
in both weight bearing and non weight bearing positions, as observed by both techniques. This 
partial extrusion, located more anteriorly than posteriorly, implies an increase in contact area 
between the femoral condyle and tibial plateau. The transplanted lateral meniscus, however, shows 
no tendency to extrude more if axially loaded, as demonstrated by the ultrasound evaluation in 
different load bearing positions.  
Two studies on cadaveric knees have shown that the lateral transplanted meniscus does not fully 
restore normal contact pressures on cartilage. Paletta et al. tested peak pressure and contact area in 
ten cadaveric knee in compression (1800N) before and after lateral meniscal transplantation using 
bone block fixation
12
. A significant decrease in contact pressure was observed in the allograft 
situation. This improvement however was immediately lost when the anterior and posterior horn 
were cut, leading to contact stresses similar to the meniscectomized situation. Huang et al. noted 
significant difference in maximum pressure, mean pressure and contact area between the intact 
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Figure 6. MR images of 2 transplanted lateral menisci. Variable extrusion of the transplanted lateral meniscus can be 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. US evaluation of the same patient’s transplanted and contralateral lateral meniscus in three different positions: 
supine position, bipodal and unipodal stance. The surface area is depicted in gray. Significant difference in the extrusion 
between the contralateral normal meniscus and the transplanted lateral meniscus is noted. 
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lateral meniscus, lateral autograft with cemented bone block fixation and meniscectomized knees 
when tested at 1200N and different angles of flexion
17
. Chen et al. tested contact pressure in six 
cadaveric knee joints in compression (310N) before and after lateral meniscus transplantation using 
different fixation techniques
11
. They concluded that no difference in contact pressure could be 
observed between fixation with a tibial bone bridge, horn fixation and the normal intact meniscus. 
The overall conclusion of these studies is that up till now, no fixation system exists that is able to 
mimic the biomechanical characteristics of the native lateral meniscus under physiological 
compression. Nevertheless, these cited fixation methods produce better biomechanical results in 
vitro than the meniscectomized knee. No biomechanical studies have been performed on lateral 
allografts fixed with peripheral sutures to an intact rim and sutured to their original entheses at the 
anterior and posterior horn on the tibia. Although a bone bloc fixation has been proven to be 
superior to any soft tissue allograft fixation in the in vitro setting, overall clinical results do not 
implicate one method being superior to the other
4
.
 
 
The ultrasound results presented in this paper are obtained under different compression loads; 
almost 0 Newton in the supine position, approximately 250 to 500 Newton (half body weight (kg) x 
gravity) in the bipodal stance position according to patient body weight and approximately 500-
1000 Newton (full body weight (kg) x gravity) in the unipodal stance position. No significant 
difference could be observed between the different positions, indicating no increase in extrusion of 
the lateral meniscus (normal or transplanted). Based on the observed behaviour of the normal lateral 
meniscus under pressure, the authors assume that although the transplanted lateral meniscus is 
initially partially extruded from the joint cavity, the meniscal rim together with the horn fixation are 
capable to withstand the different hoop stresses under axial load, thus preventing an increase in 
extrusion. If the meniscal rim and horn fixations were to be biomechanically inadequate, one would 
expect an increase in extrusion under load, which is not the case.   
The partial extrusion of the lateral transplanted meniscus could be explained by the fact that the 
cross-sectional area of the transplanted meniscus together with the cross sectional area of the 
meniscal rim is possibly bigger than the original cross-sectional area of native meniscus, resulting 
in overstuffing of the lateral compartment. This would result in expulsion of a part of the meniscal 
body out of the knee joint cavity. The tighter postero-lateral capsule of the lateral compartment 
(lateral corner, LCL) probably prevents excessive extrusion, while the more lax anterior part of the 
joint capsule is probably less able to contain the lateral meniscal transplant.  The lateral parapatellar 
approach to the knee further weakens the anterior capsule of the knee joint. Overall, the authors 
hypothesize that the functional cross-sectional area of the meniscus, i.e. the part of the meniscus 
situated between the articular surfaces and thus capable to transmit load, is almost equal to the 
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Figure 8. Possible explanation for the parabolic course of the femoral extrusion of the normal lateral meniscus measured 
by MRI, is the natural occurring step-off between femoral condyle and tibial plateau, creating a zone where the middle 
part of the lateral meniscus is not covered by the femoral condyle. 
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normal meniscus in the posterior region considering the increased cross sectional area of the 
transplanted meniscus-meniscal rim complex minus the cross sectional area of the extruded part. In 
the anterior portion of the lateral compartment, however, the functional cross-sectional area is 
probably decreased. Newer MRI technology is able to perform exact cross sectional area 
calculations and volume scans of the meniscus. This technology could substantiate our hypothesis.       
The transplanted lateral meniscus firmly fixed to a functional meniscal rim and the anterior and 
posterior horn, is capable to transmit load from the femur to the tibia and hence it performs a 
biomechanical function. The ability of the transplanted lateral meniscus to function 
biomechanically, is reflected in the good mid and long term follow-up clinical results regarding 
pain and function
5,8,9
. Van Arkel and De Boer published a survival rate of 76% at 5 years for the 
lateral meniscus
5
. Long term follow-up results published by Wirth et al show an improved Lysholm 
score at 14 years for the medial meniscus
9
.
 
Our personal series demonstrates a significant 
improvement (P<0.001, Wilcoxon test) of the HSS score (108 preop to 178 postop at 10 years) in 
case of a lateral meniscus transplantation with more than 10 years of follow-up
6,8
. 
Although the presented results show an increased extrusion of the lateral meniscus transplant, the 
contact stresses on the cartilage are presumably decreased when compared to the meniscectomized 
situation. Any decrease relative to the contact stresses of the meniscectomized knee possibly results 
in a good clinical pain relief and improved function. There is however no reasonable proof that 
meniscal transplantation prevents or slows down cartilage degeneration in the lateral 
compartment
18
. 
Our results regarding the normal lateral meniscus, measured by MRI, are comparable to previously 
published data, where the extrusion was said to be the maximal extrusion distance measured from 
the tibial plateau
15
. We found the maximal mean extrusion of the lateral meniscus, if measured from 
the tibial plateau, to be 0.8 mm (SD=0.92) compared to 0.23 mm (SD=0.96) in the previously 
published study
15
. In the normal lateral meniscus the lateral maximal extrusion distance was 
situated near the anterior horn. The femoral extrusion histogram, on the other hand, shows a 
peculiar parabolic course. A possible explanation for this phenomenon is the natural step-off 
between the lateral femoral condyle and the lateral tibial plateau, creating a zone where the middle 
part of the lateral meniscus is not covered by the femoral condyle (fig 8).    
Finally, this study has some limitations. First, meniscal extrusion is not exclusively directed 
laterally. There may have been an extrusion more anteriorly or posteriorly. Because of  ease and 
reproducibility, only coronal MR images and US images near the LCL were analyzed to measure 
laterally directed extrusion of the lateral meniscus. Second, no direct comparison can be made 
between the results obtained by the MR and US technique due to a difference in methodology. 
115
  
Extrusion distance was measured on MR between the femoral condyle or tibial plateau to the outer 
edge of the meniscus, while on US this distance was measured between the middle of the line 
connecting femur and tibia and the transition line, which could be visualized on Doppler. Again, 
this difference in methodology was based on the need for a good reproducibility.  Third, both MR 
and US investigations were performed under static circumstances with the knee extended. Flexion 
of knee could increase stress on the posterior horn of the meniscus and subsequently increase 
extrusion, both laterally and posteriorly, of the normal and transplanted meniscus. This could be 
visualized using open dynamic MR technology. 
In conclusion, our data shows that the transplanted lateral meniscus, without bone block fixation but 
with firm fixation of the horns to the original entheses, extrudes in the lateral direction significantly 
more than the normal meniscus. The transplanted lateral meniscus, however, does not extrude more 
in the lateral direction under axial load. The anterior horn of both normal and transplanted menisci 
is extruded more laterally than the posterior horn.  
Both methods are adequate to measure laterally directed extrusion of the normal and transplanted 
lateral meniscus, but have distinctive advantages and disadvantages: MRI in this series visualizes 
the complete - from posterior to anterior - meniscal body, but only in the supine, non weight bearing 
position. Using ultrasound one can evaluate the meniscal extrusion in different conditions of axial 
loading, but only from a single examination point. 
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III.C Bioengineered meniscus - preparative studies on cell phenotype 
and extracellular matrix of the meniscus 
The objective of this study was to assess survival/proliferation of human meniscus cells in different 
culture conditions and to characterize the extracellular matrix produced by these cells in these 
artificial environments. The composition of this extracellular matrix offers a variable to define the 
distinct meniscus cell phenotype.  
Human meniscus cells were isolated enzymatically from visually intact lateral and medial knee 
menisci. Cells were cultured in monolayer conditions or in alginate gel. The composition of the cell 
associated matrix (CAM) accumulated by the isolated cells during culture was investigated and 
compared to the CAM of articular chondrocytes cultured in alginate using flow cytometry with 
FITC-conjugated monoclonal antibodies against type I collagen, type II collagen and aggrecan. 
Additional cell membrane markers analysis was performed to further identify the different meniscus 
cell populations in the alginate culture conditions and meniscus tissue sections. Proliferation was 
analyzed using the Hoechst 33258 dye method. In some experiments, the effect of TGF1 on some 
of these variables was investigated.    
The CAM of monolayer cultured meniscus cells is composed of high amounts of type I and II 
collagen and low amounts of aggrecan. A major population of alginate cultured meniscus cells on 
the other hand synthesized a CAM containing high amounts of type I collagen, low amounts of type 
II collagen and high amounts of aggrecan. This population is CD44+CD105+CD34-CD31-. In 
contrast, a minor cell population in the alginate culture did not accumulate extracellular matrix and 
was mainly CD34+. The CAM of  alginate cultured articular chondrocytes is composed of low 
amounts of type I collagen, high amounts of type II collagen and aggrecan. The expression of 
aggrecan and of type II collagen was increased by the addition of TGF1 to the culture medium. 
The proliferation of meniscus cells is increased in the monolayer culture conditions. Cell numbers 
decrease slightly in the alginate culture, but can be increased after the addition of TGF1. 
These results demonstrate that the human meniscus is populated by different cell types which can 
be identified by a distinct CAM composition and membrane marker expression. Unlike the 
monolayer culture conditions, the alginate culture conditions appear to favour a more 
fibrochondrocyte-like cell accumulating a cell associated matrix resembling the native tissue 
composition. This CAM composition is distinctly different from the CAM composition of 
phenotypically stable articular cartilage chondrocytes cultured in the same alginate matrix.  
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Introduction 
The meniscus plays an important role in the complex biomechanics of the knee joint. It has 
functions in load bearing, load transmission, shock absorption, joint stability, joint lubrification and 
joint congruity. The function of the meniscus is reflected in its cellular and biochemical 
composition in such a way that shear stresses, compressive forces, tensile hoop stresses and 
circumferentially directed forces are redirected properly. Knee meniscal fibrocartilagenous tissue 
contains mainly water (72%), collagens (22%) and glycosaminoglycans (0,8%)
1-2
. Type I collagen 
accounts for over 90 % of the total collagen content. Type II, III and V collagen are the remaining 
meniscal collagens
3-4
. The peripheral two-thirds of the meniscus solely consist of type I collagen, 
whereas type II collagen comprises a significant portion of the fibrillar collagen in the inner 
meniscus
5
. Type III and V collagen are trace elements in the peripheral part of the meniscus. Type I 
collagen fibers are radially and circumferentially orientated, providing resistance to tensile forces
6
. 
Aggrecan is a major proteoglycan in meniscal tissue
7
 and aggrecan aggregate content is higher in 
the inner and middle part than in the peripheral part of the meniscus
8
. Aggrecan plays an important 
role in the maintenance of optimal viscoelastic behaviour, compressive stiffness and tissue 
hydration. Other proteoglycans present are fibromodulin, biglycan and decorin
9
. The biochemical 
constitution of the extracellular matrix is a direct reflection of the tissue adaptation to local loads 
and is build up by the sparsely distributed meniscus cells, whose DNA accounts for 0.12% of the 
total wet weight of meniscal tissue
1
. 
Current concepts on meniscus cell biology indicate the existence of at least two cell populations in 
the human meniscus
10
. The main cell type in the inner and middle part of the meniscus has been 
termed the fibrochondrocyte
4
. This cell is defined as round or oval shaped surrounded by an 
abundant extracellular matrix
4,10
. The outer one third of the meniscus is populated by mainly 
fibroblast-like cells within a dense connective tissue
10
. The outer portion of the meniscus is also 
characterized by the presence of vascular and nervous elements
11-12
. This is in contrast to the middle 
and inner part of the meniscus which is avascular, aneural and alymphatic. Due to the absence of 
vasculature, lesions located in the inner and middle part of the meniscus, have less repair and 
regeneration potential than lesions located in the outer one third. 
Loss of meniscus tissue results in higher peak stresses on the articular cartilage and eventually leads 
to cartilage degeneration and osteoarthrosis
13
. This cartilage degeneration is directly proportional to 
the amount of meniscus that was removed
14
. 
Tissue engineering could be an alternative and promising option for the treatment of  meniscus 
defects. Tissue engineering is based on 3 basic ingredients: scaffolds, growth factors and cells. An 
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obvious cell type for this therapeutical approach would be the meniscus cell.. Since our knowledge 
about meniscus cell biology and behavior in vitro and in vivo is very limited, these investigations 
aimed at the characterization of the proliferation potential of the meniscus cell and the accumulation 
of the cell associated extracellular matrix. The cell associated matrix (CAM) is an integral part of 
the larger pericellular or territorial matrix of the meniscus cell. The biochemical composition of this 
CAM can easily be identified with flow cytometry and is an instant reflection of the cellular 
phenotype
15
. Ultimately, this cellular phenotype determines the biochemical and biomechanical 
characteristics of the tissue engineered construct. Since type I collagen, type II collagen and 
aggrecan are three important extracellular matrix components, these molecules were chosen to be 
analyzed in the CAM. The investigations were performed on two different culture conditions:  the 
monolayer culture and the culture in alginate hydrogel. The former allowed articular cartilage 
chondrocytes to proliferate and dedifferentiate. The latter allows low proliferation of articular 
cartilage chondrocytes maintaining their original phenotype. In parallel with the investigations on 
articular cartilage chondrocytes, the metabolical characteristics and behaviour of human knee 
meniscus cells were investigated in both culture conditions.   
 
Materials and methods 
 
MENISCUS CELL ISOLATION 
Complete, visually intact human lateral and medial menisci were harvested 24 hours postmortem in 
accordance with the currently accepted transplantation protocol of the hospital and approved by the 
local ethics committee. All donors had died after a short disease. None received corticosteroids or 
cytostatic drugs. 
Menisci were inspected macroscopically for gross degeneration. Anterior and posterior entheses and 
all synovial tissue was carefully trimmed of by sharp dissection. The specimens were then diced 
into 1x1x1 mm pieces. 
In order to obtain a single cell suspension these pieces were enzymatically digested for 4 to 6 hours 
with 3 mg/ml collagenase grade II (Clostridium Histolyticum, ICN Biomedicals Inc., Aurora , Ohio, 
USA) in Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO Invitrogen Co, Merelbeke, 
Belgium), supplemented with 10% fetal bovine serum (FBS, GIBCO Invitrogen Co), antibiotics and 
antimycotics (penicillin 10U/ml, streptomycin 10mg/ml, fungizone 0.025 mg/ml) (GIBCO 
Invitrogen Co), 0.002M L-glutamine followed by the addition for 1 to 2 hours of 2mg/ml pronase 
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(streptomyces griseus pronase E, Merck, Darmstadt, Germany) in DMEM, antibiotics and 
antimycotics, 0.002M L-glutamine
16
. Cells were washed, filtered and resuspended in Hanks 
balanced salt solution  without Ca
2+
 or Mg
2+
 (HBSS, GIBCO Invitrogen Co) at the appropriate 
concentration depending on the culture conditions. Cells were counted and viability checked using 
trypan blue exclusion test. Forty to 50 million cells could be isolated from 2 medial and 2 lateral 
menisci from one donor. Over 90% of isolated cells were viable. 
 
ARTICULAR CHONDROCYTE ISOLATION 
Human articular chondrocytes were isolated from the same donors as described elsewhere, with a 
few modifications
17
. Intact cartilage removed from the femoral condyles was diced into small 
fragments and chondrocytes were isolated by sequential enzymatic digestion (hyaluronidase, 
pronase and collagenase) of the extracellular matrix as described in detail
18
. Cells were washed, 
filtered and resuspended in HBSS without Ca
2+
 or Mg
2+
  at the appropriate concentration depending 
on the culture conditions. Cells were counted and viability checked using trypan blue exclusion test. 
 
THREE DIMENSIONAL CULTURE IN ALGINATE HYDROGEL 
Meniscus cell and articular chondrocyte cultures in alginate were prepared as described elsewhere, 
with some modifications
19
. Cells suspended in one volume of HBSS were carefully mixed with an 
equal volume of 2% (weight/volume) alginate (low-viscosity alginate from macrocystis pyrifera, 
Sigma-Aldrich, St Louis, MO, USA) in HBSS (previously autoclaved for 15 minutes), obtaining a  
final concentration of 5 x 10
6
 cells per ml in 1% alginate. Alginate beads formed when this cell-
alginate suspension was carefully dropped in an 102mM CaCl2 solution through a 23 Gauge needle. 
After a 10 minute polymerization period, the beads were washed twice in 0.9% NaCl and then 
cultured in 5ml of culture medium (DMEM, antibiotics, FBS 10% , L-glutamine, ascorbic acid 2-
phosphate 50g/ml). The culture medium was changed 3 times a week. The cells were cultured in a 
6 well plate (each well containing 30 beads, ± 1,5 x 10
6
 cells/well). In some experiments TGF1 
(25ng/ml final concentration, R&D Systems, Minneapolis, USA) was added to the meniscus cells 
cultured in alginate. 
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MENISCUS CELL MONOLAYER CULTURE  
Cells were seeded in a T25 flask (Nunc, Roskilde, Denmark) at an initial density of 2 x 10
5
 cells per 
square cm. The same culture medium was used as for the cells cultured in the alginate beads. 
Medium was changed 3 times a week.  
When monolayer cultures became confluent after 5 to 7 days of culture, cells were washed with 
phosphate buffered saline without Ca
2+
 and Mg
2+
 (PBS, GIBCO Invitrogen Co) prior to treatment 
with trypsin-EDTA (GIBCO Invitrogen Co) for 10 minutes. Culture medium with 10% FBS was 
used to neutralize the trypsine-EDTA solution. The cell suspension was centrifuged (1500 rpm, 10 
min) and washed with culture  medium. This allowed cell isolation with over 95% viability. Cells 
were reseeded at an initial seeding density of 2 x 10
4
 cells per square cm. 
 
MONOCLONAL ANTIBODIES  
Monoclonal antibodies (mAb) against different extracellular matrix (ECM) proteins included mouse 
anti-human aggrecan
20
 (clone 969D4D11, IgG1, Biosource, Nivelles, Belgium), type I (clone I-8H5, 
IgG2a, ICN Biomedicals Inc) and type II (clone II-4CII, IgG1, ICN Biomedicals Inc) collagen
21
. 
Mouse IgG1 and IgG2a (Becton Dickinson, Erembodegem, Belgium) were used as isotype – 
matched negative controls. 
The anti-human aggrecan mAb was shown to react specifically with the G1-domain of the 
invariable hyaluronan-binding region of the human aggrecan molecule. No cross-reactivity with 
other known matrix components has been detected
20-22
. Anti-human type I and type II collagen 
mAbs were raised in BALB/c mice after immunization with human placental type I collagen and 
human costal cartilage type II collagen, respectively. On western blots anti-type I collagen was 
shown to react specifically with the alpha chain and the triple helix molecular form of type I 
collagen. The anti- type II collagen mAb reacted specifically with the alpha2(II) chain of human 
type II collagen
21
.  
 
PREPARATION OF FITC-CONJUGATED MAB FOR FLOW CYTOMETRY 
Selected monoclonals were conjugated with fluorescein isothiocyanate isomer I (FITC, Sigma-
Aldrich) for direct immunofluorescence as described with some modifications
23
. Briefly, 1 mg/ml 
of the antibody was conjugated with FITC (0.2 mg/ml) in 0.5M carbonate/bicarbonate buffer, pH 
9.0 at 4°C in the dark during 24 hours. Conjugated mAb were separated from free FITC using 
Sephadex G-25 (Pharmacia, Uppsala, Sweden) gel permeation HPLC chromatography in PBS 
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solution at pH 7.2 . The optical density of the FITC-conjugated antibodies was measured at 495 nm 
(FITC) and 280 nm (mAb) by spectrometry (Ultraspec 1000E, Pharmacia Biotech). The degree of 
conjugation was calculated according to the following equation FITC/Protein= (2.87 x A495)/ (A280-
(0.35xA495)). Optimal conjugation requires a ratio between 3 and 5. Conjugated antibodies were 
stored at 4°C, in the dark, with 0.01% sodium azide.  
 
CELL MEMBRANE MARKERS 
Additional cell membrane markers were used during flow cytometric analysis to further identify the 
cell population isolated from human meniscal tissue. All markers were FITC conjugated mAbs and 
used according to manufacturer’s instructions. FITC-mAbs used were: FITC-CD31 (clone WM59, 
IgG1), FITC-CD34 (clone 581, IgG1,), FITC-CD44 (clone G44-26, IgG2b), FITC-CD45 (clone 
HI30, IgG1),  all from Becton Dickinson Pharmingen, Erembodegem, Belgium  and FITC-CD105 
(clone SN6, IgG1) from  Serotec, Oxford, UK. 
The expression of CD31, also named PECAM-1, is limited to endothelial cells, platelets, 
leukocytes, and their precursors
24
. CD34 is expressed on early lymphohematopoietic stem and 
progenitor cells, small-vessel endothelial cells, embryonic fibroblasts, and some cells in fetal and 
adult nervous tissue
24
. CD44 serves as a recyclable receptor for hyaluronan and is widely expressed 
on the surface of most cell types, including articular cartilage chondrocytes and bone marrow 
derived mesenchymal stem cells
24
. CD45 is expressed on all hematopoietic cells
24
. CD105 or 
endoglin modulates the cellular response to TGF1 and is expressed on many cell types including 
endothelial cells, articular chondrocytes, bone marrow derived mesenchymal stem cells, monocytes 
etc
24
. 
 
FLOW CYTOMETRIC ANALYSIS OF THE CELL ASSOCIATED MATRIX (CAM) OF CULTURED 
MENISCUS CELLS AND ARTICULAR CHONDROCYTES 
Meniscus cell cultures were analyzed on different time points of culture (week 1, week 2 and week 
3). Cells obtained from at least three donors were tested for every experimental condition. All tests 
were performed in threefold. 
Articular cartilage chondrocytes, cultured in alginate for 7 days, served as control.   
Cells cultured in alginate beads could be released from the gel by the addition of 2 ml sodium 
citrate 55mM to each culture followed by gently shaking. Ten ml of PBS without Ca
2+
 or Mg
2+
 
were then added to the cell suspension prior to centrifugation.  
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Meniscus cells cultured in monolayer conditions were harvested non-enzymatically by incubation 
with 1 mM EDTA in PBS without Ca
2+
 or Mg
2+
 for 30 minutes
15
. It was impossible to obtain a 
single cell suspension of the three week old monolayer cultures with the non-enzymatical protocol 
due to cell clustering. Therefore the analysis for this time point for the monolayer cultures was 
omitted.  
After centrifugation (1500 rpm, 10 min) the cell pellets were resuspended in PBS without Ca
2+
 or 
Mg
2+
. Hundred microliter of this suspension was incubated with 10l of the appropriate mAb 
(0.1g/l) during 30 min. After washing with 4 ml PBS without Ca2+ or Mg2+ cells were analyzed 
on a FACSort (Becton Dickinson) using Cellquest and WinMDI software. For each sample 
approximately 20,000 events were analyzed. Dead cells were excluded using propidium iodide (PI) 
staining as previously described
25
. Median cell fluorescence intensity (MFI) values were calculated 
per sample after binding of the mAb-FITC complex to the specific epitopes. This was done by 
substracting the MFI of the negative control from the MFI of the stained cell samples.   
 
PROLIFERATION ASSAY 
Meniscus cell proliferation was assayed by measuring the DNA content per culture in threefold per 
time point, using the Hoechst H 33258 dye method (Pharmacia Biotech Inc, San Francisco, CA, 
USA)
26
. Cells were isolated from alginate beads using sterilized sodium citrate solution or from 
monolayer  cultures using trypsin-EDTA solution. Cells were washed, pelleted and resuspended in 
500l sterile PBS without Ca2+ or Mg2+ and frozen at 80°C for further analysis. Prior to analysis the 
frozen aliquots were thawed at room temperature and sonicated for 1 minute . A 40l sample was 
added to a 2 ml Hoechst dye solution in TNE buffer (Tris 10mM, NaCl 200mM, EDTA Na2-2H2O 
1mM). Fluorescence was measured in a Hoefer dynaquant 200 fluorometer, using double strand calf 
thymus DNA (Sigma-Aldrich) in PBS as a standard. The emission was measured at 460 nm for an 
excitation wavelength of 365 nm
26
. 
 
HISTOLOGY  
To analyze cell morphology, histology was performed on both culture models as well as on native 
meniscus tissue. Native meniscus tissue was fixed in 4% aqueous parafolmadehyde and embedded 
in paraffine. Alginate beads were washed, fixed in 4% aqueous parafolmadehyde , 0,1M cacodylate 
buffer, pH 7,4 containing 10 mM CaCl2 for 4 hours at 20°C, then washed overnight at 4°C in 0,1M 
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cacodylate buffer containing 50mM BaCl2 and embedded in paraffine
27
. Five m paraffine sections 
were deparaffinized in xylene and rehydrated through ethanol before staining.  
A hematoxylin and eosine counter staining was performed to visualize cell body morphology. 
Additional immunohistochemistry, using monoclonal antibodies directed against CD31 
(monoclonal mouse anti human, isotype IgG1 Kappa, Clone JC70A, DAKO Cytomation Denmark) 
and CD34 (monoclonal mouse anti human, isotype IgG1 Kappa, Clone QBEnd 10, DAKO 
Cytomation Denmark) was performed on the meniscus tissue sections. This was preceeded by  
intrinsic peroxidase blocking with H2O2 0,3% in methanol  for 10 minutes. Non-specific antibody 
sites were blocked by ten percent human serum in PBS. Adequate isotype negative controls (mouse 
IgG1 and IgG2a, 100mg/L, DAKO, Carpenteria, CA, USA) were used in the same concentration. 
The sections were incubated with the mAB for 30 minutes at room temperature. After washing, 
samples were treated with biotinylated anti-mouse antibody, conjugated streptavidin peroxidase and 
AEC chromogen for respectively 15, 15 and 10 minutes (LSAB
®
+ system, DAKO).  
 
STATISTICS 
All experiments were done in threefold. Values obtained for the different variables, i.e. 
accumulation of ECM compounds, were expressed in mean ± 1 SD. Increase in DNA content 
during culture were depicted in Box-Whisker plots. Data were analyzed statistically using SPSS 
(version 11.0) and Medcalc software. Student’s t-test was used to examine whether variables for the 
meniscus cell cultures became significantly different over time in culture or after TGF1 treatment. 
P values of 0.05 were considered significant.  
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Results 
 
MENISCUS TISSUE HISTOLOGY AND CYTOLOGICAL TYPING 
Paraffin sections of full thickness meniscus tissue sample clearly show the presence of both  oval or 
round shaped fibrochondrocytes (fig 1.3 and 1-b) and spindle-shaped fibroblast-like meniscus cells 
(fig 1.2 and 1-a). The fibrochondrocyte is located in the avascular portion of the meniscus and is 
situated in a lacuna surrounded by an abundant extracellular matrix (fig 1.5). The fibroblast-like cell 
on the other hand is located in the outer portion of the meniscus (fig 1.5). In this dense connective 
tissue vascular structures can also be observed (fig 1.2). A synovial fold is observed at the edges of 
the meniscus (fig 1.1). The synovial sublining consists of a loose fibrous tissue with vascular 
structures.  
Additional staining for specific membrane markers revealed the existence of 3 distinct populations 
of  CD34 positive cells in the outer vascular portion of the meniscus body (fig 1.2), the superficial 
zone of the meniscus (fig 1.c) as well as in the sublining of the synovium. The first of these CD34 
positive cell populations has a fibroblast-like morphology, is mainly situated in the synovial 
sublining and the outer portion of the meniscus and is CD31 negative (fig 1.a). The synovial 
sublining tissue is interdigitated with the vascular region of the meniscus body. The second CD34 
positive-CD31 negative population is located in the superficial zone of the meniscus body and has a 
more round or oval shaped morphology (fig 1.c). The third distinct CD34 positive population is the 
endothelial lining of the vascular structures and is positive for CD31 (fig 1.1 and 1.2). The synovial 
lining (fig 1.1) itself does not stain for these markers nor does the deeper, avascular part of the 
meniscus body (fig 1.2 and 1.b). 
Figure 1. CD34 staining of the human meniscus. Figure 1.5 is a schematic representation of the meniscus within the knee 
joint showing both the vascularized outer third (vascular) as well as the avascular (avascular) part of the meniscus. 
Histological sections of 4 regions of interest are presented (fig 1.1-4). 
Figure 1.1: region located at the edge of the synovial-meniscus transition zone. The synovial lining itself is negative for both 
CD34 (arrow) and CD31 (data not shown). The subsynovial fibrous connective tissue is positive for CD34 but negative for 
CD31 (data not shown), while the endothelial lining of the vascular elements is positive for both CD34 (arrowhead) and 
CD31 (inset Fig 1.2). The superficial as well as the more deeper part of the outer one third of the meniscus contain CD34 
positive-CD31 negative fibroblast-like cells.  
Figure 1.2: region located within the vascularized one third of the meniscus. The inset figure represents a deeper region 
within the vascularized part of the meniscus stained for CD31. Vascular elements are observed within this region 
(arrowheads). Both endothelial lining as well as fibroblast-like cells stain positive for CD34. Only endothelial linig cells 
stain positive for CD31, while fibroblast-like cells do not (inset). A higher magnification of these fibroblast-like cells is 
shown in fig 1.a (CD34 staining).  
Figure 1.3. region within the avascular part (fig 1.5: avascular) of the meniscus. Oval or round shaped fibrochondrocytes 
situated within lacunae and surrounded by an abundant extracellular matrix, stain negative for CD34. A magnification of 
these cells is presented in fig 1.b. 
Figure 1.4: a superficial region of the meniscus body (avascular region). Fusiform to round shaped cells stain negative for 
CD31 (data not shown) and frequently positive for CD34. The deeper region of the meniscus however does not stain for 
CD34 (asterix). A magnification of this superficial region is presented in fig 1.c.  
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CELL MORPHOLOGY AND PROLIFERATION IN VITRO 
Meniscus cell morphology was studied on paraffin embedded alginate sections or directly on in 
vitro cultured cells using the inverted light microscopy. Cells seeded in monolayer conditions 
attached within 24 hours to the plastic surface. Two different cell types could be observed initially: 
round chondrocyte-like cells and fibroblastic spindle-shaped cells (fig 2A). After 4 to 5 days the 
round chondrocyte-like morphotype started to disappear from the culture and after one week all 
cells had a fibroblastic spindle-shaped appearance. Cells suspended in alginate beads were all round 
chondrocyte-like cells (fig 2B and fig 3). These cells are located within lacunae (fig 3). Cell 
morphology within the bead was uniformly stable for up to ten weeks. After 3 to 4 weeks in 
alginate culture, small cytoplasmatic projections could be observed in some cells. Cells remained 
viable for up to ten weeks of culture in alginate beads. 
Meniscus cells seeded in monolayer conditions expanded logarithmically (fig 2C). 
Meniscus cells cultured in alginate gel displayed a slight decrease in cell number, as reflected in the 
total DNA amount (fig 2D). In the presence of TGF1, however, meniscus cells cultured in alginate 
initially showed an increased proliferation (fig 2E).   
 
MEMBRANE MARKERS OF MENISCUS CELLS CULTURED IN ALGINATE 
Flow cytometric analysis from meniscus cells cultured in alginate reveals the presence of 4 distinct 
regions in the propidium iodide/ forward scatter (PI/FSC) plot according to cell size (FSC, X-axis) 
and propidium iodide staining intensity (PI, Y-axis):  PI-positive dead cells (fig 4A, R1), PI- 
negative debris (fig 4A, R2), and 2 distinct populations of PI-negative viable cells (fig 4A, R3a & 
R3b). R3a is clearly delineated from R3b.  
One day after enzymatic release, 80% and 15% of meniscus cells in R3a were positive for CD44 
and CD105, respectively (fig 4B). Less than 20% of these cells was positive for CD34 while less 
than 5% was positive for CD31 and  CD45 (fig 4B). The number of CD44 and CD105 positive cells 
subsequently increased over time to over 90 and 70 % , respectively (fig 4B). These numbers 
became stable around day 7 of culture, while the percentage of CD34 positive cells steadily dropped 
to less than 5% at day 14 (fig 4B). 
R3b contained 60% CD34-positive cells at initial evaluation, and <5% of cells were positive for 
CD31 or CD45 (fig 4C). The percentage of CD34 positive cells dropped to approximately 40% at 
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Figure 2. Morphology as observed with inverted microscope and growth characteristics of meniscus cells. A: Spindle-
shaped monolayer cultured (day 6) fibroblast-like meniscus cells. A sporadic round cell can still be observed (arrowhead) B: 
Oval or round shaped chondrocyte-like meniscus cells cultured in gelled alginate. C, D, E: Percentage increase in DNA 
content per culture in monolayer cultured meniscus cells (C), in meniscus cells cultured in alginate gel (D) and in meniscus 
cells cultured in alginate when exposed to TGF1 (E). Box plots are shown. Percentage increases over weeks in monolayer 
culture were 24% (p=0.162), 155% (p=0.001), and 562% (p=0.0001) after 7, 14 and 21 days, respectively. Percentage 
changes in alginate culture were  -14% (p=0.102), -4% (p=0.366), -13% (p=0.084) after 3, 6 and 14 days in culture, 
respectively. Percentage increase in alginate culture after exposure to TGF1 were 34% (p=0.173), 41% (p=0.049) and 51% 
(p=0.030) after 3, 6 and 14 days in culture, respectively. Abcissae: culture time in days. Ordinates: amount of DNA (g) per 
culture.  P-values result from 1-sided t-test on unpaired samples. 
 
 
 
 
 
 
 
 
 
 
 
Figure  3. Paraffin sections of meniscus cells cultured in 
alginate (week 3). Oval or round shaped meniscus cells located 
in lacunae can be observed.  
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day 7, while the percentage of CD44 and CD105 positive cells increased to 50% and 20%, 
respectively (fig 4C).    
However, the absolute cell number in R3b decreased steadily throughout the culture period and R3b 
disappeared completely from the scatter plot after approximately 2 weeks of culture (Fig 5). 
Taken all together, the percentage of cells expressing the different markers became stable after 
approximately 7 days of culture in alginate gel (fig 4B,C). 
 
 
 
THE CELL-ASSOCIATED MATRIX OF THE MENISCUS CELL IN ALGINATE 
Cells isolated from meniscal tissue are not a homogeneous population. The 2 distinct populations of 
viable, PI-negative cells that were identified as R3a and R3b (fig 6A) when gated on the PI/FSC 
plot, were defined as CAM-coated cells  and cells-without-CAM, respectively. The CAM-coated 
cells express type I collagen in high amounts, type II collagen in lower amounts and aggrecan in 
high amounts (fig 6C,D,E; table 1). The cells-without-CAM are devoid of  collagen and aggrecan in 
their CAM (fig 6F,G,H; table 1).  
The CAM profile of the CAM-coated cells differs from the profile of the articular chondrocytes 
cultured in alginate. The MFI values for type I collagen (fig 6I) are higher in the former while type 
II collagen (fig 6J) MFIs are lower. The CAM of articular chondrocytes contains higher amounts of 
aggrecan (fig 6K) than the CAM of the CAM-coated cells from meniscal tissue. Articular cartilage 
chondrocytes and meniscus cells were obtained from the same joint. Experiments performed on the 
respective tissue cells of a second donor yielded exactly the same results. 
An overview of the composition of the CAM of the one-week cultured CAM-coated cells  and cells-
without-CAM of 6 different donors is given in table 1. The CAM expression profile of the CAM-
coated cell population was followed for 3 weeks. The different meniscal cell samples varied widely 
in their capacity to accumulate matrix components in the CAM (table 1: C.V on average MFI 
values). Average cell MFI values due to the accumulation in the CAM of type I collagen decreased 
slightly though significantly over 2 weeks of culture, to reach a plateau from the second week on. 
The inverse was observed for CAM type II collagen kinetics. Average cell MFI values due to the 
accumulation in the CAM of aggrecan did not change over 3 weeks.  
The level of aggrecan in the CAM of CAM-coated cells, when cultured in the presence of TGF1 
(25 ng/ml) for one week, was significantly upregulated with 103 to 303% (p=0.042) (Table 2). 
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Figure 4. Expression of cell membrane markers by meniscus fibrochondrocytes during a two-week culture period in 
gelled alginate. A: propidium iodide (PI)/ forward scatter (FSC) plot according to cell size (FSC, X-axis) and PI 
staining intensity (PI, Y-axis):  R1: region 1 are PI-positive dead cells, R2: region 2 are PI- negative debris. R3a and b: 
region 3a and b are 2 distinct populations of PI-negative viable cells. B and C: Expression of cell membrane markers by 
cells gated in R3a and R3b, respectively. Abcissae: culture time in days. Ordinats: Percentage of positive cells. : CD 
44; : CD105; : CD34; : CD 45; : CD 31; : negative control IgG. 
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Figure 5. Propidium iodide (PI)/ forward scatter (FSC) plot according to cell size (FSC, X-axis) and PI staining 
intensity (PI, Y-axis) of meniscus cells at distinct time points (day 0, 1, 3, 7, 14) and cultured in gelled alginate. Donor: 
47-year-old male.The number of cells in region 3b (arrowhead) steadily decreased  over the culture period.  
 
 
 
Figure 6. Flow cytometric analysis of the cell-associated matrix (CAM) contents of human meniscus cells and articular 
cartilage chondrocytes. Donor: 55-year-old female. Cells harvested after one week of primary culture in gelled alginate. 
Propidium iodide/forward scatter plot of meniscus cells (A) and articular cartilage cells (B). See legend figure 4 for 
description of the regions of interest. Viable cells in R3a and b, and in R3 of dot plots A and B, respectively, were gated 
and analyzed for their CAM contents. Fluorescence intensity histograms are presented showing the expression of type I 
collagen, type II collagen and of aggrecan by viable meniscus cells in regions R3a (C,D,E) and R3b (F,G,H), and by 
viable articular cartilage chondrocytes gated in region R3 (I,J,K), respectively. White curves: negative controls, Grey 
curves: Mab-FITC labelled cells. Abcissae: cell fluorescence intensity. Ordinates: events (cells) observed by the flow 
cytometer.  
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Table 1: Composition of the cell-assocated matrix of meniscus cells cultured in alginate. 
MFI values due to the presence of FITC-mAb stained extracellular matrix compounds in 
CAM-coated cells and in cells without CAM      
 
                       CAM-coated cells                               cells without CAM 
 
          week 1           week 2         week 3                   week 1  
donor    mean ± 1SD   mean ± 1SD mean ± 1 SD       mean ± 1SD  
type I collagen 
M69      9.99 ± 0.77     8.10 ± 1.64  20.38 ± 1.09            0.37 ± 0.14  
M42      8.97 ± 0.62     7.56 ± 0.80    7.41 ± 0.67         0.48 ± 0.25  
F69    28.02 ± 1,78   24.96 ± 0,91  25.57 ± 8,21                  n.d   
M47    29.94 ± 3.96   25.08 ± 3.36          n.d           3.84 ± 0.24  
M65    22.35 ± 3.95   19.97 ± 6.33  14.60 ± 2.58               n.d   
F56    12.96 ± 2.08           n.d                         n.d           0.54 ± 0.23  
Average    18.71 ± 9.27   17.13 ± 8.74  16.99 ± 7.80         1.31 ± 1.69  
C.V             51.01               51.02               45.91     129.01  
p-value                         0.0106               n.s.         0.0052 
 
type II collagen       
M69 1.69 ± 0.07 3.24 ± 0.09  5.92 ± 0.18        0.30 ± 0.14  
M42 3.14 ± 0.41 4.17 ± 0,83  3.99 ± 0,77        0.35 ± 0.25  
F69 3.27 ± 0.58 5.16 ± 0.06  6.06 ± 1.52              n.d   
M47 4.59 ± 0.13 4.91 ± 0.16        n.d         2.36 ± 0.46  
M65 3.88 ± 0.58 4.20 ± 0.18  3.90 ± 0.71  n.d   
F56 2.65 ± 0.21       n.d         n.d         0.34 ± 0.04  
Average 3.20 ± 1.00  4.34 ± 0.75  4.97 ± 1.18        0.84 ± 1.02  
C.V             31.25               17.28               23.74     121.43  
p-value                         0.0324               n.s.         0.0095 
 
aggrecan  
M69 4.59 ± 1.15 9.16 ± 1.02          16.12 ± 1.58        0.08 ± 0.14  
M42 8.71 ± 1.69 7.12 ± 1.29  4.96 ± 1.08        0.28 ± 0.11  
F69            21.09 ± 2.35         16.84 ± 3.60          16.18 ± 1.53              n.d    
M47           23.07 ± 2.83         29.57 ± 5.76        n.d         1.38 ± 0.15  
M65           20.36 ± 4.46         23.76 ± 9.89          10.92 ± 2.88              n.d   
F56 4.47 ± 0.72       n.d         n.d         0.04 ± 0.05  
Average      13.72 ± 8.72         17.29 ± 9.52          12.05 ± 5.33         0.45 ± 0.63   
C.V            63.56               55.06               44.23     140.00 
p-value                         n.s.               n.s.         0.0134 
 
Donor: Sex/age are given; MFI: median fluorescence intensity value; CAM: cell-associated 
matrix; Mean ± 1SD for all individual experiments in triplicate are given in the table; bottom 
lines: Average: mean ± 1SD for all meniscus cell cultures. CV: Coefficient of Variation 
(1SD*100/mean) for the averages of the respective variables. The different meniscal cell 
samples vary widely in their capacity to accumulate matrix compononents in the CAM. P-
values: 2-sided t-test was done to test for differences in accumulation of ECM products by 
CAM-coated cells over 3 weeks. T-test for paired samples was done to evaluate differences 
in accumulation of ECM products by CAM- coated cells and cells without CAM at week 1. 
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Table 2: Influence of TGF1 on type I and II collagen and on aggrecan production in one-week 
cultured CAM producing meniscus cells in alginate 
 
      controls         TGF1            
type I collagen mean ± 1SD mean ± 1SD        difference (%)    p-value  
F69 28.02 ± 1.78 23.66 ± 2.76   -15.56        
F56 12.96 ± 2.08  15.04 ± 0.55    16.05       0.328    
M69   9.99 ± 0.77    9.37 ± 0.06     -6.26     
           
type II collagen mean ± 1SD mean ± 1SD         difference (%)     
F69   3.27 ± 0.58   3.59 ± 2.76     9.90     
F56   2.65 ± 0.21   3.21 ± 0.55   21.28       0.060    
M69   1.69 ± 0.07   1.81 ± 0.06     6.59     
     
aggrecan mean ± 1SD mean ± 1SD         difference (%)     
F69 21.09 ± 2.35 42.96 ± 2.12 103.75     
F56   4.47 ± 0.72 18.02 ± 0.93 303.06       0.042    
M69   4.59 ± 1.15 11.34 ± 1.15 147.06     
          
Donors: Sex/Age are given; Mean values ± 1SD for Cell Median Fluorescence Intensities 
are given for the 3 ECM components and for 3 donors; experiments done in triplicate. p-
values result from 1-sided t-tests on paired samples. 
 
 
 
Table 3: Comparison of cell-associated matrix composition of meniscus 
cells cultured in monolayers at different time points.  
 
         week 1         week 2  
type I collagen mean ± 1SD mean ± 1SD p-value 
M65 21.25 ± 5.15 14.47 ± 3.78 
M69 24.15 ± 3.25 13.57 ± 1.40   0.295 
F69 13.81 ± 5.22 20.92 ± 7.61 
 
type II collagen  mean ± 1SD mean ± 1SD 
M65 13.57 ± 3.21          13.41± 3.58 
M69 12.36 ± 5.40            6.37± 1.22   0.490 
F69   8.36 ± 2.95          14.81± 4.67 
  
aggrecan mean ± 1SD mean ± 1SD 
M65   4.57 ± 1.33  1.98 ± 1.07 
M69   4.51 ± 0.62 1.98 ± 1.05   0.057 
F69   1.71 ± 0.39 1.23 ± 0.27 
 
Monolayer cultured cells were investigated after a 1
st
 and 2
nd
 week of primary 
culture. Donors: Sex/age are given; mean values ± 1SD for cellular Median 
Fluorescence Intensities are given for the 3 ECM components and for 3 
donors; experiments done in triplicate. p-values result from 1-sided t-tests on 
paired samples. 
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CAM-coated cells are therefore capable to increase aggrecan production when cultured in alginate. 
A trend to increase was observed in the expression of type II collagen (range 6.5- 21.3%, p=0.060), 
while no clear effects could be noted in the expression of type I collagen. 
 
THE CELL-ASSOCIATED MATRIX OF MONOLAYER CULTURED MENISCUS CELLS 
Flow cytometric analysis of meniscus cells cultured in monolayer conditions reveals only three 
distinct populations: PI positive dead cells, PI negative debris and PI negative living cells . The 
CAM of the monolayer cultured meniscus cells contains high amounts of type I and II collagen (fig 
7A,B) and almost no aggrecan (fig 7C). The levels of type II collagen are however lower than type I 
collagen. Specific MFI values for the 3 matrix components in 3 different donors are presented in 
table 3. The CAM profile of meniscus cells cultured as monolayer is therefore distinctly different 
from the CAM profile of cells derived from the same donor but cultured in alginate (fig 7D,E,F); 
alginate cultured CAM-associated-cells have high amounts of type I collagen and aggrecan and low 
amounts of type II collagen in their CAM.   
When assessed over a 2-week culture period, aggrecan was apparently downregulated in monolayer 
cultured meniscus cells (table 3, p=0.057), whereas no changes were observed for both collagen 
types (Table 3)  
 
Discussion 
Human meniscus tissue is said to be populated mainly by round or oval matrix associated cells, 
comparable to the articular cartilage chondrocyte, and fibroblast-like cells
10
. The round or oval cells 
of the meniscus, however, produced more type I collagen than the articular chondrocytes
4
. The 
major fibrillar collagen produced by chondrocytes from the articular cartilage is type II collagen. 
Hence this meniscus cell was termed a fibrochondrocyte based on the difference in expression of 
collagen types
4
. Two other connective tissue cell types have been described in meniscus tissue 
according to their shape, location and presence of extracellular matrix: the superficial cell and a cell 
type of intermediate morphology between that of a fibrochondrocyte and fibroblasts
10,28
.  
Little is known about the cellular biology of the human meniscus or of these different distinct cell 
populations present in this tissue. Difficulties still arise when attempts are made to isolate and to 
characterize these different meniscus cell types in vitro. The cellular phenotype can be modulated 
by different culture conditions and certain culture conditions can favor one phenotype over another. 
Most data available are derived from whole tissue explant cultures or from monolayer cultured cells 
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Figure 7. Flow cytometric analysis of human meniscus cells. Donor: 55-year-old female. Cells harvested after one week 
of primary culture as monolayer (left histograms) or in gelled alginate (right histograms). Histograms show the 
expression of type I and II collagen and of aggrecan in monolayer cultured meniscus cells (A,B,C) and the expression of 
type I and II collagen and of aggrecan in meniscus cells that were maintained in culture in gelled alginate (D,E,F). 
White curves: negative controls, Grey curves: Mab-FITC labelled cells. Abcissae: cell fluorescence intensity. Ordinates: 
events (cells) observed by the flow cytometer.   
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where protein and mRNA levels are obtained from collections of cells 
29-32
. No specific data, 
however, exists on the cellular protein expression level.  
To our knowledge, this is the first study performed on isolated human meniscus cells, cultured in 
different conditions, where the production of the extracellular matrix is analyzed using flow 
cytometric analysis of the CAM. Flow cytometry allows study of the composition of the CAM of 
connective tissue cells
12,33,34
. This technique has allowed protein expression in the CAM of articular 
cartilage chondrocytes to be analyzed on a cellular level. After staining with the appropriate specific 
mAbs, the composition of the CAM of single cells has been analyzed and quantified according to 
their fluorescence intensity
15,33
. This CAM is an distinct part of the territorial matrix of the cell. 
Although the distribution and turn-over of the extracellular matrix have been shown to differ in the 
territorial and interterritorial matrix of articular cartilage cells, the CAM has been shown to 
represent about 25% of the newly formed extracellular matrix of these cells in culture 
36,37
. The 
content of the CAM, e.g. type I collagen, type II collagen and aggrecan, have been considered to 
define the instant cellular phenotype of articular cartilage cells
33
. Since no known standard exists, 
the CAM composition of meniscus cells cultured in different conditions was eventually compared 
to that of phenotypically stable human articular chondrocytes cultured in alginate
37
. Human 
articular chondrocytes are said to be phenotypically stable when maintained in gelled alginate
37
. 
The same articular chondrocytes cultured in monolayer conditions loose their chondrocyte specific 
characteristics and gain a more fibroblast-like appearance. This process is termed dedifferentiation 
and has been described numerous times on the cellular protein level, as well as on whole culture 
protein and mRNA levels
38-40
. Typically, type I collagen production by these cells was upregulated, 
and type II collagen together with aggrecan downregulated
15
. As hydrogels such as alginate or 
agarose are considered the artificial matrix of choice to culture phenotypically stable articular 
cartilage chondrocytes, the alginate gel was finally chosen for meniscus cell culture.  It was 
hypothesized that this culture model could possibly stabilize the meniscus fibrochondrocyte 
phenotype. Others have already demonstrated that isolated meniscus cells cultured in alginate 
synthesize proteoglycans similar to explant cultures in amount and composition, indicating a 
phenotype resembling the native situation
8
.  
With flow cytometry, we have analyzed the cells present in the human meniscus after culture for up 
to three weeks in alginate, and initially found 2 cell populations surviving the isolation procedure. A 
minor fraction consisting of CD34 positive-CD31 negative cells was mainly derived from the 
vascular portion of the meniscus body and was probably unable to remain viable in the alginate gel. 
However, the exact fate of this population in culture remains to be determined. This cell population 
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also did not accumulate significant amounts of extracellular matrix products in its CAM. Additional 
histology on human meniscus tissue confirmed the presence of CD34 positive-CD31 negative 
fibroblast cells in the vascular portion of the meniscus as well as the synovial sublining. 
Surprisingly, CD34 positive-CD31 negative cells were also observed in the superficial region of the 
meniscus body. These cells had a fusiform or more round/oval shaped morphology. It has been 
hypothesized previously that the CD34 positive-CD31 negative population, residing in the synovial 
sublining represents a possible pool of endothelial progenitor cells responsible for vasculogenesis
41
. 
The intriguing possibility has been raised previously that the superficial zone contains specialized 
cells, perhaps progenitor cells, that could initiate wound-healing
42-43
. Further research is however 
necessary to elucidate the exact phenotype and function of this cell population. CD34 positive-
CD31 positive cells were only observed within the vascular structure and are considered mature 
endothelial cells. 
The main fraction of isolated meniscus cells persisted in culture, accumulated significant amounts 
of ground substance in its immediate pericellular environment and displayed a stable phenotype. 
These cells were CD34 negative-CD31 negative. Morphologically, these round or oval shaped cells 
were very similar to the meniscus fibrochondrocyte. CAM composition consisted of high amounts 
of both type I collagen and aggrecan and low amounts of type II collagen. This composition 
resembles the native composition of the human meniscus extracellular matrix. Overall the 
proportion of type I collagen to type II collagen is said to be approximately 9 to 1 in meniscus 
tissue
4,44
. However, this proportion is known to vary considerably depending on the meniscus 
region. The proportion of type I to type II collagen in the inner meniscus is for example 1 to 1.5
45
.  
In this paper, interpretation of the flow cytometric results on cells maintained in alginate shows a 
proportion between 3 and 6 to 1 (type I to type II collagen). One should take into account (1) that 
this is only the CAM and not the complete matrix and (2) this is newly synthesized matrix since 
these cells have been isolated enzymatically, whereas values obtained in mature tissue are these of 
an extracellular matrix in homeostasis. The high proportions of aggrecan relative to that of type I 
collagen can be explained in a similar fashion as for articular cartilage chondrocytes. Metabolical 
half-life of aggrecan is known to be much shorter than that of collagen molecules
46-47
. Therefore, to 
obtain a stable amount of aggrecan in the extracellular matrix, aggrecan production has to be higher 
than collagen production.  
When compared to articular cartilage chondrocytes, the biosynthesis and accumulation of ECM 
compounds in the CAM of meniscus cells is clearly different: more type I collagen is synthesized, 
less type II collagen and aggrecan. Hence, the meniscus cell maintained in alginate appears to be a 
140
  
unique cell type with a unique CAM composition. Furthermore, our results indicate that TGF1 
increases cell proliferation and the synthesis of type II collagen and aggrecan. TGF1 is known to 
induce a similar increase in production of collagen type II and aggrecan  in articular chondrocytes
48
, 
intervertebral disc cells
49
 and chondroprogenitor cells
50-52
. It is therefore generally accepted that 
TGF1 promotes a chondrogenic phenotype. Others also observed an increase in aggrecan synthesis 
rates, an aggregation of aggrecan monomers in hyaluronan/aggrecan complexes and an increase in 
the production of the larger of the two small proteoglycans, putatively biglycan, in alginate cultures 
of meniscus cells, in the presence of TGF18  
The monolayer culture condition, known to induce articular chondrocyte dedifferentiation towards a 
more fibroblast-like cell type, resulted in a completely different CAM composition of the meniscus 
cell when compared to meniscus cell cultured in alginate. Aggrecan levels in the CAM were 
dramatically lower while type II collagen synthesis apparently was upregulated. Monolayer cultured 
meniscus cells all had a fibroblast-like morphology.  
Previous reports on monolayer cultured meniscus cells indeed indicate a significant and rapid 
decrease in synthesis of large aggregating proteoglycans, irrespective of the meniscus region from 
where they were derived
8
. 
No definite explanation can be given for the observed difference between monolayer cultured 
meniscus cells and those cells cultured in alginate. In light of the current knowledge on meniscus 
cell biology in situ and the different cell types present in the meniscus, it is tempting to state that 
both culture models favor the existence of a different meniscus cell type
43
. Anchorage independent 
cells such as articular chondrocytes and most probably meniscus fibrochondrocytes thrive in the 
alginate culture conditions, while anchorage dependant cells such as meniscus fibroblast-like cells 
would prefer monolayer culture conditions. It is therefore possible that meniscus fibroblast-like 
cells overgrow meniscus fibrochondrocytes in the monolayer condition. A second hypothesis could 
be that the fibrochondrocyte morphology and CAM composition can be modulated by the different 
culture conditions, as is generally accepted for the articular cartilage chondrocyte.  
This knowledge can be applied in cell-based tissue engineering applications. The biochemical and 
biomechanical characteristics of an engineered tissue are ultimately defined by the cell phenotype 
and should resemble native tissue. 
In conclusion, these studies aimed at the characterization of the human meniscus cell’s CAM 
synthesis and turnover in two different culture conditions. The composition of this extracellular 
matrix offers a variable defining the distinct phenotype of the cells homing in the meniscus. The 
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alginate culture conditions appear to favor the fibrochondrocyte meniscus cell with a cell associated 
matrix rich in type I collagen and aggrecan and lower quantities of type II collagen, while 
monolayer cultured meniscus cells have considerable amounts of type I and II collagen but almost 
no aggrecan in their CAM. This CAM composition is distinctly different from the CAM 
composition of phenotypically stable articular cartilage chondrocytes. These studies warrant further 
research into in vitro meniscus cell behavior and further definition of the different meniscus cell 
types. 
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III.D Bioengineered meniscus - preparative studies with candidate 
cells for implantation 
In this in vitro study, the authors investigated the fibrochondrogenic differentiation potential of 
human bone marrow derived mesenchymal stem cells (hBMSC) after expansion in autologous 
serum. In a second setup, the combination of hBMSC with a meniscus-shaped type I collagen 
scaffold was evaluated. hBMSC were isolated from adult human bone marrow aspirates and 
expanded in monolayer condition using DMEM supplemented with 10% autologous serum. 
hBMSC were subsequently either spun down to form a micropellet or loaded on a biodegradable 
type I collagen scaffold. Fibrohondrogenic differentiation was initiated by serum-free culture 
conditions and the addition of TGF1, dexamethasone, Ascorbic Acid-2-Phosphate and ITS premix 
to the medium. Immunohistochemical analysis revealed a specific time-dependent pattern of 
expression of the different extracellular matrix components (type I and II collagen, aggrecan). At 
week 3 the extracellular matrix composition resembled closely the composition of native meniscus 
tissue. Depending on the method used to load the hBMSC on the scaffold, these cells were either 
located superficially or more evenly distributed within the scaffold. In summary, hBMSC expanded 
in autologous serum have a meniscus cell-like differentiation potential. hBMSC can be combined 
with a biodegradable meniscus-shaped scaffold. This cell-scaffold combination can be implanted 
easily into the meniscus defect thereby delivering autologous hBMSC with meniscus repair 
potential to this defect.  
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Introduction 
The meniscus plays an important role in the complex biomechanics of the knee joint. It has function 
in load bearing, load transmission, shock absorption, joint stability, joint lubrication and joint 
congruity. Loss of this important anatomical structure results in higher peak stresses on the cartilage 
and eventually leads to cartilage degeneration and osteoarthritis, as observed by Fairbank over fifty 
years ago.
1
 
 
The human meniscus is also known to have a poor healing potential, partly due to the absence of 
vasculature: blood vessels are present only in the outer 10-30% of the meniscal body.
2
 Lesions 
located in this area can be surgically sutured with a high success ratio.
3
 The more frequent lesions 
situated in the avascular part, however, show no or only limited tendency to heal and should hence 
be resected.
4
 A partial instead of total meniscectomy is proposed, knowing that cartilage 
degeneration is proportional to the amount of meniscus that was removed.
5
 Still, partial 
meniscectomy results in approximately 4% articular cartilage volume loss per year.
6 
Substantial research has already been performed to substitute the resected meniscus in case of a 
total or partial meniscectomy, in order to prevent or delay cartilage degeneration, improve 
biomechanics and relieve pain. Possible surgical approaches include the use of autologous or 
allogenic tissues: e.g. tendon
7
, pediculated Hoffa fat pad
8
, periosteal tissue
9
, perichondral tissue
10
, 
small intestine submucosa
11
, meniscal allografts
12-14
, meniscus scaffolds based on native polymers 
(collagen and hyaluronic acid)
 15
 or purely synthetic scaffolds such as poly-lactic acid, poly-
glucuronic acid and poly-urethane
16
. Other than meniscal allografts and a collagen type I based 
meniscus scaffold (CMI®, Regen Biologics, Franklin Lakes, NJ, USA), none of these materials 
have advanced to human clinical use. These surgical approaches are based on the concept of a 
timely colonization of the acellular scaffold or allograft tissue by host cells which are probably 
derived from the synovium and joint capsule.
17,18
 The phenotype of these host-derived scaffold-
colonizing cells ultimately determines the biochemical composition and biomechanical behaviour of 
these repopulated scaffolds or tissues. Another variable in this approach is the time needed for 
colonization of the scaffold or tissue: since these scaffolds or tissues are biodegradable, the 
colonization and healing by host cells should be faster than the degradation process, for the 
regeneration or healing of the meniscus substitute to be successful. Previous animal studies have 
provided evidence that fresh meniscus allografts are quickly invaded by host cells within one month 
after transplantation.
17,19
 In the human model, however, only limited data is available. A previous 
study performed at our institution, has provided evidence that this process of colonization is 
considerably slower in the human model: DNA fingerprint analysis, performed on human viable 
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meniscal allograft biopsies taken up to 36 months after transplantation, showed that these allografts 
contained only donor-derived cells in a number of case.
20
 These data substantiate observations 
published elsewhere on transplanted human deep-frozen meniscal allografts and collagen scaffolds. 
Histological sections on these specimens showed a decreased cellularity after transplantation, 
indicating insufficient repopularisation of the graft or scaffold.
18,21
   
Hence, an increase of the initial cell number at the defect site and thereby a decrease of the time 
needed for colonization can be accomplished by seeding autologous cells with a proven meniscus 
repair potential on or in a biodegradable scaffold prior to implantation.    
Several different autologous cell types have already been described in the literature for meniscus 
repair and substitution: meniscus cells
22
, articular chondrocytes
23
 and bone marrow derived 
mesenchymal stem cells.
24-26
 
In this in vitro study, the authors investigated the combination of human bone marrow derived 
mesenchymal stem cells (hBMSC) with a type I collagen scaffold for the repair of meniscus defects. 
hBMSC are multipotent cells capable to differentiate into multiple mesenchymal cell lineages such 
as myoblasts, chondrocytes, adipocytes and osteoblasts.
27
 These cells can be easily isolated from 
human bone marrow and expanded without loosing their multipotent characteristics in monolayer 
conditions.
27
 Therefore, after hBMSC expansion, the use of these autologous cells for tissue 
engineering purposes appears reasonable.  
Bovine serum is the usual supplement to the medium for hBMSC expansion. However, bovine 
serum proteins attach to the cell membrane and could thus elicit unfavorable immune responses in 
the host. In addition, the transmission of bovine diseases remains to be an issue. Autologous serum 
could replace serum of bovine origin for cell expansion, thus eliminating these concerns.  
Therefore, in a first setup, the fibrochondrogenic (or meniscus cell-like) differentiation potential of 
hBMSC after expansion in autologous serum was investigated in vitro. In a second setup, hBMSC 
were seeded on a type I collagen scaffold. Different cell-seeding protocols were investigated. 
Again, the cell differentiation potential and the colonisation behaviour were investigated. 
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Materials and Methods 
 
PREPARATION AND CULTURE OF HUMAN BONE MARROW DERIVED MESENCHYMAL 
STEM CELLS (HBMSC) 
Human bone marrow was obtained from patients undergoing spinal surgery. Patients were 
otherwise healthy. Fifteen to 20 ml of bone marrow was harvested from the posterior iliac crest in a 
syringe (Becton Dickinson biopsy needle for bone marrow) containing 20.000U of heparin and was 
processed immediately. The study protocol was approved by the local ethics committee.   
The bone marrow sample was diluted with one volume of phosphate buffered saline (PBS, Gibco 
Invitrogen Corp, Merelbeke, Belgium).  Four milliter aliquots of bone marrow suspension were 
applied on 4 ml aliquots of Ficoll Paque PLUS  density gradient medium (Amersham Bioscience, 
Freiburg, Germany). After centrifugation (1500 rpm, 20 min), interfaces were collected and washed 
once with medium: Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco Invitrogen Corp) 
supplemented with antibiotics (penicillin 10U/ml, streptomycin 10mg/ml, fungizone 0.025 mg/ml) 
and 0.002M L-glutamine (Gibco Invitrogen Corp). The pellet was resuspended and the cells were 
seeded on plastic dishes (Nunc, Roskilde, Denmark) at an initial seeding density of 200.000 to 
400.000 cells/cm
2
. Non-adherent cells were removed from the culture by subsequent medium 
changes. Culture medium consisted of DMEM supplemented with either 10% autologous serum. 
Autologous serum was prepared under sterile conditions from approximately 40 ml of autologous 
blood collected by a venipuncture immediately prior to the general anaesthesia.  
hBMSC were selected based on their capacity to adhere and proliferate under the specified 
conditions. Colony forming unit were generally observed after 4 to 5 days. Cells were expanded in 
monolayer conditions for up to 2 weeks before the first subculture. Cultures were trypsinized 
(Trypsin/EDTA solution, Gibco Invitrogen Corp) at 80% confluence and replated at a seeding 
density of 2000 to 5000 cells/cm
2
 from then on. Cell proliferation was quantified with a Bürker 
chamber at the time of replating. All cells used in this study had undergone no more than 2 passages 
and had an undifferentiated morphotype.  
 
FLOWCYTOMETRY  
Flowcytometry was performed on a FACScan (Becton Dickinson, Erembodegen, Belgium) to 
observe homogeneity of the hBMSC. All markers were used according to the manufacturer’s 
instructions. Monoclonal antibodies (mAb) used were: FITC-CD34 (clone 581, IgG1), FITC-CD44 
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(clone G44-26, IgG2b), FITC-CD45 (clone HI30, IgG1),  PE-CD73 (clone AD2, IgG1) all from 
Becton Dickinson Pharmingen, Erembodegem, Belgium  and FITC-CD105 (clone SN6, IgG1) from  
Serotec, Oxford, UK. 
CD34 is expressed on early lymphohematopoietic stem and progenitor cells, small-vessel 
endothelial cells, embryonic fibroblasts, and some cells in fetal and adult nervous tissue.
28
 CD44 
serves as a recyclable receptor for hyaluronan and is widely expressed on the surface of most cell 
types, including articular cartilage chondrocytes and bone marrow derived mesenchymal stem 
cells.
28
 CD45 is expressed on all hematopoietic cells.
28
 CD105 or endoglin modulates the cellular 
response to TGF1 and is expressed on many cell types including endothelial cells, articular 
chondrocytes, bone marrow derived mesenchymal stem cells, monocytes, etc.
28
 CD73 reacts with 
ecto-5’-nucleotidase, a 70 kDa, glycosyl phosphatidylinositol (GPI)-anchored glycoprotein. CD73 
is expressed on subsets of T and B lymphocytes, follicular dendritic cells, epithelial cells and 
endothelial cells.
28
 
Appropriate negative controls were used according to the instructions of the manufacturer 
(IgG1FITC, IgG1PE). 
 
FIBROCHONDROGENIC DIFFERENTIATION ASSAY OF HBMSC EXPANDED IN MEDIUM 
SUPPLEMENTED WITH 10% AUTOLOGOUS SERUM 
Expanded hBMSC were washed twice in phosphate buffered saline (PBS, Gibco Invitrogen Corp) 
and resuspended at a final cell concentration of 500.000 cells/ml in differentiation medium 
consisting of DMEM supplemented with rhTGF1 (final concentration 10ng/ml, R&D systems, 
Minneapolis, MN, USA), dexamethasone (final concentration 100ng/ml, Sigma-Aldrich, Bornem, 
Belgium), Ascorbic Acid 2 phosphate (final concentration 50g/ml, Sigma-Aldrich) and ITS 
premix (Becton-Dickinson, prepared according to the instructions of the manufacturer) [15]. This 
cell suspension was added to a round bottom polypropylene tube (Eppendorf AG, Germany) and 
pelleted down for 6 min at 800 rpm. The differentiation medium was changed twice a week. These 
culture conditions yielded reproducible cell condensations or so-called micropellets. These 
micropellets were cultured for up to 3 weeks. This differentiation protocol has previously been 
described to induce so-called chondrogenic differentiation.
27,29
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COMPOSITION AND PERMEABILITY OF THE COLLAGEN SCAFFOLD 
Techniques for the formulation and fabrication of the collagen meniscus implant have been reported 
in detail previously.
15
 Briefly, the collagen meniscus implants are fabricated from type I collagen 
derived from U.S.-origin bovine Achilles tendons. After the tendon tissue is trimmed and minced, 
the type I collagen fibers are purified by various chemical treatments to remove noncollagenous 
materials and lipids. Next, the purified collagen fibers are swelled in hyaluronic acid and 
chondroitine sulphate, and then homogenized. The swollen collagen fibers plus the 
glycoaminoglycans are coprecipitated by the addition of ammonium hydroxide. The precipitated 
fibers are dehydrated, lyophilized and chemically crosslinked. Terminal sterilisation is performed 
by  irradiation. Pore sizes range from 50 to 500 m.  
To visualize the permeability of the collagen scaffold, different cell-seeding protocols were 
pretested using 250 l of India ink. India ink, traditionally used for drawing, is a dispersion of 
carbon black (dye) in water (solvent). Carbon black particle size varies roughly between 10 and 400 
nm. India ink was applied in the identical way as for cell-seeding from (1) the dorsal side (D) of the 
scaffold (figure 1A), (2) the lateral sides (L) (figure 1B) or (3) injected into the scaffold from the 
dorsal side (I) (figure 1C). For both D and L seeding, the India ink was applied with a tipped pipette 
in aliquot of 50 l while the scaffold was gently squeezed and relaxed to enhance ink adsorption, 
comparable to a sponge. For I, aliquots of 50 l where injected into the scaffold from the posterior 
side at different levels. The scaffold (thickness 5 mm) was subsequently dried and cut in two both 
axially and transversely to observe staining of the centre of the scaffold. Macroscopic pictures were 
taken for later analysis. 
 
Figure 1. Overview of the different techniques used to load the India Ink or the cells on the scaffold. (A,D,G) 
application from the dorsal side of the scaffold with a tipped pipette; (B,E,H) application from the lateral sides with a 
tipped pipette; (C,F,I) injection from the dorsal side. The India Ink-loaded scaffolds were subsequently dried and cut 
sagitally (D-F) and axially (G-I) to visualize staining of the core of the scaffold.  
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HBMSC SEEDING ON COLLAGEN SCAFFOLD 
At the end of the second passage, monolayer cultured cells were trypsinized, washed and 
resuspended in Hank’s balanced salt solution (HBSS, Gibco Invitrogen Corp) at a density of 10 
million cells per ml. Two and a half million cells suspended in 250 l were seeded on the type I 
collagen scaffold (CMI®, Regen Biologics, Franklin Lakes, NJ, USA) (thickness of the scaffold 3 
mm) according to the previously described seeding protocols (D+L, I). To allow the cells to attach 
to the scaffold, the cell-scaffold combination was transferred to the incubator for 4 hours. 
Differentiation medium was added after these 4 hours. Medium was changed three times a week. 
Cell-seeded-scaffolds were cultured for three weeks.  
 
IMMUNOHISTOLOGY 
Immunohistological analysis of the extracellular matrix was performed to determine the cellular 
phenotype during differentiation. Immunohistology was performed on frozen sections of 
micropellets (Jung tissue freezing medium, Leica Instruments, Nusslock, Germany) and parafffine 
embedded samples of the scaffold-cell combination cultured for 1, 2 or 3 weeks. Monoclonal 
antibodies (mAb) raised against meniscus specific proteins included mouse anti-human 
aggrecan
30
(clone 969D4D11, IgG1, Biosource, Nivelles, Belgium), type I (clone I-8H5, IgG2a, ICN 
Biomedicals Inc, Aurora , Ohio, USA) and type II (clone II-4CII, IgG1, ICN Biomedicals Inc) 
collagen
31
. Mouse IgG1 and IgG2a (Becton Dickinson) were used as isotype – matched negative 
controls. 
The anti-human aggrecan mAb was shown to react specifically with the G1-domain of the 
invariable hyaluronan-binding region of the human aggrecan molecule. No cross-reactivity with 
other known matrix components has been detected.
30-32
 Anti-human type I and type II collagen 
mAbs were raised in BALB/c mice after immunization with human placental type I collagen and 
human costal cartilage type II collagen, respectively. On western blots anti-type I collagen was 
shown to react specifically with the alpha chain and the triple helix molecular form of type I 
collagen. The anti- type II collagen mAb reacted specifically with the alpha2(II) chain of human 
type II collagen.
32
  
Toluidine blue staining was performed to visualize the proteoglycan content in the extracellular 
matrix. 
Immunohistology for type I and type II collagen on frozen or paraffin embedded sections was 
performed as describe previously.
33
 Briefly, a number of sections were pretreated with 
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chondroitinase ABC (40 mU/ml, 30 min, 37°C, Sigma-Aldrich) in order to enhance collagen 
epitope presentation. The sections were subsequently incubated for 1 hour at room temperature with 
10 % human serum to reduce aspecific reactivity. After washing, the appropriate mAb was applied 
for 1 hour. Subsequently, the sections were incubated with a secondary biotinylated anti-mouse 
antibody for 15 minutes, followed by 15 minutes with a streptavidine-peroxidase complex (LSAB+ 
kit, DAKO, Glostrup, Denmark). The color reaction was developed using 3-amino-9-ethylcarbazole 
(AEC) substrate (DAKO) as chromogen. Finally, the sections were counterstained with 
haematoxylin. 
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Results 
 
FLOW CYTOMETRY 
Cell membrane analysis performed at the end of the second passage revealed a homogenous 
population positive for CD44, CD105 and CD73 and negative for CD34 and CD45, indicating the 
absence of hematopoeietic stem cells in the culture. CD44, CD105 and CD73 are considered as 
unspecific hBMSC membrane markers.  
 
FIBROCHONDROGENIC DIFFERENTIATION ASSAY ON HBMSC EXPANDED IN MEDIUM 
SUPPLEMENTED WITH 10% AUTOLOGOUS SERUM. 
hBMSC from bone marrow samples of three consecutive patients were expanded in culture medium 
supplemented with 10% autologous serum and subjected to the differentiation assay. Cell 
condensations were reproducibly observed after 1 day in every assay. Immunohistochemical analyis 
revealed a specific time-dependent pattern of expression of the different extracellular matrix 
components. Figure 2 depicts the immunohistological results for the fibrochondrogenic assay of 
hBMSC derived from a 28 years old patient. Comparable results were obtained for all three patients 
(aged 28, 42 and 35). Type I collagen was observed early on (week 1, figure 2A) and remained 
present throughout the culture period (figure 2B,C). Type I collagen immunoreactivity was also 
observed throughout the full diameter of the micropellet. This was in contrast with the expression of 
type II collagen (figure 2D-F) and aggrecan (figure 2G-I). Both extracellular matrix components 
were clearly observed at week 2 and week 3 but were absent or only slightly present at week 1. The 
expression of both components was first observed close to the periphery of the micropellet and 
progressed to the center of the micropellet over time. 
Overall, the diameter of the micropellets as well as the distance between cells increased over time 
indicating an accumulation of extracellular matrix. Cells inside the micropellet became more 
rounded and were situated in lacunae. A layer of more fibroblast-like cells could be visualized at the 
periphery of the micropellet (figure 3A). This cell-layer was 3-5 cells in thickness and did not stain 
for type II collagen and aggrecan .    
 
PERMEABILITY OF THE COLLAGEN SCAFFOLD 
A clear difference in the staining pattern could be observed between the different seeding protocols. 
Application of the India ink from the dorsal side (figure 1A) or from the lateral sides (figure 1B) 
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Figure 2. Immunohistological results of the fibrochondrogenic differentiation assay of hBMSC expanded in medium 
supplemented with 10% autologous serum of a male patient (28 years of age). (A-C) Type I collagen; (D-F) Type II 
collagen; (G-I) Aggrecan. (A,D,G) Week 1; (B,E,H) Week 2; (C,F,I) Week 3. Type I collagen is already expressed at 
week 1 (A), while type II and aggrecan expression becomes clear at week 2 (E,H). At week 3 type I collagen, type II 
collagen and aggrecan can be visualized throughout the entire micropellet diameter (C,F,I). With increasing culture 
time, a clear increase of the micropellet diameter can also be observed.  
 
Figure 3. A peripheral fibroblast-like cell layer with a thickness of 3-5 cells can be observed in both (A) the micropellet 
culture system and (B) the cell-scaffold culture. This layer does not stain for type II collagen and aggrecan. 
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Figure 4. Immunohistological results of the hBMSC-seeded biodegradable scaffold after 3 weeks of culture. Staining 
for type I collagen (A,B), type II collagen (C,D) and aggrecan (E,F).  Fibrochondrocyte-like cells are mainly situated at 
the periphery of the scaffold when the hBMSC were loaded from the dorsal and lateral sides (A,C,E). Injection of 
hBMSC from the dorsal side resulted in fibrochondrocyte-like cells distributed more evenly throughout the scaffold 
(B,D,F).  
 
Figure 5. Toluidine blue staining of hBMSC-seeded biodegradable scaffold. (A) Week 1: high cellular  density with 
only minimal extracellular matrix, negative for toluidine blue. (B) Week 2: abundant extracellular matrix, staining 
positive for toluidine blue. Again a superficial fibroblast-like cell layer can be visualized, which does not stain for 
toluidine blue. 
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resulted in a staining of the periphery of the scaffold only. The core of the scaffold did not stain as 
is clearly shown in figure 1 (dorsal: figure 1D,G; lateral: figure 1E,H) This is in contrast with 
staining by injection of the India ink; both the periphery and the core of the scaffold stained 
completely (figure 1F,I,).     
 
HBMSC SEEDED ON A COLLAGEN SCAFFOLD  
a. seeding from dorsal and lateral (D+L) side 
hBMSC attach and encapsulate the type I collagen scaffold (fig 4A,C,E). Histological observations 
comparable to hBMSC cultured as a micropellet were made for the cell-seeded scaffold. Multiple 
cell layers were observed at the surface of the scaffold. A slow ingrowth of these cells into the 
scaffold was present. The most superficial two to three cell layers are more fibroblastic in 
appearance (figure 3B), while the deeper cell layers produce an abundant extracellular matrix 
consisting of type I collagen (figure 4A), type II collagen (figure 4C) and aggrecan (figure 4E) at 
week 3 of culture. These cells in the deeper layers were situated in lacunae, as seen in native 
meniscus tissue. Toluidine blue staining became positive at week 2, indicating the accumulation of 
proteoglycans in the extracellular matrix (figure 5B). 
A slow colonisation of the scaffold by hBMSC was observed over the culture period. This 
colonisation started at the surface of the scaffold and was more pronounced at the corners of the 
scaffold. A complete colonisation of the scaffold, however, was never observed after 3 weeks.   
b. seeding by injection (I) 
Concerning time of expression and staining intensity for the different extracellular matrix 
compounds (type I collagen, type II collagen and aggrecan) after seeding by injection (I), the 
histological observations were completely comparable with the observations made using previously 
described seeding (D+ L) protocols (figure 4B,D,F). A clear difference however was noted on the 
depth of penetration of the cells into the scaffold. Cells could be observed almost completely 
throughout the scaffold, both at the periphery and the core. The cells were situated in between the 
lamellar structure of the scaffold (figure 6).  
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Figure 6. Type I collagen stain of hBMSC-loaded biodegradable scaffold (injection, week 3). The cells are situated in 
lacuna and surrounded by an abundant extracellular matrix, comparable to native meniscus tissue (arrow). Laminar 
remnants of the scaffold are visible (asterix). Note the ‘interdigitation’ of the extracellular matrix and the scaffold, proof 
of ingrowth. 
 
Discussion 
Lesions of the inner two-thirds of the meniscus have no healing potential because of the absence of 
vasculature. It is common practice to excise these lesions because they cause a mechanical conflict 
inside the knee joint. Unfortunately, compartimental cartilage degeneration and osteoarthritis is 
frequently observed after meniscectomy. Therefore, repair or regeneration of meniscal tissue has 
been considered as a therapeutic option for irreparable meniscus damage. It would safeguard the 
underlying cartilage from degeneration and improve biomechanics of the knee joint.  
Several different scaffolds and cell-types can be used for this purpose. To our knowledge, only the 
type I collagen scaffold has shown some repair and regeneration potential of meniscus-like tissue in 
the clinical situation.
15,34
 Reproducible, full restoration of meniscal tissue however has never been 
obtained.
 15,34
  Multiple explanations for this incomplete restoration can be offered, among which 
(1) too slow a repopulation of the scaffold by recipient cells derived from the synovium and joint 
capsule (2) combined with an uncertain fibrochondrogenic differentiation potential of these cells.  A 
previous study performed at our institution, has provided evidence that this process of repopulation 
is considerably slower in the human model than in animal models: DNA fingerprint analysis, 
performed on human viable meniscal allograft biopsies taken up to 36 months after transplantation, 
showed that these allografts contained only donor-derived cells in a number of cases.
20
 These data 
substantiate histological observations published elsewhere on transplanted human deep-frozen 
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meniscal allografts and collagen meniscus implants (CMI). Histological sections on these 
specimens showed a decreased cellularity after transplantation, indicating incomplete repopulation 
of the graft or scaffold.
 18,21
 Evidence for fibrocartilagenous or meniscus-like tissue regeneration by 
host cells derived from the synovial tissue and capsule has been provided in animal 
experiments.
35,36
 Again, human data on this subject are scarce and not conclusive. Deep-frozen 
meniscal allografts are repopulated by a mainly fibroblast-like cell type of probable synovial 
origin.
18
 Histological analysis of specimen obtained 6 months after CMI implantation showed 
remnants of the scaffold and connective tissue with newly-formed vessels and fibroblast-like cells.
21
  
The authors therefore chose to further investigate the combination of this commercially available 
type I collagen meniscus implant (CMI) scaffold in combination with autologous cells. This 
combination of a biodegradable scaffold and autologous cells with a reproducible repair potential 
could increase the initial number of cells present in the scaffold at the time of transplantation and 
thus decrease the time needed for repopulation. 
Several autologous cell-types have been considered for this application. Meniscus cells can be 
isolated from the resected torn meniscus or from a biopsy of healthy tissue. In both cases is the 
number of cells usually small and the quality of the cell phenotype possibly compromised by in 
vitro expansion.
22
 A biopsy would imply additional damage to functional tissue. Autologous 
articular chondrocytes have shown repair potential of meniscus tears in a pig model.
23
 Potential 
drawbacks are however the biochemical composition of the extracellular matrix and again the need 
for an additional invasive biopsy. Mesenchymal stem cells have generated a great deal of interest in 
the field of regenerative medicine and tissue engineering because of their ability to proliferate in 
monolayer conditions without losing their differentiation potential towards several connective tissue 
lineages including bone, fat, cartilage and muscle.
7
  
Human bone marrow provides a convenient source of mesenchymal stem cells.
7
 Other sources 
including synovial tissue, periost, muscle and adipose tissue have been described and tested 
extensively.
37-40
 Of these, synovial tissue and bone marrow showed superior chondrogenic potential 
and proliferation.
40
 For this study, human bone marrow derived mesenchymal stem cells (hBMSC) 
were used because of the ease with which these cells can be isolated and expanded while retaining 
their differentiation potential.  
The potential clinical applicability of autologous cells in combination with a scaffold depends not 
only on the cells source and type, but also on the cell expansion conditions. Usually, serum of 
bovine origin is used to expand human cells and more specifically hBMSC. The use of bovine 
serum for cell expansion for transplantation purposes, however, is disadvantageous. The concerns 
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of disease transmission and unfavourable immune responses can be solved if autologous human 
serum provides adequate differentiation potential to hBMSC.  
In this study, we have provide proof that hBMSC expanded in monolayer conditions with culture 
medium supplemented with 10% autologous serum demonstrate, in a reproducible way, a cellular 
phenotype characterized by the presence of type I collagen, type II collagen and aggrecan in the 
extracellular matrix, when subsequently cultured in serum-free conditions and stimulated by TGF 
beta 1 and dexamethasone. These three compounds are typical for the extracellular matrix build-up 
by fibrochondrocytes from the native human meniscus.
41
 Therefore, we define this cellular 
differentiation pattern to be fibrochondrogenic or meniscus cell-like. Previous studies have defined 
this differentiation pattern as chondrogenic.
27,29
 We strongly disagree with this definition as type I 
collagen is not an extracellular matrix compound of human hyaline articular cartilage. With regards 
to isolation, expansion and osteogenic differentiation of hBMSC, others have demonstrated that 
10% autologous serum is comparable to 10% fetal bovine serum.
42-44
 
We have also demonstrated that hBMSC attached and were able to undergo fibrochondrogenic 
differentiation when seeded onto the type I collagen scaffold or injected into it. Injection of the cells 
resulted in a significantly higher number of cells present within the scaffold compared to superficial 
seeding. Therefore, for the clinical application of a cell-scaffold construct injection would result in a 
higher number of cells at the site of injury and thus a decrease in the time needed to completely 
repopulate the scaffold. Fibrochondrogenic differentiated hBMSC showed a limited capacity to 
repopulate the scaffold when seeded superficially. The India Ink results substantiated these 
findings: small black carbon particles were  excluded from the core of the scaffold probably as a 
result of the relatively watertight laminar structure of the scaffold when the ink was applied dorsally 
or laterally. This could also partially explain the incomplete repopulation of acellular scaffolds and 
grafts observed in the clinical situation today.  
Although full characterisation based on membrane markers of hBMSC is still in progress, it is 
generally accepted that these cells are CD44+CD105+CD34-. Previous studies performed at our 
institution have shown that phenotypically stable meniscus fibrochondrocytes cultured in alginate 
are CD44+CD105+CD34-, comparable to the expression pattern of monolayer cultured hBMSC.
41
 
A specific cell population of the normal human meniscus is however CD34+ and is located in the 
superficial layers of the normal human meniscus.
41
 This cell type is not observed in osteoarthritic 
meniscus tissue (unpublished data). Although the exact biological function of this specific cell 
population is still under investigation, its presence and location appears to be essential in the normal 
tissue. hBMSC therefore have potential in human meniscus tissue engineering applications, 
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although other cell types may be necessary to obtain a fully functional tissue.  Preclinical data have 
already shown the feasibility of the application of bone marrow derived mesenchymal stem cells 
delivered as a cell suspension in a hyaluronic acid gel for meniscus regeneration in a caprine 
osteoarthritis model.
26
 These cells appeared to have homed to the site of injury and to have induced 
a regenerative response.  The potential advantages of a cell-scaffold combination, as in this study, 
over a cell suspension are (1) the manual delivery of the cell-scaffold construct to the injury site 
thereby eliminating the process of homing of hBMSC towards the injury site and (2)  the predefined 
3-dimensional shape of the scaffold supporting fibrochondrogenic differentiation.
24,25
  
 
Conclusion 
hBMSC expanded in autologous serum have a fibrochondrogenic differentiation potential. hBMSC 
can also be combined with a biodegradable meniscus-shaped scaffold. This cell-scaffold 
combination can be implanted easily into the meniscus defect thereby delivering autologous 
hBMSC with meniscus repair potential to this defect. This could increase repair potential of the 
defect, which allows faster repair and regeneration with meniscus-like tissue and thus shortens the 
rehabilitation period.  
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III.E Further protection of degenerated articular cartilage 
Ultimately the general aim of meniscus tissue engineering is to reduce or prevent the degenerative 
effect on the underlying cartilage secondary to a meniscectomy. Therefore, metabolic pathways 
were investigated in the articular chondrocyte that could be targeted by specific pharmaceuticals in 
order upregulate any anabolic effect. Such pharmacological interventions should optimise the 
results of meniscal transplant procedures. 
In normal articular cartilage cells, the IGFRI/insulin-like growth factor 1 (IGF-1) autocrine pathway 
was shown to overrule the catabolic effects of the IL-1/IL-1RI pathway by up-regulation of the IL-
1RII decoy receptor. In the first study, the activity of the IGF-1/IGFR1 and IL-1/IL-1R pathways, 
and of the IL-1RII control mechanism in the synthesis and turnover of the extracellular matrix 
(ECM) by chondrocytes from normal and osteoarthritic (OA) articular cartilage was compared in 
order to identify possible therapeutic targets of this disease. 
Phenotypically stable human articular cartilage cells were obtained from normal and OA cartilage 
of the same knee showing focal OA. The cells were cultured in alginate beads over 1 week to re-
establish the intracellular cytokine and growth factors, to reexpress the respective plasma membrane 
receptors and to reach equilibrium in accumulated cell-associated matrix (CAM) compounds. 
Following liberation of the cells from the alginate beads, the levels of cell-associated matrix (CAM) 
aggrecan, type II collagen and fibronectin, of intracellular IGF-1, IL-1 and  and of their 
respective plasma membrane-bound receptors, IGFR1, IL-1RI and the decoy receptor IL-1RII, were 
assayed using flow cytometry. 
Coordinated production and accumulation of CAM aggrecan and type II collagen under the effect of 
the IGFR1/IGF-1 autocrine pathway—as documented for chondrocytes from healthy controls—was 
absent when the chondrocytes had been obtained from OA joints. 
When compared with cells obtained from normal tissues, chondrocytes from fibrillated OA 
cartilage expressed significantly higher intracellular IGF-1 levels and plasma membrane-bound 
IGFR1. At the same time, significantly higher intracellular IL-1  and  levels and 
upregulated plasma membrane-bound IL-1RI were observed. Plasma membrane-bound IL-1RII 
decoy receptor was downregulated in OA chondrocytes. The levels of CAM aggrecan, type II 
collagen and fibronectin were significantly reduced in the chondrocytes obtained from 
pathological tissue. 
Paired analysis of normal and OA chondrocytes from the same knee joint has shown an enhanced 
capacity of chondrocytes from OA cartilage to produce ECM macromolecules. However, the same 
cells have increased catabolic signalling pathways. As a consequence of this increased IL-1 activity 
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and the reduced amounts of IL-1RII decoy receptor, less of the produced ECM macromolecules 
may persist in the CAM of the OA chondrocytes.  
The aim of the second study was to evaluate the influence of cyclodextrin polysulphate (CDPS) on 
the extracellular matrix (ECM) metabolism of human articular 
cartilage chondrocytes. 
Isolated chondrocytes from femoral condyle cartilage of human knee joints were cultured in gelled 
alginate to maintain their differentiated phenotype. During 1 week of culture, the cells were exposed 
to different concentrations of CDPS. Synthesis of aggrecans was investigated in these cultures after 
using Na2
35
SO4 as a radioactive precursor during the last 24 h of culture. The arti.cial matrix was 
then solubilised with Na-citrate and newly synthesised aggrecan aggregates, accumulated during 
culture, were liberated and assayed. The isolated chondrocytes were labelled with antibodies against 
aggrecan and type II collagen to analyse the ECM molecules in the cell-associated matrix (CAM). 
Plasma membrane levels of receptors for insulin-like growth factor-1 (IGF-1RI) and for interleukin-
1 (IL-1RI and IL-1RII), as well as levels of IGF-1, IL-1 and - were determined after the cells had 
been permeabilized and stained with the appropriate antibodies. The release of IL-6 in the culture 
media was used as a variable reflecting auto/paracrine IL-1 activity of the cells in different 
experimental conditions. 
CDPS significantly increased total 
35
S-incorporation rates in ECM aggrecan. When compared with 
controls, CDPS-treated chondrocytes expressed significantly higher CAM aggrecan and type II 
collagen levels. As plasma membrane-bound IGFR1 and intracellular IGF-1 levels remained 
unchanged, this increase in accumulated CAM compounds may have resulted from suppressed 
catabolic activities by the chondrocytes in culture. CDPS-treated cells expressed significantly lower 
amounts of intracellular IL-1   and - levels. Plasma membranebound 
IL-1RI and decoy IL-1RII remained unchanged. -cyclodextrin-treated chondrocytes released 
significantly less IL-6 in the supernatant culture media. 
CDPS is a novel polysulfated polysaccharide showing cartilage structure modifying effects in vitro 
as it improves the synthesis of aggrecan and the accumulation of CAM macromolecules. This effect 
probably resulted in part from the downregulation of IL-1. 
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Introduction  
Homeostasis of the extracellular matrix (ECM) of articular cartilage in normal and pathological 
conditions is dependent on the responses of articular cartilage cells to auto- and paracrine anabolic 
and catabolic pathways
1,2
. Several studies have highlighted the importance of insulin-like growth 
factor 1 (IGF-1) as promoter of growth and matrix synthesis by articular cartilage cells. IGF-1 has 
been shown to enhance the synthesis of aggrecan and type II collagen by chondrocytes
3-6
 and to 
indirectly decrease both the basal and the cytokine-stimulated degradation of proteoglycan in 
cartilage
7,8
 and was more potent than IGF-2 in the same batches of articular cartilage when their 
effects on biosynthesis and catabolism of proteoglycans were considered
9
. Several reports suggest 
that IGF-1 produced locally in cartilage may be as physiologically important as the circulating 
hormone IGF-2
10,11
.  
Both IGFs act through their respective receptors
12-14
. IGF-1 interacts with its specific membrane 
receptor (IGFR1), which also interacts with IGF-2 and insulin though with substantially lower 
affinity. Most of the known effects of IGF-1 and-2 are mediated by IGFR1
15
. IGF binding proteins 
(IGFBP) that are produced by the chondrocytes and bind to IGF are important controlling factors of 
IGF activity
16-19
. The secretion of IGFBPs is controlled by the cytokines IL-1 and TNF- 17. 
Turnover and degradation of the matrix is dependent on the responsiveness of the articular cartilage 
cell to catabolic cytokines of which IL-1 and  are the main agonists20,21. Beside capability to 
induce resorption of articular cartilage, IL-1 has been shown to directly depress the synthesis of 
aggrecan and collagen by the chondrocyte
22,23
. In addition, IL-1  may depress chondrocytes by 
reducing IGF-I access to these cells by enhancing IGFBP synthesis
17,19
. The IL-1 effects are 
mediated through a high affinity cell surface receptor (IL-1RI) receptor
24,25
. The most important 
controlling factor of IL-1 activity is the type 2 IL-1 decoy receptor (IL-1RII). IL-1RII is expressed 
on the chondrocyte plasmamembrane, binds IL-1  and , but does not transmit the IL-1 signals26,27.  
We examined the autocrine/paracrine anabolic/catabolic pathways that are potentially relevant to 
ECM homeostasis in normal and OA femoral condyle cartilage. We focused on the in vitro 
accumulation of aggrecan, type II collagen and of fibronectin in the cell-associated matrix of 
phenotypically stable chondrocytes obtained from normal and fibrillated cartilage of knee joints 
showing focal OA lesions. Flow cytometry allows the amounts of these ECM macromolecules in 
the cell-associated matrix (CAM) of isolated articular cartilage cells to be quantified
28,29
. 
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Material and Methods   
Isolation of chondrocytes: Human articular chondrocytes were isolated as described elsewhere
30
 
with a few modifications
31
. Articular cartilage was obtained at autopsy within 24 hours post 
mortem. All donors had died after a short illness and had not been receiving corticosteroids or 
cytostatic drugs. Visually intact cartilage was sampled from the knee joints of 10 donors. These 
knee joints showing focal OA lesions were used to obtain visually intact cartilage and OA cartilage. 
The cartilage tissue was sampled from the femur condyles, diced in small fragments and digested in 
a spinner bottle with a series of enzymatic solutions in Dulbecco’s modified Eagle’s medium 
(DMEM; GIBCO BRL, Grand Island, NY) with 0.002M/ml L-glutamine and antibiotics and 
antimycotics (GIBCO BRL). Cartilage was first treated with 0.25% (w/v) of sheep testes 
hyaluronidase (Sigma, St. Louis, MO, USA) for 120 min and 0.25% of Pronase (Streptomyces 
griseus Pronase E; Sigma) for 90 min at 37°C. After an overnight period in DMEM supplemented 
with 10% foetal calf serum (FCS, GIBCO BRL), a 3 to 6 hours’ incubation with 0.25% collagenase 
(Clostridium histolyticum; Sigma) in DMEM containing 10% FCS at 37°C resulted in the liberation 
of isolated cartilage cells. Depending on the condition of the tissue, 50-150106 chondrocytes could 
be obtained from femoral condyles of one individual and over 95% of the cells were viable (Trypan 
Blue exclusion test) after isolation. 
Culture of chondrocytes in alginate gel: Chondrocyte cultures in alginate beads were prepared as 
described elsewhere
32
 with some modifications. Chondrocytes suspended in 1 vol. double-
concentrated Hanks’ Balanced Salts Solution without calcium and magnesium (HBSS; Gibco) were 
carefully mixed with an equal volume of 4% alginate (low-viscosity alginate from Macrocystis 
pyrifera; Sigma) in HBSS, autoclaved for 15 min. The final cell concentration was 5 x 10
6
 
chondrocytes per ml in 2% alginate. The chondrocyte/alginate suspension was then slowly dripped 
through a 23-gauge needle into a 102 mM calcium chloride solution. The beads were allowed to 
polymerise for 10 min. at room temperature. The calcium chloride was then removed, the beads 
were washed three times with 0.15 M sodium chloride and finally maintained in a 6-well plate in 4 
ml of DMEM with 10% FCS and 50 μg ascorbate per ml in an incubator at 37°C under 5% CO2. The 
chondrocyte cultures consisted of 1 x 10
6
 cells per culture (each well containing 20 alginate beads; 
±50.000 chondrocytes per bead). The nutrient medium was replaced twice weekly for 7 days. 
Preparation of chondrocytes for flow cytometry: After the respective culture periods, the medium of 
the cultures was aspirated and the alginate beads were washed and dissolved by incubation for 10 
min. with 3 ml of 55 mM tri-sodium citrate dihydrate pH 6.8, 0.15 M NaCl at 25 °C. The resulting 
suspension was centrifuged at 1500 rpm for 10 min. to separate cells with their cell-associated 
173
  
matrix (CAM)
33
 from the constituents of the interterritorial matrix. IGFR1, IL-1RI and -II on the 
cell membrane, and aggrecan, type II collagen and fibronectin in the CAM were tested directly after 
incubation with the appropriate antibodies for 30 min in the dark at 4°C. 20l of 50g/ml FITC-
labelled antibodies were used to react with 2x10
5 
cells resuspended in 100l PBS. In order to 
evaluate the expression of IGF-1, IL-1 and  inside the cells, chondrocytes were permeabilized 
using Cytofix/Cytoperm Plus
TM
 Kit (PharMingen, San Diego, CA, USA) according to the 
manufacturer’s instruction. Briefly, cells in culture were incubated with monensin (GolgiStop
TM
, 
4l/6ml medium) for 5 hours to block the protein transport from Golgi apparatus. The cells were then 
isolated from alginate and permeabilized using Cytofix/Cytoperm
TM
 solution for 20 min. After a wash 
in 1x Perm/Wash
TM
 solution, the procedure was followed by the incubation with monoclonal 
antibodies (Mabs).  
Antibodies used for flow cytometry: Mouse anti-human monoclonal antibodies (Mab; subclass: 
IgG1) against IGFR1, IL-1RI, IL-1RII, IL-1 and the mouse IgG1 negative control were bought 
from R&D systems (Abingdon, United Kingdom; IGFR1: clone 33255.111; IL-1RI: clone 
35730.111; IL-1RII: clone 34141.11; Il-1: clone 8516.311). Mouse anti-human IGF-1 and IL-1 
Mabs were purchased from Biosource Europe (Nivelles, Belgium; IGF-1: clone AHG0014; IL-1: 
clone 624B3F2). Polyclonal anti-fibronectin rabbit IgG were from Chemicon International (Harrow, 
UK). Mouse anti-human chondrocyte-specific aggrecan Mab (clone 4D11-2A9, Biosource Europe) 
was shown to react specifically with the G1-domain of the invariable hyaluronan-binding region of 
the human aggrecan molecule, and was used to detect the aggrecan in the chondrocyte CAM. 
Mouse anti-human type II collagen Mab (clone II-4C11, ICN Biochemicals, Ohio, USA) was 
chosen to detect type II collagen. All the antibodies (except aggrecan and type II collagen) were 
conjugated with FITC (Fluorescein isothiocyanate, Isomer I, Sigma-Aldrich, Belgium) as 
previously described
28
. The anti-aggrecan and type II collagen Mabs were conjugated with 
Phycoerythrin (PE, Sigma-Aldrich) as described
34
. The conjugated Mabs were used in a direct 
immunofluorescent staining protocol for flow cytometry. Appropriate FITC- or PE-labelled isotype 
matched mouse or rabbit IgG1 (Becton Dickinson: clone X40) were used as a negative control. 
Flow cytometric analysis: Stained cells were analysed on a flow cytometer (FACSort, Becton 
Dickinson, San Jose, CA, USA) with CELLQuest software. From each sample, 15,000 events were 
analysed. Cells were gated on forward and side scatter to exclude celldebris and aggregates. 
Propidium iodide was additionally used to exclude dead cells when the epitopes outside the cells, 
i.e. IGFR1, IL-1RI and -II and ECM molecules, were analysed
28,29
. The mean fluorescence intensity 
(MFI) of the positive cell population, which is due to the binding of the conjugated antibodies to the 
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specific antigen, was used to quantify the presence of IGFR1, IL-1RI and -II on the 
plasmamembrane, of the ECM molecules in the CAM, and the accumulation of IGF-1, IL-1 and  
inside the cells. MFI values were obtained by subtraction of the MFI of the negative control 
population from the MFI of the positive stained population. For comparison between experiments 
Quantum Simply Cellular Microbead Kit (Sigma) was used to calibrate the fluorescence scale of the 
flow cytometer. The product contains a mixture of four uniform microbead populations, which 
differ by their incremental capacities to bind mouse IgG. The microbeads were stained and 
processed in parallel with the cell samples using the same amount of FITC-labelled antibodies and 
incubation time. The fluorescence scale of the cytometer was adapted before every experiment in 
order to keep identical MFIs for the four peaks of the calibration beads. The MFI of cell samples 
was then analysed without changing any instrument settings. 
Statistical analysis: Mean values and Standard Deviations (SD) of the MFI values were calculated 
from triplicate cell cultures. Means and SD for the different variables obtained from the whole 
donor population were also presented. The correlations between the mean values of different 
parameters in chondrocyte cultures in equilibrium were done with the Spearman’s test. Since the 
classical Bonferoni correction is not applicable for large number comparisons, a value of p<0.05 
was taken to indicate statistical significance. Such an approach has been previously used in other 
studies of large number comparisons
35
. The t-test for paired samples was used to compare the 
expression of the respective variables (mean MFI values) by chondrocytes obtained from affected 
and unaffected articular cartilage of the same knee joint. Significance levels for Student’s t-tests 
were set at p=0.05. 
 
Results 
Intracellular cytokine and growth factor levels, expression of the respective plasmamembrane 
receptors, and homeostasis of CAM molecules in articular cartilage from OA joints: Chondrocytes 
were obtained from 10 donors (4 males, 6 females, age range 37-80 years. Expression of different 
antigens was quantified using chondrocyte MFI values after staining with the respective specific 
conjugated antibodies. The mean and 1SD values of the different variables obtained in triplicate 
samples of each donor were presented in table 1 and 2. Average coefficient of variation (CV) values 
for each of these variables were calculated from these data and illustrated the reliability of the 
technique (Legend Table 1 and 2). The MFI values reflect the number of FITC-conjugated 
antibodies fixed on the chondrocytes and - as monoclonal antibodies were used - the number of 
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detected epitopes. The MFI values for each of these items varied widely through the chondrocyte 
populations.  
IGFR1/IGF-1 auto/paracrine pathway: When compared with unaffected tissue, chondrocytes that 
were isolated from affected tissues showed significantly increased MFI values for IGFR1 (normal 
versus OA: 1.9±1.2 and 3.2±2.1; p=0.004) and IGF-1 (normal versus OA: 41.4±32.3 and 57.1±42.4; 
p=0.010). On average, chondrocytes from degenerated tissues expressed 64.6±35.1% more IGFR1 
and showed 43.0±16.8% more intracellular IGF-1 (Fig 1).  
 
Figure 1. Percentage changes in Mean Fluorescence Intensity (MFI). Comparison of chondrocytes from degenerated 
and normal cartilage. AGGR: aggrecan; COLL: type II collagen; FNECT: fibronectin  
IL-1R/IL-1 auto/paracrine pathway: Significant increases in MFI values were also observed for 
intracellular IL-1 (normal versus OA: 21.5±9.8 and 24.5±9.9; p=0.009), IL-1 (normal versus 
OA: 38.6±20.8 and 51.7±23.8; p=0.015), and for plasmamembrane IL-1RI (normal versus OA: 
0.86±0.48 and 1.61±0.94; p=0.001). When compared with chondrocytes from visually intact 
cartilage, average increases of 17.7±13.3%, 39.0±31.9% and 88.5±51.1% were calculated for 
intracellular IL-1 and , and for plasmamembrane IL-1RI, respectively (Fig 1). Chondrocytes 
derived from OA sites expressed less membrane-bound IL-1RII (normal versus OA: 2.33±0.83 and 
1.66±0.58; p=0.011). An average decrease in IL-1RII of –32.7±14.4% was seen in OA 
chondrocytes (Fig 1).  
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The accumulation of ECM compounds in the CAM: Mean chondrocyte MFI values for aggrecan, 
type II collagen and fibronectin were found significantly lower in chondrocytes isolated from 
degenerated tissue (normal versus OA: aggrecan: 15.5±9.1 and 9.5±5.9; p=0.046; type II collagen: 
4.8±2.8 and 3.3±2.5; p=0.014; fibronectin: 324.5±189.9 and 245.3±151.6; p=0.006). When 
compared with chondrocytes from visually intact cartilage, average decreases of CAM accumulated 
aggrecan, type II collagen and fibronectin amounted to –37.1±18.4%, -36.9±23.2% and –
29.2±11.5%, respectively (Fig 1). 
Correlations between intracellular cytokine and growth factor levels, expressed plasmamembrane 
receptors and accumulated CAM molecules in articular cartilage tissues from OA joints: 
Correlations between the expression of the receptors on the cell membrane, IGF-1, IL-1 and  
levels inside the cells and the accumulation of CAM molecules are shown in Table 3 and 4.  
CAM levels of aggrecan and type II collagen were correlated in unaffected cartilage-derived  
chondrocyte cultures (r=0.896, p=0.006). Aggrecan and fibronectin levels were related in the  
CAM of osteoarthritic cartilage-derived chondrocytes (r=0.844, p=0.017). In cell cultures obtained 
from unaffected cartilage a correlation was observed between the functional IL-1RI on the 
plasmamembrane and the intracellular IL-1 levels. A correlation between the 2 isoforms of IL-1 
was obvious in both affected and unaffected tissue-derived cultures (visually intact cartilage: 
r=0.762, p=0.028; OA cartilage: r=0.692, p=0.057). IGFR1, but not IGF, significantly correlated 
with CAM fibronectin in both affected and unaffected tissue-derived cultures (intact cartilage: 
r=0.761, p=0.011; OA cartilage: r=0.815, p=0.041). Furthermore, there was a significant correlation 
between membrane-bound IGFR1 and CAM type II collagen in OA tissue-derived chondrocyte 
cultures (r=0.754, p=0.050). In none of the cultures, levels of CAM ECM molecules did correlate 
with the agonists of the IL-1 pathway.  
 
Discussion 
The objective of these studies was to search for differences in the auto/paracrine pathways directing 
the homeostasis of the ECM in chondrocytes from normal and osteoarthritic articular cartilage. The 
experiments have been conducted on human articular cartilage chondrocytes that maintained their 
original phenotype in vitro when cultured in alginate. We focused on the accumulation of aggrecan, 
type II collagen and of fibronectin in the CAM of these chondrocytes. Flow cytometry allowed the 
amounts of these ECM macromolecules in the CAM of the isolated articular cartilage cells to be 
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quantified, as well as the levels of growth factors and cytokines inside the cells and the expression 
of the respective plasmamembrane-bound receptors
28,29
.  
Amongst other growth factors, both isoforms of IGF enhanced the production of extracellular 
matrix (ECM) by chondrocytes in different in vitro culture systems
36,37
 and in tissue-cultured 
normal and diseased cartilage
3-6
. Recently, the accumulation of a series of ECM macromolecules in 
the cell-associated matrix (CAM) of chondrocytes cultured in an artificial environment has been 
used to explore the effects of IGF on synthesis and turnover of the ECM
8
. It was shown that the 
amount of ECM compounds in the CAM of chondrocytes significantly correlated with the strength 
of the IGF/IGFR pathway, but not with the levels of the IL-1/IL-1RI pathway. Additional 
experiments demonstrated that IGF-1 upregulated IL-1RII thereby overruling the catabolic effects 
of  IL-1
8
. IL-1RII binds IL-1 , and to a much lesser extent IL-1, without participating in their 
signalling
38,39
. 
The most striking difference between chondrocytes obtained from normal and degenerated tissue 
was the loss of the IGFR1/IGF-1-orchestrated accumulation of cell-associated ECM compounds
8
. 
Although chondrocytes from degenerated tissues - when compared with those from unaffected 
tissues from OA joints - showed a significantly increased expression of IGFR1 and IGF-1, equally 
significant increases of intracellular IL-1, IL-1, and of plasma membrane IL-1RI were observed 
in these cartilage cells. On the other hand, chondrocytes derived from degenerated tissue of OA 
joints expressed less membrane-bound IL-1RII than the cells that were isolated from unaffected 
cartilage of the same knee. Therefore, IL-1-activity around chondrocytes from degenerated tissue 
was not neutralized and mean chondrocyte MFI values for CAM aggrecan, type II collagen and 
fibronectin were found to be significantly lower in these cells. 
Others have reported the up-regulation of both catabolic
1,2
 and anabolic
1,2,40-42
 pathways in OA 
chondrocytes or cartilage. A correlation with the occurrence and the degree of OA pathology was 
noted for IL-11,2,43 and these elevated catabolic cytokine levels are embodied by well-documented 
increases in metalloprotease activities, which were higher in OA cartilage compared with 
morphologically normal cartilage from the same joint
43-46
.   
In addition, an increase in IL-1RI receptor density was found in OA chondrocytes as compared with 
normal chondrocytes. As a consequence of the increased IL-1RI density, the IL-1 concentration 
required for half-maximal metalloprotease stimulation was several times lower in OA chondrocytes 
than in normal cells
47
. 
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IL-1 in particular could be implicated in the up-regulation of the IGFR1/IGF-1 autocrine/ 
paracrine axis in OA chondrocytes
48
. IGF-1 and IGFR1 mRNA and protein levels were significantly 
higher in fibrillated osteoarthritic cartilage, than in non-fibrillated cartilage of OA hip joints
40,41
. 
The strongest IGF-1 message signals or protein levels were observed in chondrocytes of more 
advanced lesions
41,42
. 
Expression of different antigens that were quantified using chondrocyte MFI values showed high 
variability among the chondrocytes obtained from different donors. However, in contrast with 
earlier observations on chondrocytes obtained from intact articular cartilage from unaffected knee 
joints
8
, no significant correlations were found between the main actors of the anabolic pathways 
after one week in culture. Coordinated production and accumulation of the different CAM 
compounds under the effect of the IGFR1/IGF-1 autocrine pathway was not obvious anymore when 
the chondrocytes had been obtained from OA joints. Merely, there was a significant correlation 
between membrane-bound IGFRI and CAM type II collagen in OA tissue-derived chondrocyte 
cultures. CAM aggrecan and type II collagen levels were correlated in unaffected cartilage-derived 
chondrocytes cultures but not in the cultures derived from degenerated tissue. In none of these 
cultures, however, levels of CAM ECM molecules did correlate with the agonists of the IL-1 
pathway. The shortage of the agonists of the IGF pathway to organize the ECM was seen in both 
affected and unaffected tissue-derived cultures. These findings suggest a more widespread 
metabolic disorder in the entire cartilage of the OA knee joint.  
The data presented here strongly advocate the role of the plasmamembrane receptors as the factors 
controlling the effects of the respective ligands. Since monoclonal antibodies (Mab) were used for 
all the epitopes (except for fibronectin) studied, it was assumed that equimolar amounts of Mab 
reacted with the target molecules. MFI values thus correlated with the amount of the plasma 
membrane-bound receptors and their ligands. The low MFI values for plasma membrane receptor 
IGFR1, IL-1RI and –II levels reflected the presence of merely a few thousand of these molecules on 
a chondrocyte in normal tissues
49,50
. MFI values of intracellular growth factors and cytokines, 
which represent a reservoir of biologically active agents that can be secreted as a consequence of 
various metabolical stimuli, were found to outnumber the MFI values of their respective plasma 
membrane receptors by a factor 10. The dimly expressed IL-1RI and –II, and especially the ratio 
between both receptors will likely decide for accumulation or release of ECM compounds in the 
cell-associated matrix. This quotation lays emphasis on chondrocyte IL-1RI and –II as an important 
target in the therapy of osteoarthritis.   
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It can be concluded that whereas the IGFR1/IGF-1 pathway controlled the homeostasis of the ECM 
and overruled the agonists of the IL-1 pathway through an upregulation of IL-1RII in normal 
cartilage, this organization was not obvious in cartilage tissue from the osteoarthitic joint. 
Chondrocytes from osteoarthritic were hyperactive but concurrently expressed significant catabolic 
activities. Under these circumstances newly synthesized ECM compounds were not able to 
accumulate in a cell-associated matrix. Surprisingly, this disturbed metabolism was observed in 
both degenerative and visually intact articular cartilage of OA joints. This underscores the role of 
IL-1RI and –II in the maintenance of articular cartilage integrity, and their potential as therapeutic 
targets for osteoarthritis.   
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Introduction 
Sulphated polysaccharides have been licensed for the use in different pathophysiological conditions, 
e.g. to modulate plasma anticoagulant and fibrinolytic activities, to exert hypolipaemic effects, to 
inhibit retroviral multiplication. Interestingly, most of these distinct effects are shared by different 
polysulphated polysaccharides.  
Where degenerative joint diseases are concerned, the most interesting biological activities of these 
sulphated substances are their effects on synthesis and turnover of important compounds of the 
extracellular matrix of connective tissues. The first reports already dated from the early seventies
1-4
 
but extended reviews on the potential use of these polysaccharides have appeared more recently
5,6
. 
Amongst other glycosaminoglycans, chondroitin sulphate was shown to increase aggrecan synthesis 
by articular cartilage cells
7
 and both chondroitin sulphate and chondroitin polysulphate increased 
hyaluronan synthesis by synovial lining cells in vitro
8
 and in vivo
9,10
. Interestingly, hyaluronan 
molecular weight significantly increased when synovial cells were treated with chondroitin 
polysulphate and other sulphated polysaccharides
9-11
. Similarly, human articular chondrocytes in 
monolayer culture responded with an increased synthesis of highly polymerised hyaluronan when 
chondroitin polysulphate was supplemented to the culture medium
12
. Under the same conditions 
these articular cartilage cells increased their production of aggrecans in the aggregate form
13
. 
Electron microscopic studies confirmed the immobilisation of higher numbers of aggrecans on 
longer hyaluronan filaments synthesised by differentiated human cartilage cells exposed to 
chondroitin polysulphate and other sulphated polysaccharides such as xylosan polysulphate
13
.  
Considering their capability of increasing synthesis rates and improving the immobilisation of 
physiologically important extracellular matrix molecules, some of these sulphated polysaccharides 
have been considered to be important therapeutical tools in OA, where declining aggrecan synthesis 
rates and the decreased capability of assembling large molecular size aggregates illustrates the 
progressive failure of the repair function of articular cartilage cells. A damaged articular cartilage 
can affect the normal function of the joint and this ultimately results in clinical symptoms in a 
proportion of the patients
14
. Structure/Disease Modifying OA Drugs (DMOADs) are expected to 
prevent structural damage in normal joints at risk for development of OA, or to retard the progression 
of structural damage in joints already affected by OA
15
.  
A major flaw when these substances are introduced for pharmacological use in humans is their poor 
chemical definition. The exact molecular weight is varying. The degree and type of sulphation is 
different on each of the individual molecules. One class of biologically occurring polysaccharides 
with well-defined molecular structure and weight are the cyclodextrins. -, - and -cyclodextrin 
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are cyclic polysaccharides containing 6, 7 or 8 glucopyranose units, respectively, linked through 1-
4 glycosidic bonds. Classical sulphation procedures result in the sulphation of the 3 free hydroxyl 
groups of the glucopyranoses.  
-, - and -cyclodextrins have been fully sulphated and the influence of these cyclodextrin 
polysulphates on the extracellular matrix metabolism of human articular cartilage chondrocytes 
have been evaluated. The incorporation of radiosulphate in proteoglycan was used as a variable to 
assess which concentrations of the cyclodextrins would result in an effect on chondrocyte 
metabolism. Once the optimal working concentrations were defined, the effects on factors known to 
affect the homeostasis of the extracellular matrix by chondrocytes from intact articular cartilage 
were assessed in more detail.   
 
Materials and methods 
 
Preparation of sulphated -, -, and -cyclodextrins: Commercially available -
, -, and -cyclodextrins (Sigma Chemical Company, St.-Louis, US) were sulphated according to 
the procedure described by Astrup et al
16
. Briefly, drop-by-drop, one vol. of chlorosulphonic acid 
was added to 6.6 vol. ice-cold pyridine. Approx. 300 mg of the polysaccharides was added to 5 ml 
of the chlorosulphonic/pyridine mixture. The solution was then kept at 100°C during 5 hours. After 
cooling, 25 ml of distilled water was added. 100 ml of 10% (w/v) Na-acetate in methanol was then 
added to this solution to precipitate the polysaccharide polysulphuric acids. The precipitate was 
washed 2 times in methanol and dissolved in an appropriate amount of distilled water before being 
applied to a Sephadex G10 gel permeation chromatography column to elute the remaining 
chlorosulphonic acid, pyridine and buffer salts. The void volume fractions containing the 
polysaccharides were lyophilised. The cyclodextrin polysulphates were recovered as a dry white 
powder. Electrophoresis on cellulose acetate in a LiCl/HCl (0.01/0.06N) buffer pH 3.5, at 1mA/cm 
during 20 min. was done to evaluate the degree of sulphation of the cyclodextrins and showed the 
polysulphated cyclodextrins migrating as homogeneous bands and with the same velocity as the 
chondroitin polysulphate or xylosan polysulphate standards (Fig 1). Mass Spectrometry was done in 
the Institut de Recherche SERVIER Laboratories (Orleans, France; Dr. F Lefoulon) and confirmed 
complete sulphating of all cyclodextrin glucopyranoses. Considering initial molecular weights of 
973, 1135 and 1297 for the unsulphated -, -, and -cyclodextrins respectively, on sulphation of 
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the 3 free hydroxyl groups of the glucopyranoses their molecular weights increased to 2413, 2815 
and 3217. The cyclodextrin polysulphates were used as such in our experimental in vitro models. 
 
Figure  1. A: Synthesis of cyclodextrin polysulphates - Schematic representation. B: cellulose acetate electrophoresis of 
the sulphated polysaccharides. + : positive pool;  : start; lane 1: hyaluronan, chondroitin sulphate; lane 2: chondroitin 
sulphate; lane 3; chondroitin polysulphate; lane 4: -cyclodextrin polysulphate; lane 5: -cyclodextrin polysulphate; 
lane 6: -cyclodextrin polysulphate; lane 7: xylosan polysulphate. 
Isolation of articular chondrocytes: Human articular chondrocytes were isolated as 
described elsewhere
17
. Briefly, human articular cartilage was obtained at autopsy from femoral 
condyles of 10 different donors within 24 hours post-mortem. All donors had died after a short 
illness. None of them had received corticosteroids or cytostatic drugs. Both visually intact and 
fibrillated osteoarthritic femoral condyle cartilage samples were harvested separately and prepared 
for culture. The cartilage samples were diced into small fragments and the chondrocytes were 
isolated by sequential enzymatic digestion (hyaluronidase, pronase and collagenase) of the 
extracellular matrix as described in detail
22
. Isolated cells were then centrifuged for 10 min. at 1500 
rpm, washed three times in DMEM with 10% (v/v) FCS, tested for viability (Trypan Blue exclusion 
test) and counted. More than 95% of the cells were usually viable after isolation. 
 
Cultures in alginate gel: Chondrocyte cultures in alginate beads were prepared as 
described elsewhere
18
, with some modifications. Chondrocytes suspended in 1 vol. double-
concentrated Hanks’ Balanced Salts Solution without calcium and magnesium (HBSS; Gibco) were 
carefully mixed with an equal volume of 2% (w/v) alginate (low-viscosity alginate from 
Macrocystis pyrifera; Sigma) in HBSS, autoclaved for 15 min. The final cell concentration was 
5x10
6
 chondrocytes per ml in 1% alginate. The chondrocyte/alginate suspension was then slowly 
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dripped through a 23-gauge needle into a 102 mM calcium chloride solution. The beads were 
allowed to polymerise for 10 min at room temperature. The calcium chloride was then removed, the 
beads were washed three times with 0.15 M sodium chloride and finally maintained in a 6-well 
plate with 1x10
6
 cells per culture (each well containing 20 alginate beads; ±50.000 chondrocytes 
per bead) in 4 ml of DMEM with 10% FCS and 50 μg ascorbate per ml in an incubator at 37°C 
under 5% CO2.  The nutrient medium was replaced twice weekly for 7 days. Recently, we described 
that ECM metabolism by chondrocytes reached steady state after one week in this alginate culture 
system
19
. 
 
Incorporation of 
35
Sulphate to measure newly synthesized aggrecans by 
chondrocytes cultured in alginate was investigated using Na2
35
SO4 as a radioactive precursor. As 
the optimal working concentrations of the oversulphated cyclodextrins were not known, 
chondrocytes obtained from 6 donors were used to test different concentrations (0.5 – 10.0 g/ml) 
of the oversulphated cyclodextrins. The cyclodextrins were supplemented to the nutrient media 
during the whole culture period.  After a one-week culture period in alginate, 10 Ci/ml of the label 
was included in the incubation medium over 24 h. During this period, newly synthesized 
35
S-
aggrecans partly accumulated in the artificial matrix. The alginate was then solubilized with 3 ml of 
55 mM tri-sodium citrate dihydrate pH 6.8, 0.15 M NaCl at 25 °C for 10 min. and suspension was 
centrifuged. 
35
S-labelled macromolecules from the resulting supernatant were pooled with 35S-
material that had escaped to the nutrient medium, and stored for further chromatography. Aliquots 
of pools of combined media and alginate digests were desalted through Sephadex G25 (Pharmacia) 
chromatography gels in 0.067 M phosphate (K2HPO4/Na2HPO4) pH 6.8, containing 0.01M Na2SO4, 
to separate 
35
S-labeled aggrecans (void volume) from free 
35
Sulphate (retarded fraction). The eluted 
fractions were counted for radioactivity. The radioactivity in the void volume is related to the total 
incorporation of 
35
Sulphate in newly synthesized aggrecans by the respective cultures. Considering 
the amount of pooled culture medium that ultimately was analysed after chromatography, the 
specific activity of the incubation medium (mCi 
35
SO4 per mM cold SO4), the decay of 
35
Sulphate, 
the labelling period in hours and the numbers of cells per culture, we were able to express sulphate 
incorporation as picog of SO4 incorporated per 1x10
6
 chondrocytes per hour
20
.  
 
IL-6 release by chondrocytes: Chondrocytes obtained from both visually intact and 
fibrillated cartilage of a 69-year-old female donor who presented a focal osteoarthritic lesion, were 
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kept in culture separately, and exposed to 0.0 and 5.0 g/ml of -cyclodextrin polysulphate during 1 
week. Aditionally, normal chondrocyte cultures with and without -cyclodextrin were exposed to 
100 pg/ml of TNF (R&D systems (Abingdon, United Kingdom) during the last 48 hours in culture. 
Culture media were then assayed for IL-6 by conventional ELISA.  
 
Flow cytometric assay of cell-associated extracellular matrix (CAM) 
molecules and of intracellular cytokine and growth factor levels: 
Chondrocytes obtained from 3 additional donors were used to test the effects of the cyclodextrins 
on the activity of autocrine cytokine and growth factor pathways and on the presence of CAM 
molecules. The chondrocytes were cultured in alginate and in the presence of 0.0, 2.5 and 5.0 g/ml 
of cyclodextrin polysulphate for a period of 7 days after which time culture medium was removed 
and alginate beads processed as described above. The resulting suspension was centrifuged at 1500 
rpm for 10 min. to separate cells with their cell-associated matrix (CAM)
19,21
 from the constituents 
of the interterritorial matrix. The pellet with the chondrocytes was recovered to assess the CAM 
macromolecule contents, the plasma membrane bound receptors and the intracellular levels of 
cytokines and growth factors. IGFR1, IL-1RI and -II on the cell membrane, and aggrecan, type II 
collagen and fibronectin in the CAM were tested directly after incubation with the appropriate 
antibodies for 30 min in the dark at 4°C. 20l of 50g/ml FITC-labelled antibodies were used to react 
with 2x10
5 
cells resuspended in 100l PBS. In order to evaluate the expression of IGF-1, IL-1 and 
 inside the cells, cultures were incubated with monensin (GolgiStopTM, 4l/6ml medium) for 5 hours 
to block the protein transport from Golgi apparatus. Following this, chondrocytes were permeabilized 
using Cytofix/Cytoperm Plus
TM
 Kit (PharMingen, San Diego, CA, USA) according to the 
manufacturer’s instruction. The cells were treated with Cytofix/Cytoperm
TM
 solution for 20 min. After 
a wash in 1x Perm/Wash
TM
 solution, the procedure was followed by the incubation with monoclonal 
antibodies (mAb).  
 
Antibodies used for flow cytometry: Mouse anti-human monoclonal antibodies (mAb; 
subclass: IgG1) against IGFR1, IL-1RI, IL-1RII, IL-1 and the mouse IgG1 negative control were 
purchased from R&D systems (Abingdon, United Kingdom; IGFR1: clone 33255.111; IL-1RI: 
clone 35730.111; IL-1RII: clone 34141.11; Il-1: clone 8516.311). Mouse anti-human IGF-1, IL-
1 and anti-human chondrocyte-specific aggrecan mAbs were purchased from Biosource Europe 
(Nivelles, Belgium; IGF-1: clone AHG0014; IL-1: clone 624B3F2; aggrecan: clone 4D11-2A9). 
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Polyclonal anti-fibronectin rabbit IgG were from Chemicon International (Harrow, UK). Mouse 
anti-human type II collagen mAb (clone II-4C11, ICN Biochemicals, Ohio, USA) was chosen to 
detect type II collagen. All the antibodies (except aggrecan and type II collagen) were conjugated 
with FITC (Fluorescein isothiocyanate, Isomer I, Sigma-Aldrich, Belgium) as previously 
described
22
. The anti-aggrecan and type II collagen mAbs were conjugated with Phycoerythrin (PE, 
Sigma-Aldrich)
23
. The conjugated mAbs were used in a direct immunofluorescent staining protocol 
for flow cytometry. Appropriate FITC- or PE-labelled isotype matched mouse or rabbit IgG1 
(Becton Dickinson: clone X40) were used as a negative control. 
 
Flow cytometric analysis: Stained cells were analysed on a flow cytometer (FACSort, 
Becton Dickinson, San Jose, CA, USA) with CELLQuest software. From each sample, 15,000 
events were analysed. Cells were gated on forward and side scatter to exclude debris and 
aggregates. Propidium iodide was additionally used to exclude dead cells when the epitopes outside 
the cells, i.e. IGFR1, IL-1RI and -II and ECM molecules, were analysed
22,24
. The median 
fluorescence intensity (MFI) of the positive cell population, which is due to the binding of the 
conjugated antibodies, was used to quantify the presence of IGFR1, IL-1RI and -II on the plasma 
membrane, of the ECM molecules in the CAM, and the accumulation of IGF-1, IL-1 and  inside 
the cells. To differentiate the positive mAb-stained cells, the interface channel for positivity was set 
at the point where less than 2% of the control fluorescence (cells exposed to FITC/PE isotype 
matched IgG) was positive. MFI values of these mAb-stained chondrocyte populations were then 
calculated. For comparison between experiments the Quantum Simply Cellular Microbead Kit 
(Sigma) was used to calibrate the fluorescence scale of the flow cytometer. The product contains a 
mixture of four uniform microbead populations, which differ by their incremental capacities to bind 
mouse IgG. The microbeads were stained and processed in parallel with the cell samples using the 
same amount of FITC-labelled antibodies and incubation time. The fluorescence scale of the 
cytometer was adapted before every experiment in order to keep identical MFIs for the four peaks 
of the calibration beads. The MFI of cell samples was then analysed without changing any 
instrument settings. 
 
Statistics: Mean 
35
S-incorporation rates or mean MFI values for the different parameters in 
each of the donor chondrocytes were calculated from triplicate cell cultures. As the 
35
S-
incorporation experiments were done on the cells obtained from 6 donors, the mean 
35
S-
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incorporation values in the untreated controls were normalized to 100 to allow percentage changes 
after the exposure to different concentrations of cyclodextrin polysulphate to be presented. Mean 
MFI values in the untreated controls were compared with these obtained after the exposure to 
different concentrations of cyclodextrin polysulphate. Paired Student’s t-tests were used to test 
significance and to study the effect sizes of the changes in the chondrocyte cultures after cyclodextrin 
polysulphate treatment. Significance levels for all tests were set at p=0.05. 
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Results 
 
Effect of different concentrations of -, - and -cyclodextrins on 
aggrecan synthesis rates: Synthesis of aggrecans was investigated using Na2
35
SO4 as a 
radioactive precursor. The incorporation of SO4 was expressed as pg of SO4 incorporated in aggrecan 
macromolecules per 1.10
6
 chondrocytes per hour (table 1). As optimal doses of use of the -, - and 
-cyclodextrins were not known, and information about any differential effects of the 3 cyclodextrin 
was lacking, broader dose ranges were used in the first 2 donor cells. The chondrocytes of the last 4 
donors were used to explore effects of and/or differences between the 3 cyclodextrin types at the 
optimal concentration of 2.5-5.0 g/ml of culture medium. -, - and -cyclodextrins, used at 0.5, 1.0 
and 10.0 g/ml concentrations, failed to provoke consistent significant increases in 35S-incorporation 
in aggrecan in 2 first donors. At concentrations ranging between 2.5 and 5.0 g/ml, -, - and -
cyclodextrins significantly improved aggrecan synthesis by the chondrocytes of 4 other donors. Higher 
concentrations of the oversulphated cyclodextrin inhibited 
35
S aggrecan synthesis (table 1). In a control 
experiment on the cells obtained from donor F53, unsulphated cyclodextrin (2.5/g/ml) failed to affect 
35S-incorporation in proteoglycans (table 1). Percentage changes in 35S-incorporation in aggrecan 
induced by different concentrations of the 3 cyclodextrins are given in figure 2.  
 
Figure  2. Percentage changes in 35S-incorporation in aggrecan induced by different concentrations of cyclodextrin 
polysulphates. Dots represent mean values of experiments in triplicate. Bars represent median values.  O : effect of -
cyclodextrins,   : effect of -cyclodextrins,   : effect of -cyclodextrins. 
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Table 2. Effects of -cyclodextrin polysulphate on the expression of growth factors,  
cytokines, their receptors and ECM components by chondrocytes in alginate 
M18      control      2.5 g/ml      5.0 g/ml        % change 
 
IGFRI    12.5 ±   0.1    13.3 ±   0.6    13.6 ±   1.0  
IGF-1    47.6 ±   0.3      48.5 ±   1.4    49.6 ±   0.4 
  
IL-1RI    14.0 ±   0.5    13.4 ±   1.4    15.1 ±   1.2 
IL-1RII   13.2 ±   0.3    13.8 ±   0.6    14.2 ±   1.3 
IL-1    82.8 ±   1.5    67.7 ±   2.3 *1   53.0 ±   0.6 *2    - 36.0 
IL-1    86.7 ±   2.2    82.0 ±   3.4 *1   81.5 ±   2.0 *1    -    6.0 
 
Aggrecan   37.6 ±   1.0    52.3 ±   1.8 *
2
   66.4 ±   3.4 *
2    
+
 
76.6 
Collagen II   21.7 ±   1.7    42.6 ±   2.2 *
2
   42.6 ±   3.0 *
2    
+
 
96.3 
Fibronectin 219.8 ± 18.0  325.6 ± 10.1 *
2
 326.2 ± 15.8 *
2    
+
 
48.4 
F55      control      2.5 g/ml      5.0 g/ml 
IGFRI    12.9 ±   0.4    12.3 ±   0.2    12.8 ±   0.4  
IGF-1    65.9 ±   2.3      63.7 ±   1.4    61.9 ±   2.0 
 
IL-1RI    12.4 ±   0.3    12.0 ±   0.6    12.0 ±   0.5 
IL-1RII   12.8 ±   0.4    13.2 ±   0.8    12.9 ±   0.2 
IL-1    29.5 ±   1.8    25.0 ±   0.6 *1   25.2 ±   1.0 *1   - 14.6 
IL-1    24.7 ±   1.7    21.7 ±   1.0 *1   21.4 ±   1.0 *1   - 13.4 
 
Aggrecan   21.1 ±   1.1    24.5 ±   0.8 *
2
   26.3 ±   0.3 *
2  
+
 
24.6 
Collagen II   22.0 ±   2.1    29.0 ±   1.7 *
1
   27.4 ±   2.1 *
1  
+
 
24.5 
Fibronectin 387.1 ±   8.4  411.4 ±   8.2 *
1
 434.4 ± 16.8 *
1  
+
 
12.2 
F68      control      2.5 g/ml      5.0 g/ml 
 
IGFRI    12.4 ±   0.8    12.1 ±   0.2    12.4 ±   1.0  
IGF-1    35.9 ±   0.9      36.7 ±   1.2    39.6 ±   3.6 
 
IL-1RI    11.0 ±   1.0    11.8 ±   1.0    13.2 ±   0.6 
IL-1RII   12.0 ±   0.3    11.7 ±   0.5    11.8 ±   0.5 
IL-1    46.8 ±   0.5    26.7 ±   0.8 *3   24.3 ±   0.3 *3   - 48.1 
IL-1    31.5 ±   0.8    25.2 ±   0.5 *2   24.3 ±   0.3 *2   - 22.9 
 
Aggrecan   15.0 ±   0.7    19.4 ±   1.1 *
1
   19.7 ±   0.2 *
2  
+
 
31.3 
Collagen II   18.2 ±   1.0    22.5 ±   1.5 *
2
   25.4 ±   0.9 *
2  
+
 
39.6 
Fibronectin   98.4 ±   5.9  120.0 ±   8.3 *
1
 163.4 ± 10.9 *
1  
+
 
66.1 
 
Experiments done in triplicate. Median MFI values of the cell population ± 1SD are given.  
Donor: M/F-NR: male/female-age; 
*NR 
: significance levels: 
*1 
:p<0.05; 
*2 
:p<0.01; 
*3  
:p<0.001; % change: percentage differences between values of control chondrocytes and 
chondrocytes under 5.0 g/ml of -cyclodextrin polysulphate 
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Flow cytometric analysis of the cell-associated matrix (CAM) content: 
Following the results of the dose-finding studies, -cyclodextrin at 2.5 and 5.0 g/ml concentrations 
was used in flow cytometry experiments on the cells of 3 additional donors. When compared with 
controls, 2.5 g/ml of -cyclodextrin polysulphate-treated chondrocytes showed a significantly 
increased accumulation of aggrecan, type II collagen and of fibronectin in their CAM (table 2). 5.0 
g/ml of -cyclodextrin polysulphate in the culture medium did not cause larger effects. The effect 
sizes of these increases varied amongst the 3 donor chondrocyte populations. Some illustrative flow 
cytometer patterns are given in figure 3.  
 
Figure 3. Fluorescence intensity patterns of chondrocytes labelled with FITC-mAb directed against intracellular IL-1 
and –, cell-associated matrix (CAM) aggrecan, type II collagen and fibronectin illustrate how small changes in IL-1 
producing cells, induce vast increases in the accumulation of CAM products. Isotype control curves and fluorescence 
intensity patterns of 5.0 g/ml of -cyclodextrin (bCD)-treated and control cells are shown for each of the tested 
variables. Donor: M18; Ordinate: events (number of cells) studied; abscissa: fluorescence intensity. 
 
The IGF-1/IGFR1 autocrine pathway and IL-1RII: When compared with controls, -
cyclodextrin polysulphate did not induce any changes in plasma membrane-bound IGFR1. 
Intracellular IGF-1 levels also remained unchanged after exposure to the polysulphated 
cyclodextrin. Likewise, plasma membrane-bound decoy IL-1RII did not change under cyclodextrin 
polysulphate treatment (table 2).  
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Effects on the IL-1/IL-1RI autocrine pathway: Membrane-bound IL-1RI did not 
change under cyclodextrin polysulphate treatment. However, intracellular IL-1 and  levels were 
found downregulated after exposure of the chondrocytes to - or -cyclodextrin polysulphate (table 
2). No significant differences in IL-1 repression were observed under 2.5 and 5.0 g/ml of the 
cyclodextrins, which were the optimal concentrations revealed in the 35S-incorporation 
experiments. Percentage decreases of both IL-1 isoforms exposed a more pronounced effect on IL-
1. The effect sizes of this inhibition also varied amongst the 3 donor chondrocyte populations and 
ranged in between 14.6 and 48.1%, and 6.0 and 22.9% of inhibition for intracellular IL-1 and -, 
respectively (table 2). The smallest change in IL-1 levels concurred with the least increase in 
accumulated CAM compounds. 
 
Effects on IL-6 production: Chondrocytes from osteoarthritic regions secreted 2 to 3 
times more IL-6 in the supernatant media than cells from intact cartilage. Hundred pg/ml of TNF 
caused a fourfold increase in IL-6 release by normal chondrocytes in culture. Five g/ml of -
cyclodextrin polysulfate depressed IL-6 release by normal and osteoarthritic chondrocytes to 
approximately 60% of the baseline values. A 25% repression of the release of IL-6 by 5.0 g/ml -
cyclodextrin-treated TNF-primed chondrocytes was observed (Fig 4).  
 
 
Figure  4. IL-6 release by normal (NO), normal TNF-primed (NO+TNF), and osteoarthritic (OA) chondrocytes.  : 
control cultures,  : -cyclodextrin-treated cells; Experiments were done in triplicate. Mean values ± 1 SD are shown  
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Discussion 
Catabolic cytokines e.g. IL-1 affect the homeostasis of the ECM in normal and OA cartilage and are 
produced by chondrocytes themselves
25,26
. In osteoarthritic (OA) chondrocytes or cartilage, the 
upregulation of the catabolic IL-1 and  pathways has been reported27,28 and a correlation with the 
occurrence and the degree of OA pathology was noted for IL-125,26,29. Increased IL-1-release by 
chondrocytes has been reported to be mediated by TNF30. Auto/paracrine TNF resulting from 
apoptosis of chondrocytes following excessive mechanical stress
31,32
 may thus induce an IL-1-
induced destruction of the extracellular environment of articular cartilage. 
Agents that possibly alter the evolution of degenerative joint disease (Disease Modifying 
Osteoarthritis Drugs (DMOAD) should at least demonstrate in how far they affect connective tissue 
metabolism in suitable in vitro models. Human articular chondrocytes maintain their original 
phenotype and metabolic characteristics when cultured in alginate gel
21,33-47
. Articular cartilage cells 
in this culture condition synthesize cartilage-specific collagens and extracellular matrix 
aggrecans
34,35
. Recently, it has been shown that chondrocytes obtained from intact tissues of 
maintain their normal metabolism, whereas chondrocytes from osteoarthritic cartilage retain their 
catabolic phenotype when cultured in alginate
38
. The system is suitable for the study of the effects 
of putative pharmaceutical agents on behaviour in vitro of human chondrocytes.  
In most in vitro conditions tested so far, 
35
SO4 used by phenotypically stable cartilage cells is 
incorporated for the most part in aggrecan. Variations in low hydrodynamic size proteoglycans such as 
decorin, biglycan, fibromodulin, type XI collagen and other physiologically important but less 
abundant extracellular macromolecules are not studied with these approaches. Hence, the incorporation 
by chondrocytes of 
35
Sulphate in macromolecules is commonly considered to be a variable reflecting 
aggrecan synthesis. Increased 35S-incorporation would unlikely have resulted from an increase in 
cell numbers or from an improved sulphating of the aggrecan glycosaminoglycan chains during 
exposure to the -cyclodextrins. Polysulphated polysaccharides were never shown to increase cell 
proliferation. In addition, no reports exist on the degree of sulphating of glycosaminoglycan chains 
produced by phenotypically stable cartilage cells in culture in alginate. It is assumed that 
glycosaminoglycan sulphating in this condition will not differ widely from sulphating values 
reported in tissue explants. Undersulphated disaccharides represent merly 5% of the disaccharides 
in glycosaminoglycan chains in these explants
39
. A possible increase in sulphating by -
cyclodextrin of the almost 95% sulphated glycosaminoglycan disaccharides in this experimental 
condition could not explain the 30-60% increases in 35S-incorporation reported here.             
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35
Sulphate incorporation in aggrecan was thus used as a measure to find out the optimal working 
concentration with these polysulphated -, - and -cyclodextrins. The alginate is an unsulphated 
polysaccharide and differences in levels of the added sulphated polysaccharides in media and the 
artificial matrix did probably not occur. Cyclodextrin dose-response curves showed optimal effects 
at 2.5 – 5.0 g/ml of the sulphated polysaccharides. Apparently, the 3 polysulphated cyclodextrins 
did not differently affect 
35
S-aggrecan synthesis. The increase in aggrecan synthesis was obvious in 
the chondrocytes obtained from different donors. Higher doses of the 3 cyclodextrins inhibited 
35
S-
aggrecan synthesis. These bell-shaped dose-effect curves have been previously reported when other 
oversulphated polysaccharides were used
13,40,41
. The inhibition of aggrecan synthesis at higher 
concentrations of the polysulphated polysaccharides in the incubation medium was not due to direct 
toxic effects on the chondrocytes as the cells did not stain with trypan blue when exposed to these 
high cyclodextrin concentrations (results not shown). Unpublished observations in this laboratory 
showed this inhibition to occur at even lower polysaccharide concentrations when low amounts of 
serum were supplemented to the nutrient media of these chondrocyte cultures. Hence, the lowered 
synthesis rates of extracellular matrix macromolecules could be possibly explained by the tendency 
of these polysulphated polysaccharides to bind to various biological agents of protein nature. This 
quality has been exploited in various polysaccharide polysulphate (e.g. heparin, dextransulphate)-
loaded affinity chromatography columns to remove and to purify cytokines and growth factors from 
biological fluids
42,43
.  
Polysulphated polysaccharides with different molecular structures e.g. heparin, chondroitin 
sulphate, chondroitin polysulphate and xylosan polysulphate, have been found to modulate 
connective tissue metabolism. As the exposure of connective tissue cells in culture to these 
polysaccharides almost invariably caused increased extracellular amounts of 
35
S-proteoglycan and 
3
H-glucosamine-labelled hyaluronan, it was assumed that these agents directly enhanced the 
synthesis rates of these ECM macromolecules
7,8,12,13
. Our present findings, however, reveal a new 
paradigm by which increased synthesis rates of aggrecan could have resulted from a repression of 
an autocrine chondrocyte IL-1 pathway as IL-1 is known to decrease the synthesis of aggrecan via 
NO
44,,45
.  Some of these polysulphated saccharides have been shown to directly inhibit
46-51
, or to 
slow down the production
52,53
 of a variety of enzymes that are capable of digesting important ECM 
compounds. Our finding that these polysulphated cyclodextrins decreased IL-1 and  levels inside 
the cells supports their anticatabolic activities. These intracellular cytokines represent a reservoir of 
biologically active agents, of which variable amounts are secreted as a result of various stimuli. It 
can be anticipated that the intracellular amounts of these bioactive molecules predict their 
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extracellular function. Obviously, the inhibition of these auto/paracrine catabolic pathways was 
followed by a significantly increased accumulation of CAM aggrecan, type II collagen and 
fibronectin.  
The fact that -cyclodextrin polysulphate interferes with chondrocyte IL-1 was further exemplified 
by the effects on IL-6 release in the incubation media. Considering the role of auto/paracrine IL-1 
pathways in the secretion of IL-6 by articular cartilage cells
54,55
, we studied the release of IL-6 as an 
IL-1-dependent variable by chondrocytes obtained from both normal and OA cartilages. We found 
that OA cells secreted significantly more IL-6 than normal chondrocytes, illustrating the well-
documented increase of auto/paracrine IL-1 activity in OA chondrocytes. -cyclodextrin 
polysulphate inhibited the synthesis of IL-6 in both normal and OA chondrocytes. Although the 
experiments were not performed in the presence of IL-1-blocking antibodies, it is supposed that -
cyclodextrin affected the IL-1 loop and did not directly impede the production of IL-6.  
Furthermore, -cyclodextrin polysulphate inhibited the release of IL-6 by TNF-primed 
chondrocytes. Although a possible downmodulation of TNF effects by -cyclodextrin was not 
excluded in these experiments, we postulate that the impaired IL-6 release could have been obtained 
through an interference with IL-1.  
It is as yet speculative to defend the use of oversulphated cyclodextrins to protect cartilage in 
clinical conditions such as osteoarthritis. The effects, however, of these agents on articular cartilage 
cell metabolism illustrate their ‘structure modifying effects’ on connective tissues and may predict 
their properties as ‘disease modifying osteoarthritis drugs (DMOAD).  
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Chapter IV: Discussion 
In the long-term, meniscus deficiency results in degenerative arthritis
1-3
. Although short term results 
of meniscectomy are acceptable in the majority of patients, excessive pain and dysfunction are 
observed in a subgroup of them. The lateral compartment is at higher risk for these symptoms than 
the medial compartment due to differences in anatomy and biomechanics
2-6
.  
In the case of a symptomatic meniscus deficiency, meniscus allograft transplantation seemed a 
logical approach and was introduced into clinical practice in the early eighties
7
. Due to the large 
differences in types of surgical fixation, meniscal preservation techniques, the associated  
procedures, the clinical scoring systems and, very importantly, the follow-up time, the comparison 
of the different published results remains difficult 
8,9
. 
Several types of surgical fixation have been described in the literature. Fixation methods can be 
subdivided in methods using only a soft tissue fixation and methods combining soft tissue fixation 
with a bone plug fixation. In vitro biomechanical studies on human cadaveric knees have shown 
superior strength of bone plug fixation for both the medial and lateral meniscus over soft tissue 
fixation 
10-13
. These studies, however, have not taken into account the biomechanical behaviour after 
the allograft has healed to the meniscal rim. Until now it has not been documented that bone plug 
fixation or soft tissue fixation leads to a longer survival, better clinical or radiological results 
8,9
. 
Using the soft tissue fixation method, we did observe in a separate study on a group of lateral 
meniscal allografts significant extrusion of the body and anterior horn 
14
. To address this 
phenomenon we recently modified the allograft transplantation procedure itself 
15
. The anterior horn 
of the medial or lateral allograft is now fixed using an anchor (GII anchor, Depuy Mitek Inc, 
Norwood (MA), USA) to the original anatomical position of the native meniscus. Although the 
anterior horn is biomechanically of less importance compared to the posterior horn, we hope to 
reduce this extrusion and thus improve the overall biomechanics of the affected compartment by 
this additional fixation device. Future analysis will allow us to come to a conclusion regarding its 
value. This could also include the use of novel MR imaging techniques (open coil dynamic MRI) 
enabling in vivo analysis of the biomechanical behaviour of the meniscus allograft under weight 
bearing conditions 
16
.   
The biomechanical function of the meniscal allograft not only depends on the quality of the surgical 
fixation technique, but also on the phenotype of the cell population of the allograft. Preservation 
techniques such as deep-freezing, lyophylisation and cryopreservation render the graft acellular or 
hypocellular and may adversely affect graft material properties 
17-20
. In vitro cultured menisci have 
been shown to remain viable and continue to produce extracellular matrix compounds, hence the 
term ‘viable meniscal allograft’ 
21
. After a two-week culture period the meniscus is transplanted 
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into the recipient knee. The proportions of cells that survive and how long they survive in vivo are 
unknown. Jackson et al. used DNA probe analysis in a goat model and found that all donor cells 
were rapidly replaced by host cells over a period of 4 weeks 
22
. However, a previous study in this 
department demonstrated the presence of donor DNA in the viable human meniscal allograft for as 
long as 64 months after transplantation, indicating that donor cells remain viable for a longer period 
and that this replacement process by host cells is probably slower in the human model 
23
. It is not 
known if recipient meniscus-invading cells, probably derived from the synovial lining, have the 
same capacity to produce extracellular matrix as have native meniscus cells 
24
. Preliminary 
histological data on deep-frozen meniscus allografts only demonstrated superficial repopulation of 
the graft with mainly fibroblast-like cells, while viable grafts demonstrated superior repopulation 
with a more fibrochondrocyte-like cell population 
24
. One can hypothesize that the donor meniscus 
cell present in the viable meniscus allograft is capable to induce an increased repopulation rate and 
a more fibrochondrocyte-like differentiation pattern of the host meniscus-invading cells by 
paracrine pathways. This would in turn result in superior biochemical and biomechanical properties 
of the graft. To test this hypothesis, a prospective comparative study of viable vs. deep-frozen 
allografts has been started at our institution.    
 
Our studies have shown that medial and lateral meniscal allograft transplantation significantly 
reduces pain and improves function of the involved knee joint as measured by the modified HSS 
score 
25,26
. Our findings substantiate and extend the previously published results on the clinical 
success of this procedure 
8,9,27,28
. Despite this significant improvement, substantial disability and 
symptoms were present in all investigated subgroups at more than 10 years of follow-up using the 
Knee Osteoarthritis Outcome Score 
26
. 
Since clinical outcome and success rates of any surgical procedure are strongly dependent on the 
length of follow-up, we performed a Kaplan-Meier survival analysis. In this survival analysis it is 
assumed that all patients had their operation simultaneously. We thus compared survival time and 
rate for different groups of patients after viable meniscal allograft transplantation. In our series, 
mean survival times and cumulative survival rates of approximately 70% at 10 years are 
comparable between isolated lateral or medial allografts 
25
. Previous studies have shown that risk 
factors for failure and reduced survival time are lower limb malalignment, ACL deficiency and 
grade IV cartilage lesions 
29-32
. In our series, the additional beneficial effect of a corrective 
osteotomy in case of a varus malalignment, and the importance of a stable knee joint have been 
clearly demonstrated 
25
. The exact position of an associated corrective osteotomy in the valgus knee 
needs further refinement. We however could not confirm a significant correlation between the 
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initial cartilage status and clinical failure, challenging the contraindications for arthrosis severity. 
This finding was also observed in a recent publication on deep-frozen meniscus allografts 
33
 . 
Since meniscus deficiency frequently induces symptomatic articular cartilage defects, we now are 
investigating the feasibility of a combined procedure addressing the meniscus deficiency by 
allograft transplantation and the secondary articular cartilage defect by a cartilage repair procedure 
(e.g. chondrocyte transplantation, microfracture, mosaicplasty). In the beginning, focal articular 
cartilage defects were left untreated since no surgical treatment was considered successful at that 
time. Ultimately, further controlled studies will be needed to analyze any additional beneficial 
effect of such associated cartilage treatment. For now however, the articular surface restoration 
techniques do not allow extension of the indications for meniscal allograft transplantation in 
patients with extended cartilage defects or generalized compartmental degeneration 
27,29
.  
In order to overcome the observed discrepancy between clinical outcome and the status of the 
meniscus allograft and to analyse any progression of degenerative articular changes after this type 
of surgery, objective outcome measures such as MR imaging were included in our long term 
outcome study 
34-36
. No previous medium and long-term reports have indicated that meniscus 
allografting halts or slows down further degeneration. We have provided proof that progression of 
cartilage degeneration according to MRI and radiological criteria was halted in a number of 
patients, indicating a potential chondroprotective effect 
26
. A recent controlled large animal study 
was also able to confirm this chondroprotective effect 
37
. These data could support the use of a 
prophylactic meniscus transplantation in meniscectomized patients without clinical symptoms, thus 
potentially limiting the cartilage degeneration secondary to a meniscectomy. Further prospective 
comparative studies are needed to test this hypothesis.  
Based on these satisfying clinical, radiological and MRI results, viable meniscal allograft 
transplantation is the golden standard to treat symptomatic meniscus deficiency in the younger 
patient. However, several potential drawbacks are associated with meniscus allografting such as the 
limited number of grafts available, the difficulty to treat symptomatic partial meniscectomy patients 
and the potential risk for disease transmission. 
To overcome these issues alternative treatments have been developed including the use of 
autologous or allogenic tissues (e.g. tendon, pediculated Hoffa fat pad, periosteal tissue, 
perichondral tissue, small intestine submucosa), meniscus scaffolds based on native polymers 
(collagen and hyaluronic acid) or purely synthetic scaffolds such as poly-lactic acid, poly-
glucuronic acid and poly-urethane 
38-44
. Other a collagen type I based meniscus scaffold (CMI®, 
Regen Biologics, Franklin Lakes, NJ, USA), none of these materials have advanced to human 
clinical use 
43
. In parallel with meniscus allograft transplantation, these surgical approaches are 
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based on the concept of a timely colonization of the acellular scaffold or allograft tissue by host 
cells which are probably derived from the synovium and joint capsule 
24,45
. The phenotype of these 
host-derived scaffold-colonizing cells ultimately determines the biochemical composition and 
biomechanical behaviour of these repopulated scaffolds or tissues. Another critical variable in this 
approach is the time needed for colonization of the scaffold or tissue: since these scaffolds or tissues 
are biodegradable, the colonization and healing by host cells should be faster than the degradation 
process, for the regeneration or healing of the meniscus substitute to be successful. Depending on 
the composition of the graft, this initial biodegradation is the result of the mechanical wear in 
addition to enzymatic of hydrolytic degradation.   
While developing different therapeutic strategies based on combinations of different scaffolds and 
cells, we were confronted with a lack of knowledge on the definition of the meniscus cell 
phenotype. 
Therefore, a study was undertaken to characterise the different human meniscus cells by the 
expression of cell associated matrix compounds and the expression of specific membrane markers 
46
.  
Human meniscus tissue is said to be populated mainly by round or oval matrix associated cells, 
comparable to the articular cartilage chondrocyte, and fibroblast-like cells 
47
. The round or oval 
cells of the meniscus, however, produced more type I collagen than the articular chondrocytes 
48
. 
The major fibrillar collagen produced by chondrocytes from the articular cartilage is type II 
collagen. Hence this meniscus cell was termed a fibrochondrocyte based on the difference in 
expression of collagen types 
48
. Two other connective tissue cell types have been described in 
meniscus tissue according to their shape, location and presence of extracellular matrix: the 
superficial cell and a cell type of intermediate morphology between that of a fibrochondrocyte and 
fibroblasts 
48-50
.  
With flow cytometry, we have analyzed the cells present in the human meniscus after culture for up 
to three weeks in alginate, and initially found 2 cell populations surviving the isolation procedure 
46
.  
A minor fraction consisting of CD34 positive-CD31 negative cells did not accumulate significant 
amounts of extracellular matrix products in its CAM and was gradually lost from the alginate 
culture system. Additional histology on human meniscus tissue confirmed the presence of CD34 
positive-CD31 negative fibroblast cells in the vascular portion of the meniscus as well as the 
synovial sublining. Surprisingly, CD34 positive-CD31 negative cells were also observed in the 
superficial region of the meniscus body. This superficial cell layer appeared to be in continuity with 
the subsynovial lining. The intriguing possibility has been raised previously that the superficial zone 
contains specialized cells, perhaps progenitor cells, which could initiate meniscus wound-healing 
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51,52
. Further research is however necessary to elucidate the exact phenotype and function of this cell 
population. Preliminary histological results on normal and pathological (acute tear, chronic tear, 
osteoarthritis and rheumatoid arthritis; unpublished data) meniscus specimen do show that the 
CD34 positive-CD31 negative superficial cell is possibly involved in meniscus homeostasis. These 
cells were present in the normal specimen as well as in the acute meniscus tear specimen. However, 
over time a progressive proliferation of the superficial layer in chronic meniscus tears is observed 
with increased expression of smooth muscle actin (SMA) and loss of CD34 expression. It is 
hypothesized that the CD34 positive cell differentiates towards a myofibroblastic cell-line 
characterized by SMA expression. Osteoarthritic specimen were characterized by a general 
hypocellularity and absence of CD34 positive cells in the superficial layer. The cells had a more 
chondrocyte-like phenotype and the extracellular matrix stained intense for alcian blue and 
saffranin-O, two indicator of a proteoglycans-rich, articular cartilage-like extracellular matrix. This 
chondrogenic process has previously been described in the osteoarthritic rabbit meniscus models 
53
. 
It appears that CD34 expression is progressively lost in the pathological meniscus. 
The main fraction of isolated meniscus cells persisted in culture, accumulated significant amounts 
of ground substance in its immediate pericellular environment and displayed a stable phenotype. 
These cells were CD34 negative-CD31 negative. Morphologically, these round or oval shaped cells 
were very similar to the meniscus fibrochondrocyte. CAM composition consisted of high amounts 
of both type I collagen and aggrecan and low amounts of type II collagen. This composition 
resembles the native composition of the human meniscus extracellular matrix. 
The monolayer culture condition, known to induce articular chondrocyte dedifferentiation towards a 
more fibroblast-like cell type, resulted in a completely different CAM composition of the meniscus 
cell when compared to meniscus cell cultured in alginate. Aggrecan levels in the CAM were 
dramatically lower while type II collagen synthesis apparently was upregulated. Monolayer cultured 
meniscus cells all had a fibroblast-like morphology.  
Previous reports on monolayer cultured meniscus cells indeed indicate a significant and rapid 
decrease in synthesis of large aggregating proteoglycans, irrespective of the meniscus region from 
where they were derived 
54
. 
No definite explanation can be given for the observed difference between monolayer cultured 
meniscus cells and those cells cultured in alginate. In light of the current knowledge on meniscus 
cell biology in situ and the different cell types present in the meniscus, it is tempting to state that 
both culture models favor the existence of a different meniscus cell type 
52
. Anchorage independent 
cells such as articular chondrocytes and most probably meniscus fibrochondrocytes thrive in the 
alginate culture conditions, while anchorage dependant cells such as meniscus fibroblast-like cells 
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would prefer monolayer culture conditions. It is therefore possible that meniscus fibroblast-like 
cells overgrow meniscus fibrochondrocytes in the monolayer condition. A second hypothesis could 
be that the fibrochondrocyte morphology and CAM composition can be modulated by the different 
culture conditions, as is generally accepted for the articular cartilage chondrocyte. Considering the 
exact fate of the CD34 positive cell fraction in the alginate culture system, 2 hypotheses are 
proposed: the CD34 positive meniscus cell is (1) unable to remain viable or (2) remains viable but 
loses CD34 expression as a possible effect of some differentiation process.  
Because of apparent difficulties to stabilize the fibrochondrocyte phenotype in monolayer culture 
conditions, and the invasiveness of a meniscus biopsy, other cell sources have also been 
investigated for meniscus tissue engineering purposes. 
Human bone marrow derived mesenchymal stem cells (hBMSC) are multipotent cells capable to 
differentiate into multiple mesenchymal cell lineages such as myoblasts, chondrocytes, adipocytes 
and osteoblasts 
55
. Additionally, recent data suggests that these undifferentiated cells have a 
stimulatory or trophic effect on the intrinsic reparative/regenerative process 
56
. These cells can be 
easily isolated from human bone marrow and expanded without loosing their multipotent 
characteristics in monolayer conditions 
55
. 
After hBMSC expansion, the use of these autologous cells for tissue engineering purposes thus 
appears reasonable.  
Therefore, in a first setup, the fibrochondrogenic (or meniscus cell-like) differentiation potential of 
hBMSC after expansion in autologous serum was investigated in vitro. In a second setup, hBMSC 
were seeded on a type I collagen meniscus scaffold. Different cell-seeding protocols were 
investigated. Again, the cell differentiation potential and the colonisation behaviour were 
investigated. 
Using common so-called chondrogenic differentiation protocols, we have provide proof that 
hBMSC expanded in monolayer conditions with culture medium supplemented with 10% 
autologous serum demonstrate, in a reproducible way, a cellular phenotype characterized by the 
presence of type I collagen, type II collagen and aggrecan in the extracellular matrix, when 
subsequently cultured in serum-free conditions and stimulated by TGF beta 1 and dexamethasone 
55,57
. These three compounds are typical for the extracellular matrix build-up by fibrochondrocytes 
from the native human meniscus 
46
. Therefore, we define this cellular differentiation pattern to be 
fibrochondrogenic or meniscus cell-like. Previous studies have defined this differentiation pattern as 
chondrogenic 
55,57
. We strongly disagree with this definition as type I collagen is not an 
extracellular matrix compound of human hyaline articular cartilage. 
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We have also demonstrated that hBMSC attached and were able to undergo fibrochondrogenic 
differentiation when seeded onto the type I collagen scaffold or injected into it, making them an 
attractive cell source for a cell-laden scaffold for meniscus repair and regeneration. However, 
hBMSC are generally considered to be CD34 negative 
55
. hBMSC therefore have potential in 
human meniscus tissue engineering applications, although other cell types such as superficial CD34 
positive meniscus cells, may be necessary to obtain a fully functional tissue. 
The ultimate goal of meniscus tissue engineering is to prevent or delay the onset of osteoarthritis. 
This degenerative disease is a direct consequence of the higher mechanical load on the articular 
cartilage after meniscectomy 
58,59
. Cartilage volume loss after meniscectomy is considered to be 
around 4 volume% per year and is more pronounced in the lateral compartment than the medial 
compartment 
60
. Therefore, the study of the articular chondrocytes and the biological processes 
responsible for the cartilage degeneration remain important as such. The knowledge on this cell 
type is much more extended compared to the meniscus cell type. Obviously, certain biological 
pathways present in the articular chondrocyte will also be implicated in meniscus degenerative as 
well as reparative processes. Specific differences in the expression of anabolic and catabolic factors 
were analyzed in normal and degenerated articular cartilage 
61
. Analysis of paired samples of 
normal and osteoarthritic chondrocytes from the same joint clearly showed that OA chondrocytes 
have an increased capacity to synthesize extracellular matrix molecules 
61
. However, these cells also 
have increased catabolic signalling pathways 
61
. As a consequence of the increased catabolic IL-1 
expression and the decreased availability of its decoy receptor IL-1RII, this results in an actual loss 
of the extracellular compounds from the cellular matrix. The IL-1/IL-1RII system therefore is an 
interesting therapeutic target in the management of joint degeneration
 61
. The IL-1 system is 
considered to be mediated by auto/paracrine TNF which is released from apoptotic chondrocytes 
following excessive mechanical stress 
62,63
. OA secondary to meniscectomy itself is considered to 
be largely attributable to excessive mechanical stress. The novel polysulphated polysaccharide 
cyclodextrine polysulphate showed in vitro capacity to induce increased expression of aggrecan and 
type II collagen in OA chondrocytes 
64
. Metabolic pathway analysis revealed that this effect results 
in part from the downregulation of the catabolic IL-1 pathway.  
In conclusion, viable meniscus allograft transplantation has been found to be the golden standard 
treatment in the symptomatic meniscectomized knee. A potential chondroprotective effect has been 
established 
26
. Drawbacks, such as allograft availability, are however present that refrain this 
therapy to become more accessible to the average patient. Therefore, investigations aimed at the 
further characterisation of the human meniscus cell and the development of clinically usable cell-
scaffold combinations should be applauded and stimulated. Since a major part of the meniscus 
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pathology is considered degenerative, additional pharmaceutical approaches should not only aim to 
stabilise or increase the extracellular matrix synthesis by the articular chondrocyte but also by the 
fibrochondrocyte. After all, most of the load distribution in the human knee is done by the meniscus 
and not the articular cartilage!          
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Chapter V: Summary 
 
In chapter III.A.1, the surgical technique on viable meniscal allograft transplantation is 
presented. This encompasses an open procedure with end to end fixation of the graft to the native 
meniscus horns. The indications and contraindications for this procedure are clearly described. 
Included in this paper are also the surgical pitfalls of this procedure and an update on the recent 
adjustments in the surgical fixation of the anterior horn of the allograft.  
In chapter III.A.2, the clinical results and survivorship analysis of this procedure are presented 
of the first 100 patients operated on in the Ghent University Hospital with a minimal follow-up of 2 
years. These results illustrate that viable meniscal allograft transplantation reduces pain and 
improves function of the knee joint after meniscectomy. This beneficial effect remains present in 
around 70% of the patients at 10 years after surgery. If associated with an high tibial osteotomy to 
correct an varus malalignment of the lower limb, this beneficial effect remains even present in over 
83% of the patients with a medial meniscal allograft at ten years.  
In chapter III.B.1, clinical as well as radiological and magnetic resonance results are presented 
of 42 patients with more than 10 years follow-up. Again, the long term clinical results are 
encouraging in term of pain relief and improvement of function. Despite this significant 
improvement, substantial disability and symptoms remain present in all investigated subgroups. 
Nonetheless, progression of further joint space narrowing and cartilage degeneration was absent in a 
considerable number of patients, indicating a potential chondroprotective effect. 
In chapter III.B.2, we have developed new ways to describe the position of the lateral 
meniscal allograft in the human knee under weight bearing and non-weight bearing conditions. 
Partial extrusion of this graft was evident on MRI and static ultrasonography, especially of the body 
section and the anterior horn. This type of extrusion appears however stabile in the dynamic 
ultrasonographic tests. 
Taken together, the clinical results of this type of surgery are encouraging and long-lasting in a 
well-selected patient population who suffered a total meniscectomy. Meniscal allografting appears 
to become the golden standard of therapy for them. No significant clinical difference can be found 
in the literature between the different available preservation techniques used today. Based on a 
small number of postoperative histological sections of viable (our series) and deep frozen (data 
from the literature and sections from elsewhere) meniscal allografts, indications exist that the viable 
meniscal allografts are repopulated far more extensively than grafts rendered acellular by deep 
freezing or cryopreservation. These observations warrant a comparative clinical study of deep 
frozen vs. viable allografts with special attention for the biological processes of repopulation and its 
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effect on the long-term clinical situation. Additional research also seems warranted to establish and 
optimize the chondroprotective effects of this intervention.  
In light of the higher numbers of partial meniscectomies in the daily clinical office, future attention 
should also be paid to develop strategies to restore and regenerate meniscus tissue without the 
intrinsic drawback of the use of allogeneic material. 
Since the introduction of autologous chondrocyte transplantation into clinical practice in 1987 for 
the treatment of symptomatic cartilage lesions, clinical as well as basic research efforts have been 
performed to characterize and culture the articular chondrocyte. This effort has been less obvious 
for the meniscus cell. Thus, we were confronted with a lack of knowledge on the specific cellular 
composition of this tissue and the behaviour of meniscus cells in culture. These data are however 
indispensable for the further development of regenerative cell-based strategies for the human 
meniscus. 
In chapter III.C, we aimed at the characterization of the human meniscus cell’s CAM synthesis 
and turnover in two different culture conditions. The composition of this extracellular matrix offers 
a variable defining the distinct phenotype of the cells homing in the meniscus. The alginate culture 
conditions appear to favor the fibrochondrocyte meniscus cell with a cell associated matrix rich in 
type I collagen and aggrecan and lower quantities of type II collagen, while monolayer cultured 
meniscus cells have considerable amounts of type I and II collagen but almost no aggrecan in their 
CAM. This CAM composition is distinctly different from the CAM composition of phenotypically 
stable articular cartilage chondrocytes. These studies warrant further research into in vitro meniscus 
cell behavior and further definition of the different meniscus cell types. Serendipity also led to the 
description of a new cell-type within the superficial layer of the human meniscus, namely the 
CD34+ cell type. Its presence seems to be implicated in the homeostasis of the normal meniscus 
(unpublished data). Currently further research in the lab in focused on its characterization in 
pathological meniscus specimen and its isolation for in vitro culture.  
Since monolayer culture of meniscus cells appears to favor a dedifferentiated cell type with a 
fibroblast-like appearance and an extracellular matrix composed out of type I and II collagen, this 
cell type seems less ideal for the use in meniscus regenerative medicine.  
In chapter III.D, we therefore opted to use the recently described mesenchymal stem cell in 
combination with a type I collagen scaffold. We demonstrated that hBMSC expanded in autologous 
serum have a fibrochondrogenic differentiation potential. hBMSC can also be combined with a 
biodegradable meniscus-shaped scaffold. This cell-scaffold combination can be implanted easily 
into the meniscus defect thereby delivering autologous hBMSC with meniscus repair potential to 
this defect. The available clinical and histological evidence on acellular scaffolds implicates a rather 
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slow repopulation potential of the scaffolds by host-derived cells from the synovium and remnant 
meniscus with an uncertain differentiation potential. Since the biomechanical and biological 
characteristics of the graft are ultimately determined by the cellular phenotype residing in the tissue, 
it is the authors’ conviction that a specific cell-based therapy could increase repair potential of the 
defect, which allows faster repair and regeneration with meniscus-like tissue and thus shortens the 
rehabilitation period.  
In chapter III.E.1, a novel metabolic pathway is described in the normal and osteoarthritic 
articular chondrocyte. It can be concluded that whereas the IGFR1/IGF-1 pathway controlled the 
homeostasis of the ECM and overruled the agonists of the IL-1 pathway through an upregulation of 
IL-1RII in normal cartilage, this organization was not obvious in cartilage tissue from the 
osteoarthitic joint. Chondrocytes from osteoarthritic joints were hyperactive but concurrently 
expressed significant catabolic activities. Under these circumstances newly synthesized ECM 
compounds were not able to accumulate in a cell-associated matrix. Surprisingly, this disturbed 
metabolism was observed in both degenerative and visually intact articular cartilage of OA joints. 
This underscores the role of IL-1RI and –II in the maintenance of articular cartilage integrity, and 
their potential as therapeutic targets for osteoarthritis.  
In Chapter III.E.2, designer pharmaceuticals were tested on normal and degenerative articular 
cartilage to target specific anabolic and catabolic pathways in order to modify and possibly reverse 
the degenerative process. It was concluded that polysulphated cyclodextrines (CDPS) were a novel 
polysulfated polysaccharide showing cartilage structure modifying effects in vitro as it improves the 
synthesis of aggrecan and the accumulation of CAM macromolecules. This effect probably resulted 
in part from the downregulation of IL-1. 
The ultimate goal of meniscus transplantation and tissue engineering is to prevent the degenerative 
process induced by a partial or total meniscectomy and inflicted upon the articular cartilage. 
Therefore, metabolic pathways were investigated in the articular chondrocyte that could be targeted 
by specific pharmaceuticals in order upregulate an anabolic effect. Due to the embryological 
similarities between articular cartilage and meniscus tissue, comparable metabolic pathways could 
also be present within the different meniscus cell types. The different recognized pathways present 
in the articular chondrocyte should additionally be investigated in the different meniscus cells. 
Pharmaceutical therapies aimed to influence and modify these degenerative processes in the 
articular cartilage should result in an overall anabolic response of the articular chondrocyte and of 
the meniscus cell. The use of certain pharmaceuticals could thus improve the results of the meniscus 
transplant procedure in secondary osteoarthritic knee joints. Finally, future work should be focused 
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on the further characterisation and isolation of the CD34 positive meniscus cell residing in the 
superficial layer since this cell appears to be implicated into the homeostasis.  
In conclusion, this work investigated the role of viable meniscus allograft transplantation in the 
treatment algorithm of the symptomatic meniscectomized patient. Additional efforts were made to 
further characterize the human meniscus cellular and biochemical composition for tissue 
engineering purposes. One study focused on the combination of human bone marrow derived 
mesenchymal stem cells and a type I collagen scaffold for this purpose. Since ultimately the general 
aim of meniscus tissue engineering is to reduce or prevent the degenerative effect on the underlying 
cartilage secondary to a meniscectomy, metabolic pathways were investigated in the articular 
chondrocyte that could be targeted by specific pharmaceuticals in order upregulate an anabolic 
effect. 
Future work should be focused on the further characterisation and isolation of the CD34 positive 
meniscus cell residing in the superficial layer since this cell appears to be implicated into the 
homeostasis. The different recognized pathways present in the articular chondrocyte should 
additionally be investigated in the different meniscus cells.     
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CHAPTER VI 
 
SAMENVATTING 
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Hoofdstuk VI: Samenvatting 
 
In hoofdstuk III.A.1 wordt de chirurgische transplantatie techniek van een viabele 
meniscale allogreffe gedetailleerd. Deze techniek is een open chirurgische techniek waarbij de 
greffe ‘end-to-end’ wordt vastgehecht op de bestaande meniscus hoorn. De indicaties en contra-
indicaties worden uitgebreid belicht. Tevens vindt men in dit hoofdstuk de specifieke moeilijkheden 
van deze procedure, alsook de recente aanpassingen bij de fixatie van de voorste meniscus hoorn. 
In hoofdstuk III.A.2 worden de klinische bevindingen en overlevingsanalyse voorgesteld 
gebaseerd op de resultaten van de eerste 100 patiënten die werden getransplanteerd in het 
Universitair Ziekenhuis Gent. De minimale follow-up van deze studie bedraagt 2 jaar. Deze studie 
toont duidelijk aan dat viabele meniscale allogreffe transplantatie de pijn reduceert en de functie 
van het kniegewricht verbetert. Dit gunstige effect blijft bestaan bij ongeveer 70% van de patiënten 
10 jaar na de ingreep. Indien er initieel aan de mediale meniscus allogreffe transplantatie tevens een 
valgiserende osteotomie was geassocieerd, ter correctie van een malalignatie in valgus, stijgt dit 
percentage tot 83% op 10 jaar. 
In hoofdstuk III.B.1 worden naast de klinische resultaten ook de radiologische en 
magnetische resonantie resultaten gepresenteerd van 42 patiënten. De minimale follow-up in deze 
studie bedraagt 10 jaar. Opnieuw werden gunstige lange-termijn resultaten genoteerd wat betreft de 
vermindering van pijn en verbetering van functie. Echter, naast deze gunstige resultaten, moet 
vermeld worden dat ook belangrijke beperkingen en symptomen aanwezig waren in deze 
patiëntengroep. Desalniettemin werd in een belangrijk aantal patiënten geen vernauwing van de 
gewrichtspleet of verdere degeneratie van het kraakbeen gezien. Dit wijst op een mogelijk 
beschermend effect op het kraakbeen van de meniscus transplantatie. 
In hoofdstuk III.B.2 worden nieuwe technieken voorgesteld om de positie van de laterale 
meniscus te bepalen in onbelaste en belaste toestand. Partiele uitpuiling werd gezien zowel op MRI 
als op statisch belaste echografie. Deze uitpuiling was het belangrijkst in het middelste en voorste 
deel van de laterale meniscus. Tijdens dynamische belasting werd echter geen verhoging van de 
uitpuiling geobserveerd zodat deze uitpuiling als stabiel werd beschreven. 
 
Alles in beschouwing genomen, mogen we zeggen dat deze klinische resultaten gunstig en 
langdurig zijn in een goedgeselecteerde patiëntenpopulatie. Meniscus transplantatie is de gouden 
standaard voor de behandeling van pijn en functieverlies na meniscusresectie. Tot op vandaag 
worden geen duidelijke verschillen genoteerd tussen de verschillende bewaringstechnieken van 
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deze allogreffes. Op basis van een beperkt aantal postoperatieve histologische snedes van viabele 
(onze serie) en diepgevroren (data in de literatuur en van elders) meniscale allogreffes, bestaan er 
aanwijzingen dat de viabele meniscus allogreffe uitgebreider wordt gerepopuleerd dan acellulaire 
greffes (zoals diepgevroren of gecryopreserveerde greffes). Deze bevindingen duiden op de nood 
aan een vergelijkende studie tussen diepgevroren en viabele allogreffes waarbij speciale aandacht 
dient besteed te worden aan de biologische processen van repopulatie en de gevolgen hiervan op 
lange termijn. Bijkomend onderzoek is tevens nodig om het kraakbeen beschermend effect te 
bevestigen en te optimaliseren. 
 
Aangezien in de huidige klinische setting een groter aantal partiële meniscectomieën wordt 
uitgevoerd dan volledige meniscus resecties, moeten er tevens strategieën worden ontwikkeld om 
meniscus weefsel te herstellen of te regenereren zonder dat daarbij allogeen materiaal moet worden 
gebruikt met zijn intrinsieke nadelen. 
Sinds 1987 kunnen kraakbeenletsels ondermeer behandeld worden door een kraakbeencel 
transplantatie. De introductie van de toen nieuwe technologie heeft geleid tot een ‘boom’ in het 
klinische en basiswetenschappelijke onderzoek naar de karakterisatie en kweek van de kraakbeencel 
in tegenstelling tot de meniscus cel. We werden dus geconfronteerd met een relatief gebrek aan 
informatie over het in vitro gedrag en de karakteristieken van de humane meniscus cellen. Deze 
kennis is echter onontbeerlijk voor de ontwikkeling van regeneratieve strategieën gebaseerd op 
celtherapie voor de meniscus. 
 
In hoofdstuk III.C  hebben we getracht de samenstelling van de meniscuscel geassocieerde 
matrix (CAM) en diens metabolisme in twee verschillende kweeksystemen te karakteriseren. De 
specifieke samenstelling van deze CAM geeft ons een parameter om het fenotype van de 
verschillende celtypes aanwezig in de meniscus te beschrijven. Het alginaat model bleek de 
fibrochondrocyt met een CAM bestaande uit voornamelijk collageen type I en aggrecan en in 
mindere mate collageen type II te bevoordelen. Het monolayer model bevoordeelde eerder een 
meniscus cel met een CAM bestaande uit voornamelijk collageen type I en II maar bijna geen 
aggrecan. De samenstelling van de CAM was dus duidelijk verschillend van de samenstelling van 
de CAM van een kraakbeencel. Deze bevindingen tonen duidelijk de noodzaak tot verdere 
karakterisatie van de verschillende meniscus cellen. Tijdens deze studies werd ook een tot dan toe 
onbekende meniscus cel gekarakteriseerd, namelijk de CD34+ meniscus cel. Deze cel lijkt op het 
eerste zicht een functie te hebben in de homeostase van het meniscus weefsel (ongepubliceerde 
data). Op dit ogenblik wordt er in het labo onderzoek gedaan naar dit specifiek cel type in normale, 
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maar ook in pathologische meniscus weefsels, alsook naar de isolatie van dit celtype voor in vitro 
cultuur. 
Gezien het feit dat het monolayer model een eerder gededifferentiëerd cel type bevoordeelt met een 
fibroblast-achtige morfologie en een CAM die bestaat uit collageen type I en II, lijkt dit cel type 
minder geschikt voor meniscus regeneratie. 
In hoofdstuk III.D  hebben we daarom geopteerd om de recent beschreven mesenchymale 
stamcel, geïsoleerd uit het beenmerg (hBMSC), te combineren met een collageen type I matrix. In 
deze studie werd aangetoond dat hBMSC, welke werden gepropageerd met toediening van autoloog 
serum, een fibrochondrogeen differentiatie potentieel hebben. hBMSC werden tevens gecombineerd 
met een biodegradeerbare matrix in de vorm van een meniscus. Deze cel-matrix combinatie kan 
gemakkelijk in het meniscus defect genaaid worden waardoor autologe hBMSC met meniscus 
herstellend potentieel tot in het defect gebracht kunnen worden. De in de literatuur voor handen 
zijnde klinische en histologische data geven eerder een beperkte mogelijkheid van het menselijke 
lichaam aan om een acellulaire matrix te repopuleren met eigen cellen. Deze cellen zijn 
vermoedelijk afkomstig van het synovium en de meniscus restant en worden ook gekenmerkt door 
een ‘onzeker’ differentiatiepotentieel. Aangezien de biologische en biomechanische eigenschappen 
van een greffe of matrix uiteindelijk worden bepaald door het fenotype van de cel aanwezig in dat 
weefsel, is het onze overtuiging dat celtherapie het vermogen tot herstel kan verhogen. Dit leidt op 
zijn beurt tot een sneller meniscus regeneraat en dus naar een verkorte revalidatie. 
In hoofdstuk III.E.1, werd een tot dan toe onbekende metabole pathway beschreven in de 
normale en artrotische kraakbeencel. In die studie kwamen we tot de conclusie dat in normaal 
kraakbeen de IGF/IGFR1 pathway de homeostase controleert en belangrijker is dan de agonist van 
de IL-1 pathway door een opregulatie van IL-1RII, terwijl in artrotisch kraakbeen deze vorm van 
organisatie niet duidelijk was. Artrotische chondrocyten zijn weliswaar anabool hyperactief maar 
brengen tegelijkertijd een grotere katabole activiteit tot expressie. Onder deze omstandigheden 
worden de nieuw gesynthetiseerde extracellulaire molecules niet bewaard in de CAM. Tot onze 
verbazing werd dit gestoorde metabolisme niet alleen genoteerd in de cellen afkomstig van 
degeneratief kraakbeen, maar ook in cellen afkomstig van visueel intact kraakbeen uit een artrotisch 
gewricht. Deze bevindingen onderlijnen de rol van de IL-1RI en –II in de homeostase van 
gewrichtskraakbeen en wijzen op hun potentieel als ‘target’ in de behandeling van osteoartrose. 
In hoofdstuk III.E.2 werden ‘designer drugs’ of volledig synthetische medicatie getest op 
normaal en artrotische kraakbeen met als doel specifieke anabole en katabole pathways te 
beïnvloeden. Op die manier zou het degeneratieve proces kunnen worden tenietgedaan. We 
kwamen tot de conclusie dat polygesulfateerde cyclodextrines (CDPS) een nieuwe klasse van 
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polygesulfateerde polysaccharides was met een kraakbeen structuur modificerend effect in vitro. Dit 
omwille van het feit dat deze medicatie de synthese van aggrecan verbetert alsook de accumulatie 
van deze macromolecules in de CAM verhoogt. Dit effect is waarschijnlijk ten dele het resultaat 
van een downregulatie van IL-1. 
 
Het uiteindelijke doel van een meniscus transplantatie en meniscus tissue engineering is preventie 
van de degeneratieve processen ter hoogte van het gewrichtskraakbeen welke een direct gevolg zijn 
van de partiële of totale meniscus resectie. Metabole pathways werden daarom onderzocht in de 
articulaire kraakbeencel. Dergelijke pathways zouden anabool beinvloed kunnen worden d.m.v. 
specifieke farmaceutica. Gezien zowel kraakbeen als meniscus weefsel embryologisch dezelfde 
oorsprong hebben, lijkt het aannemelijk dat dergelijke metabole kraakbeen pathways ook aanwezig 
zijn in de verschillende soorten meniscuscellen. De reeds gekende metabole kraakbeen pathways 
dienen tevens onderzocht te worden in de verschillende meniscus cellen.  
Een farmacologische therapie met als doel de degeneratieve processen te beïnvloeden of te 
veranderen, zou er toe kunnen leiden om een anabool metabolisme te bewerkstelligen in de 
kraakbeencel en de meniscus cel. Bepaalde farmaceutica zouden aldus het resultaat na meniscus 
transplantatie bij secundaire artrose van de knie kunnen verbeteren. Tot slot dient een verdere 
karakterisatie en isolatie van CD34 positieve meniscuscellen uit de oppervlakkige laag te 
geschieden, daar deze cellen een rol zoude spelen in de homeostase. 
 
Tot slot, deze thesis heeft de rol van de viabele meniscus allogreffe transplantatie bestudeerd in het 
behandelingsalgoritme van de symptomatische patiënt na een meniscectomie. Vervolgens werd de 
humane meniscus verder gekarakteriseerd op vlak van zijn cellulair en biochemische samenstelling, 
dit met tissue engineering toepassingen in het achterhoofd. Een studie combineerde hiervoor 
humane mesenchymale stam cellen met een collageen type I matrix.  
Aangezien het uiteindelijke doel van meniscus tissue engineering het beschermen van het 
onderliggende gewrichtskraakbeen is, werden metabole pathways in de kraakbeencel onderzocht, 
welke op farmacologische wijze zouden kunnen worden omgebogen van eerder katabool naar 
anabool. 
In de toekomst dient verder aandacht besteed te worden aan de karakterisatie en isolatie van de 
CD34+ meniscus cel aangezien deze vermoedelijk een belangrijke functie heeft in de homeostase. 
De kennis die reeds vergaard is over de verschillende metabole pathways in de kraakbeencel, dient 
te worden getoetst aan de verschillende meniscuscellen.  
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CHAPTER VI 
 
RESUME 
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Hoofdstuk VII: Résumé  
Dans le chapitre III.A.1, l’auteur décrit une technique chirurgicale utilisant une greffe méniscale 
viable. Elle comprend une chirurgie à ciel ouvert, ainsi qu’une fixation stable de l’implant sur les 
cornes méniscales anatomiques. Les indications et les contre-indications sont décrites in extenso. 
Les points critiques de ce type d’intervention sont illustrés. Une mise au point récente pour la 
fixation de la corne antérieure du ménisque est rapportée. 
Le chapitre III.A.2 résume les résultats cliniques, ainsi qu’une analyse de la courbe de survie de 
cette intervention dans les 100 premiers malades opérés à l’Hôpital Universitaire de Gand avec une 
suivie minimum de deux ans. Ces résultats rapportent une diminution importante de la douleur, 
ainsi qu’une amélioration nette de la fonction du genou après implantation d’une allogreffe 
méniscale viable. Ces résultats satisfaisants restent valables dans le temps à plus de 10 ans dans 
environ 70% des cas. Cette chirurgie, associée à une ostéotomie de correction sur déviation axiale 
en varus du membre inférieur antécédent, donne des résultats encore satisfaisants dans plus de 83% 
des malades après greffe méniscale viable à 10 ans. 
Le chapitre III.B.1 décrit les résultats cliniques et d’imageries par radiologie à blanc et par 
résonance magnétique dans 42 malades à plus de 10 ans de recul. Dans cette étude à nouveau les 
résultats cliniques à long terme sont encourageants en relation avec la diminution de douleur et 
l’amélioration de la fonction. 
Il semble néanmoins que l’évolution du pincement articulaire soit arrêtée dans un nombre 
considérable de malades, ce qui pourrait illustrer un effet chondroprotecteur potentiel de ce type 
d’intervention. 
Le chapitre III.B.2 décrit l’étude du positionnement de la greffe méniscale externe du genou, en 
charge et en décharge, utilisant de nouvelles techniques. L’extrusion partielle de cette greffe 
apparait évidente à l’étude par résonance magnétique et ultrasonographique, tout spécialement dans 
la partie antérieure de l’allogreffe. Ce type d’extrusion, par contre, ne semble plus augmenter à 
l’étude dynamique par ultrasonographie. 
Dans l’ensemble, les résultats cliniques de ce type de chirurgie sont encourageants à long terme 
chez le malade qui a subi une méniscectomie totale. Dans la littérature, en effet, l’allogreffe 
méniscale semble devenir le « golden standard » thérapeutique. 
A ce jour, aucune différence majeure ne peut se retenir dans la littérature à l’utilisation de 
différentes techniques de préservation méniscale. 
Néanmoins, en comparant une courte série de coupes histologiques sur ménisques viables (nos 
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séries) versus ménisques congelés (séries de la littérature), l’on remarque une repopulation 
cellulaire bien plus importante dans la greffe viable vis-à-vis de la greffe congelée ou 
cryopréservée. Ces observations suggèrent une étude comparative future entre les greffes congelées 
ou cryopréservées vis-à-vis des allogreffes viables avec une étude approfondie du processus 
biologique, ainsi que de la repopulation cellulaire, surtout en relation avec un effet clinique 
potentiel à long terme. Cette recherche pourrait confirmer et optimaliser l’effet chondroprotecteur 
de ce type d’intervention. 
Dans cet ordre d’idées et tenant compte du nombre important actuel des méniscectomies partielles, 
cette étude pourrait développer une stratégie future de régénération du tissu méniscal sans les 
limitations de l’usage de tissu allogénique. 
Depuis 1987, l’utilisation de cellules cartilagineuses autologues dans le traitement des lésions 
cartilagineuses a permis d’étudier la culture et la caractérisation du chondrocyte. Cet effort a été 
moins développé dans le domaine de la cellule méniscale. De ce fait, nous étions confrontés à une 
connaissance limitée de cette cellule et de son tenant en culture. Il est clair que ces informations 
sont indispensables dans le développement ultérieur des stratégies thérapeutiques, utilisant la 
régénération méniscale cellulaire. 
Le chapitre III.C étudie la synthèse et le métabolisme de la matrice cellulaire associée (CAM) de la 
cellule méniscale dans deux types de culture. Cette matrice cellulaire associée définit une variable 
distincte dans le phénotype de la cellule méniscale. La culture sur alginate semble favoriser le 
fibrochondrocyte avec une matrice cellulaire associée riche en type I collagène et aggrécan avec une 
présence limitée du type II collagène, tandis que la culture en monolayer remarque un nombre 
considérable du collagène type I et II, mais quasiment sans aggrécan. Cette composition de la 
matrice cellulaire associée est fondamentalement différente de la composition du chondrocyte à 
phénotype stable. Ces études demandent donc une recherche approfondie dans le domaine de la 
cellule méniscale in vitro et une définition plus performante de ces différentes cellules méniscales. 
Tout cela semble avoir conduit l’auteur à une description d’une nouvelle cellule dans la partie 
superficielle du ménisque humain: la cellule CD34+. Il semblerait que la présence de cette cellule 
soit impliquée dans l’homéostase du ménisque normal (données non-publiées). Une étude 
approfondie en laboratoire s’intéresse ce jour à la caractérisation de cette cellule en milieu 
pathologique, ainsi que dans son isolation par culture in vitro. 
Etant donné que la culture méniscale en monolayer semble favoriser une dédifférentiation dans le 
sens de la cellule fibroblaste et une matrice cellulaire associée du type collagène I et II, il semblerait 
que ce type de cellule ne puisse être inclus dans la médecine régénérative du ménisque. 
239
  
C’est la raison pour laquelle dans le chapitre III.D l’auteur a opté d’utiliser la cellule souche 
(hBMSC) en combinaison avec une matrice type I collagène. L’auteur a pu démontrer que la  
hBMSC, cultivée dans un sérum autologue, présente un potentiel de différentiation 
fibrochondrogénique. Ce type de cellule peut également être combiné dans l’utilisation avec une 
matrice biodégradable de forme méniscale. Cette combinaison peut s’implanter aisément dans la 
lésion méniscale, ce qui permettrait un effet réparateur de par la cellule souche autologue. Les 
résultats cliniques et histologiques, limités dans ce type de chirurgie, semblent illustrer une 
repopulation lente par cellule synoviale de l’hôte, ainsi que par le mur méniscal, avec une 
différenciation incertaine. Les caractéristiques biomécaniques et biologiques de la greffe étant 
finalement déterminées par le phénotype cellulaire du tissu, l’auteur est convaincu que des thérapies 
cellulaires spécifiques pourraient augmenter le potentiel réparateur. Ceci permettrait une 
régénération du tissu méniscal plus rapide et une réhabilitation plus efficace. 
Le chapitre III.E.1 décrit un nouveau sentier métabolique du chondrocyte normal et 
ostéoarthritique. En effet, il a été permis de conclure que le sentier IGFR1/IGF-1 contrôlait 
l’homéostase de la matrice extracellulaire et donc neutralisait les agonistes du sentier IL-1 par une 
dérégulation du IL-1RII dans le cartilage normal, cette organisation ne semblant pas apparente dans 
le cartilage de l’articulation ostéoarthritique. En effet, les chondrocytes d’une articulation 
dégénérative semblaient hyperactifs, mais également dénotaient une activité catabolique importante. 
De ce fait, une nouvelle synthèse de la matrice extracellulaire ne semblait pas pouvoir s’accumuler 
dans la matrice cellulaire associée. De plus, ce métabolisme dérangé se faisait remarquer tout aussi 
bien dans l’articulation à apparence dégénérative, mais aussi à cartilage intacte à l’oeil nu. Tout cela 
souligne le rôle important du IL-1RI et –II dans l’entretien de l’intégrité du cartilage et leur effet 
thérapeutique dans l’articulation dégénérative. 
Le chapitre III.E.2 a permit d’étudier l’effet de nouvelles molécules sur le cartilage normal et 
dégénératif en investigant leur activité anabolique et cataboliques, qui pourrait modifier et 
éventuellement renverser le processus dégénératoire. Cette étude a aidé à conclure que les 
cyclodextrines polysulphatés semblent être une nouvelle polysaccharide polysulphatée présentant 
un effet modifiant la structure cartilagineuse in vitro. En effet, cette molécule améliorait la synthèse 
de l’aggrécan et produisait une accumulation de macromolécules dans la matrice cellulaire associée. 
Sans doute cet effet est dû en partie à une dérégulation de IL-1. 
Le but ultime de la transplantation méniscale, ainsi que du engineering tissulaire, est bien sûr 
d’arrêter le processus dégénératoire, qui est induit par la méniscectomie partielle ou totale sur le 
cartilage de portance. C’est la raison pour laquelle les systèmes métaboliques du chondrocyte 
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articulaire ont été investigués qui pouvaient être influencés de façon pharmacologique avec un effet 
anabolisant. Le tissu articulaire ainsi que le tissu meniscal, ayant certaines similarités 
embryologiques, il est d‘ordre d’accepter un  métabolisme comparable entre les différentes cellules 
méniscales également. 
C’est ce métabolisme de la cellule articulaire que l’on  connaît bien qui devrait encore être étudié 
dans les différentes cellules du tissu meniscal. Les traitements pharmaceutiques eux ont pour but 
d’influencer et éventuellement de modifier les processus dégénératoires, ce qui pourraient induire 
une réponse anabolique de la cellule cartilagineuse mais aussi de la cellule méniscale. C’est ainsi 
que l’on pourrait espérer qu’un traitement médical pourrait supporter ainsi qu’améliorer les résulats 
après la transplantation méniscale dans le genou arthrosique secondaire.  
Dans l’avenir, une recherche approfondie reste à prévoir dans l’isolation ainsi que dans la 
charactérisation de la cellule méniscale CD34 positive qui ce retrouve à la surface du corps 
méniscal et qui semble être bien impliquée dans l’homéostase tissulaire du genou.  
En conclusion, cette thèse a étudié le rôle de la transplantation de l’allogreffe méniscale viable dans 
un algorithme thérapeutique du malade ayant subi une méniscectomie devenue symptomatique. Un 
effort particulier a essayé de caractériser la cellule méniscale chez l’homme, ainsi que sa 
composition biochimique dans le but d’un engineering tissulaire. Une étude s’est centrée dans 
l’application de la cellule souche depuis l’os spongieux en association avec une matrice type I 
collagène. Il est clair que le but final de l’engineering du tissu méniscal est de réduire ou de 
prévenir l’effet dégénératoire du cartilage suite à la méniscectomie. L’étude métabolique de la 
cellule cartilagineuse traitée par de nouvelles molécules avait pour but d’améliorer leur effet 
anabolique. 
Bien sûr que dans l’avenir, une caractérisation plus appropriée de la cellule CD34, qui se remarque 
dans la surface du tissu méniscal, pourrait aider à l’élucidation de l’homéostase méniscale. 
Il faudrait donc étudier toutes ces cellules méniscales et en comparer le métabolisme avec les 
techniques appliquées à l’étude du chondrocyte. 
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APPENDIX 
 
CLINICAL SCORING 
SYSTEMS 
 
Modified H.S.S 
KOOS 
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Modified HSS scoring system. The system is subdivided into a knee score that rates only the knee joint 
itself (max. 100 points) with regard to pain (max. 50 points), range of motion (max. 25 points) and 
stability (max. 25 points). Flexion contracture, extension deficit and malalignment are dealt with as 
deductions. Additionally, a daily functional score (max 100 points) rates the patient’s ability to walk 
(max. 50 points) and to climb stairs (max 50 points), with deductions for walking aids. 
          : the pain score and functional score of the modified HSS system were used for the survival 
analysis. 
 
KNEE SCORE     FUNCTION SCORE 
 
PAIN   POINTS   WALKING   POINTS 
None   50    unlimited   50 
Mild or occasional 45    > 10 blocks   40 
Stairs only  40    5-10 blocks   30 
Walking&stairs 30    < 5 blocks   20 
Moderate      housebound   10 
Occasional  20    unable    0 
Continual  10 
Severe   0 
 
RANGE OF MOTION    STAIRS 
(5°=1 point)  25    normal up&down   50 
       normal up, down with rail  40 
       up&down with rail  30 
STABILITY      up with rail;unable down  15 
Anteroposterior      unable    0 
 <5mm  10    SUBTOTAL 
 5-10mm 5 
 10mm  0    DEDUCTIONS 
Mediolateral 
 <5°  15    cane    5 
 6°-9°  10    two canes   10 
 10°-14°  5    crutches or walker  20 
 15°  0 
       TOTAL DEDUCTIONS 
SUBTOTAL 
         
DEDUCTIONS 
Flexion contracture 
 5°-10°  2 
 10°-15°  5 
 16°-20°  10 
 >20°  15 
Extension lag 
 <10°  5 
 10-20°  10 
 >20°  15 
Alignment 
 5-10°  0 
 0-4°  3 points each degree 
 11-15°  3 points each degree 
 other  20 
 
TOTAL DEDUCTIONS 
 
KNEE SCORE  /100  FUNCTION SCORE        /100 
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Knee and Osteoarthritis Outcome Score (KOOS), English version LK1.0 1
KOOS KNEE SURVEY
Todays date: _____/______/______ Date of birth: _____/______/______
Name: ____________________________________________________
INSTRUCTIONS: This survey asks for your view about your knee. This
information will help us keep track of how you feel about your knee and how
well you are able to do your usual activities.
Answer every question by ticking the appropriate box, only one box for each
question. If you are unsure about how to answer a question, please give the
best answer you can.
Symptoms
These questions should be answered thinking of your knee symptoms during
the last week.
S1. Do you have swelling in your knee?
Never Rarely Sometimes Often Always
o o o o o
S2. Do you feel grinding, hear clicking or any other type of noise when your knee
       moves?
Never Rarely Sometimes Often Always
o o o o o
S3. Does your knee catch or hang up when moving?
Never Rarely Sometimes Often Always
o o o o o
S4. Can you straighten your knee fully?
Always Often Sometimes Rarely Never
o o o o o
S5. Can you bend your knee fully?
Always Often Sometimes Rarely Never
o o o o o
Stiffness
The following questions concern the amount of joint stiffness you have
experienced during the last week in your knee. Stiffness is a sensation of
restriction or slowness in the ease with which you move your knee joint.
S6. How severe is your knee joint stiffness after first wakening in the morning?
None Mild Moderate Severe Extreme
o o o o o
S7. How severe is your knee stiffness after sitting, lying or resting later in the day?
None Mild Moderate Severe Extreme
o o o o o
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Pain
P1. How often do you experience knee pain?
Never Monthly Weekly Daily Always
o o o o o
What amount of knee pain have you experienced the last week during the
following ativities?
P2. Twisting/pivoting on your knee
None Mild Moderate Severe Extreme
o o o o o
P3. Straightening knee fully
None Mild Moderate Severe Extreme
o o o o o
P4. Bending knee fully
None Mild Moderate Severe Extreme
o o o o o
P5. Walking on flat surface
None Mild Moderate Severe Extreme
o o o o o
P6. Going up or down stairs
None Mild Moderate Severe Extreme
o o o o o
P7. At night while in bed
None Mild Moderate Severe Extreme
o o o o o
P8. Sitting or lying
None Mild Moderate Severe Extreme
o o o o o
P9. Standing upright
None Mild Moderate Severe Extreme
o o o o o
Function, daily living
The following questions concern your physical function. By this we mean your
ability to move around and to look after yourself. For each of the following
activities please indicate the degree of difficulty you have experienced in the
last week due to your knee.
A1. Descending stairs
None Mild Moderate Severe Extreme
o o o o o
A2. Ascending stairs
None Mild Moderate Severe Extreme
o o o o o
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For each of the following activities please indicate the degree of difficulty you
have experienced in the last week due to your knee.
A3. Rising from sitting
None Mild Moderate Severe Extreme
o o o o o
A4. Standing
None Mild Moderate Severe Extreme
o o o o o
A5. Bending to floor/pick up an object
None Mild Moderate Severe Extreme
o o o o o
A6. Walking on flat surface
None Mild Moderate Severe Extreme
o o o o o
A7. Getting in/out of car
None Mild Moderate Severe Extreme
o o o o o
A8. Going shopping
None Mild Moderate Severe Extreme
o o o o o
A9. Putting on socks/stockings
None Mild Moderate Severe Extreme
o o o o o
A10. Rising from bed
None Mild Moderate Severe Extreme
o o o o o
A11. Taking off socks/stockings
None Mild Moderate Severe Extreme
o o o o o
A12. Lying in bed (turning over, maintaining knee position)
None Mild Moderate Severe Extreme
o o o o o
A13. Getting in/out of bath
None Mild Moderate Severe Extreme
o o o o o
A14. Sitting
None Mild Moderate Severe Extreme
o o o o o
A15. Getting on/off toilet
None Mild Moderate Severe Extreme
o o o o o
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For each of the following activities please indicate the degree of difficulty you
have experienced in the last week due to your knee.
A16. Heavy domestic duties (moving heavy boxes, scrubbing floors, etc)
None Mild Moderate Severe Extreme
o o o o o
A17. Light domestic duties (cooking, dusting, etc)
None Mild Moderate Severe Extreme
o o o o o
Function, sports and recreational activities
The following questions concern your physical function when being active on
a higher level. The questions should be answered thinking of what degree of
difficulty you have experienced during the last week due to your knee.
SP1. Squatting
None Mild Moderate Severe Extreme
o o o o o
SP2. Running
None Mild Moderate Severe Extreme
o o o o o
SP3. Jumping
None Mild Moderate Severe Extreme
o o o o o
SP4. Twisting/pivoting on your injured knee
None Mild Moderate Severe Extreme
o o o o o
SP5. Kneeling
None Mild Moderate Severe Extreme
o o o o o
Quality of Life
Q1. How often are you aware of your knee problem?
Never Monthly Weekly Daily Constantly
o o o o o
Q2. Have you modified your life style to avoid potentially damaging activities
       to your knee?
Not at all Mildly Moderatly Severely Totally
o o o o o
Q3. How much are you troubled with lack of confidence in your knee?
Not at all Mildly Moderately Severely Extremely
o o o o o
Q4. In general, how much difficulty do you have with your knee?
None Mild Moderate Severe Extreme
o o o o o
Thank you very much for completing all the questions in this questionnaire.
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